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ABSTRACT 
The Involvement of Sigma Receptor Modulation in the Antidepressant-Like Effects of Ketamine 
Matthew J. Robson 
 
Depression is estimated to affect at least 30% of the world’s population at some point during their lives. 
Currently marketed antidepressants require a period of at least 2 to 3 weeks to display any 
antidepressant effects in clinical populations and rates of clinical resistance to the antidepressant effects 
of these drugs are high. Ketamine is an N-methyl-D-aspartate (NMDA) antagonist and dissociative 
anesthetic that has been shown to display rapid acting and prolonged antidepressant activity in small-
scale human clinical trials. Ketamine also binds to sigma receptors, which are believed to be protein 
targets for a potential new class of antidepressant medications. The purpose of this study was to 
determine the involvement of sigma receptors in the antidepressant-like actions of ketamine. 
Competition binding assays were performed to assess the affinity of ketamine for sigma-1 and sigma-2 
receptors. The antidepressant-like effects of ketamine were assessed in vitro using a neurite outgrowth 
model and PC12 cells, and in vivo using the forced swim test. The sigma receptor antagonists, 4-
methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzeneethanamine hydrochloride (NE-100) and N-[2-(3,4-
dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine dihydrobromide (BD1047), were 
evaluated in conjunction with ketamine in these assays to determine the involvement of sigma 
receptors in the antidepressant-like effects of ketamine. Ketamine bound to both sigma-1 and sigma-2 
receptors with µM affinities. Additionally, ketamine potentiated nerve growth factor (NGF)-induced 
neurite outgrowth in PC12 cells and this effect was attenuated in the presence of NE-100. Ketamine also 
displayed antidepressant-like effects in the forced swim test; however, these effects were not 
attenuated by pretreatment with NE-100 or BD1047. Taken together, these data suggest that sigma 
receptor-mediated neuronal remodeling may contribute to the antidepressant effects of ketamine.  
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Chapter 1 
 
Introduction: Ketamine, Depression and Sigma Receptors 
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1.1. Depression  
Major depressive disorder is characterized by periods of loss of interest, general low mood and  
low self esteem that can lead to negative lifestyle changes and suicides or suicidal ideation . Depression 
is currently one of the most common health problems worldwide with an estimated 340 million people 
suffering from it at some point during their lives (Kulkarni and Dhir, 2009a). Although treatments have 
been developed, it has been estimate that up to 75% of people suffering from depression remain either 
untreated or treated with medications lacking sufficient efficacy (Kessler et al., 2007). Current 
pharmacologic treatments typically take weeks to exert any effect and are ineffective for up to 50% of 
patients (Berton and Nestler, 2006; Fava and Davidson, 1996; Kulkarni and Dhir, 2009a; Nierenberg, 
2001). Therefore, there is a clear need for better antidepressant treatments, particularly ones that are 
fast-acting and able to treat those patients who fail to respond to currently available therapies.  
 
1.2. Currently Utilized Treatments for Depression 
Treatments for depression arose in a serendipitous fashion in the 1950s as medications such as  
iproniazid and imipramine were found to display antidepressant effects in humans (Ball and Kiloh, 1959; 
Deverteuil and Lehmann, 1958). These two medications, a monoamine oxidase inhibitor (MAOI) and a 
tricyclic antidepressant, respectively, were found to alter monoamine neurotransmission thereby linking 
monoamine neurotransmission to depression (Blier and Bouchard, 1994; Chaput et al., 1991; Slattery et 
al., 2004). Subsequently, pharmacologic agents targeting serotonergic and noradrenergic signaling were 
produced namely, selective sertotonin reuptake inhibitors (SSRI’s) and serotonin-norepinephrine 
reuptake inhibitors (SNRI’s), as well as norepinephrine reuptake inhibitors (NRI’s) (Murrough and 
Charney, 2012). Although these compounds have fewer deleterious side effects than their MAOI and 
tricyclic predecessors, these compounds suffer from poor and delayed clinical efficacy and high rates of 
non-response in clinical populations (Murrough and Charney, 2012). Current research therefore centers 
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on novel targets such as neurotrophic factors, the hypothalamic-pituitary axis, glutamatergic systems 
and novel receptors and proteins believed to be involved in mood disorders (Fishback et al., 2010b). One 
of these potential new targets for the production of pharmaceutical agents aimed at treating depression 
are sigma receptors. 
 
1.3. Sigma Receptors 
Sigma receptors were initially characterized as a sub-class of opioid receptors more than thirty  
years ago when they were discovered by Martin et al. (Martin et al., 1976). Sigma receptors were 
characterized through the interactions of (+)-benzomorphans with these proteins and they initially 
received their names from the “S” of (+)-SKF-10,047 (Matsumoto et al., 2007). The ability of (+)-isomers 
of benzomorphans to interact with sigma receptors as opposed to (-)-isomer benzomorphans which 
interact preferentially with opioid receptors led to the belief that sigma receptors were a distinct subset 
of opioid receptors, much like the g-protein coupled μ, δ, and κ subtypes of opioid receptors (Iwamoto, 
1981; Matsumoto et al., 2007; Vaupel, 1983; Young and Khazan, 1984). This was ultimately found to not 
be true; however this confusion persisted for many years.  
 In later years, due to the ability of (+)-SKF-10,047 to interact with the PCP binding sites of NMDA 
receptors, it was believed that sigma receptors may actually be the PCP binding site of NMDA receptors 
(Mendelsohn et al., 1985; Quirion et al., 1981; Sircar et al., 1986). Eventually, further binding studies 
clarified that sigma receptors were distinct protein entities and not the PCP binding site of NMDA 
receptors (Su, 1982; Tam and Cook, 1984), however this led to a great deal of confusion surrounding 
sigma receptors, some of which remains today . The advent of truly selective ligands for sigma receptors 
has allowed for further clarification of the actions of these proteins and the molecular cloning of one of 
the subtypes has paved the way for many of the functional characterizations of sigma-1 receptors that 
are known today. 
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1.3.1. Sigma-1 Receptors 
Sigma-1 receptors are 223 amino acid proteins that consist of a two-transmembrane structure 
and have a molecular weight of approximately 25 kDa (Aydar et al., 2002; Hellewell and Bowen, 1990; 
Kahoun and Ruoho, 1992; Kekuda et al., 1996; Mei and Pasternak, 2001; Pan et al., 1998). They are now 
known to be ligand-activated endoplasmic reticulum (ER) chaperone proteins that reside at the 
mitochondrial-associated ER membrane (Hayashi and Su, 2007b) and share nothing functionally in 
common with the three subclasses of opioid receptors. Upon stimulation through ligand activation, 
sigma-1 receptors are believed to alter intracellular signaling through protein-protein interactions and 
through translocation to different cellular compartments acting as chaperone proteins, modulating G-
protein coupled receptors, ion channels and signaling cascades such as protein kinases, Ca2+ levels and 
modulating IP3 signaling (Hayashi et al., 2000a; Hayashi and Su, 2003, 2007b; Kourrich et al., 2013; 
Kourrich et al., 2012; Moon et al., 2013; Navarro et al., 2010; Su and Hayashi, 2003; Takebayashi et al., 
2002). Sigma-1 receptors are known to interact directly with a variety of protein partners including 
ankyrin B, heat shock protein 70, glucose-related protein (BiP) and certain potassium channels (Aydar et 
al., 2002; Hayashi and Su, 2001; Matsumoto et al., 2007). It is through the modulation of several of 
these protein-protein interactions and signaling events that sigma-1 receptors are believed to be 
involved in a variety of disease states including depression and drug abuse (Fishback et al., 2010b; 
Hayashi et al., 2011; Kourrich et al., 2013; Robson et al., 2012).  
In addition to being present within the CNS, sigma-1 receptors are also present in high 
concentrations in the heart and spleen (Matsumoto et al., 2007; Novakova et al., 1995; Wolfe et al., 
1997). The ability of sigma-1 receptors to interact with these various proteins while also being expressed 
in vastly different physiologic regions has made studying the function of sigma-1 receptors particularly 
perplexing. The location of sigma-1 receptors in various regions of the body and their inherent ability to 
modulate several of protein-protein interactions and signaling events are believed to make them 
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potential therapeutic targets for a variety of diseases including depression and drug abuse (Ehmke, 
2012; Fishback et al., 2010b; Robson et al., 2012).  
 
1.3.2. Sigma-2 Receptors 
Much less is currently known about sigma-2 receptors than sigma-1 receptors; however 
 this subtype is smaller than sigma-1 receptors and is approximately 18-22 kDa in size (Hellewell et al., 
1994). Sigma-2 receptors are localized in lipid rafts at the plasma membrane, ER, mitochondria and 
lysosomes (Gebreselassie and Bowen, 2004; Zeng et al., 2007). Although sufficient tools are currently 
lacking to study many of the mysteries surrounding sigma-2 receptors, they are highly upregulated in 
cancer cells and play a large role in cell death through the alteration of calcium signaling and 
sphingolipid products (Bowen, 2000; Vilner and Bowen, 2000; Wheeler et al., 2000). For this reason, 
they are currently believed to be viable targets for the production of novel therapeutics aimed at 
treating specific types of cancer (Spitzer et al., 2012; Zeng et al., 2012), and agents aimed at detecting 
tumors (Tu et al., 2010).  
 
1.4. Sigma Receptors and Depression 
The involvement of sigma receptors in the actions of antidepressant drugs was first suggested 
 by observations that most marketed antidepressant drugs bind to these receptors (Table 1.1), raising 
the possibility that some of their therapeutic effects may be mediated via these proteins (Itzhak and 
Kassim, 1990; Narita et al., 1996a; Schmidt et al., 1989). Recently, it has been shown that sigma 
receptors are involved in the actions of fluvoxamine in the forced swim test (FST), whereas paroxetine’s 
antidepressant-like effects in the FST are independent of sigma receptor activation (Sugimoto et al., 
2012). Fluvoxamine is known to display significant affinity for sigma-1 receptors, whereas paroxetine 
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does not have appreciable affinity for either subtype of sigma receptor (Fishback et al., 2010b; Narita et 
al., 1996b).  
Currently Marketed Antidepressant Sigma-1 Receptor Ki (nM) Sigma-2 Receptor Ki (nM) 
Fluvoxamine 36 8439 
Sertraline 57 5297 
Fluoxetine 120 5480 
Citalopram 292 5410 
Paroxetine 1893 22,870 
Imipramine 343 2107 
Desipramine 1987 11,430 
Table 1.1. Affinities of currently marketed antidepressants for sigma-1 and sigma-2 receptors (Fishback 
et al., 2010b; Narita et al., 1996b).  
 
Additionally, selective sigma receptor agonists exert antidepressant-like effects in the FST. Sigma 
receptor agonists such as di-o-tolylguaidine (DTG), igmesine, (+)-pentazocine, SA4503 and (1-(3-
phenylpropyl)piperdine oxalate (UMB23) have been shown to exert antidepressant-like effects in the 
FST, an effect that is able to be blocked by treatment with the sigma receptor antagonists N-[2-(3,4-
dichlorophenyl)ethyl]-N-methyl-2-dimethylamino)ethylamine (BD1047) or N,N-dipropyl-2-[4-meth-oxy-
3-(2-phenylethoxy)phenyl]ethylamine (NE-100) (Matsuno et al., 1996; Wang et al., 2007b). Although 
many of these compounds have mixed affinity for sigma-1/sigma-2 receptors, sigma-1 receptors are 
beleived to be the most important subtype with regards to antidepressant activity, however the specific 
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role of sigma-2 receptors in many of these effects has yet to be conclusively determined (Fishback et al., 
2010b). Furthermore, studies specifically implicating sigma-1 receptors in these actions are those 
utilizing sigma-1 receptor knockout mice, revealing that these mice display a depressed-like phenotype 
as compared to wild-type controls (Sabino et al., 2009).  
Further evidence that targeting sigma receptors may provide viable novel therapies aimed at 
treating depression are studies showing that sigma receptor ligands display antidepressant effects when 
utilized in human clinical populations. Igmesine hydrochloride is a sigma receptor ligand that has 
previously been shown in small scale trials to display significant antidepressant effects in patients 
suffering from depression with comparable efficacy to currently marketed antidepressants (Fishback et 
al., 2010b; Volz and Stoll, 2004).  
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Figure 1.1. Sigma receptor modulation affects a variety of signaling pathways believed to be relevant to 
the etiology of depression. Sigma-1 receptors specifically, when activated, are able to translocate to 
distinct cellular compartments thereby interacting with and modulating several proteins, receptors and 
ion channels relevant to depression and the actions of currently available antidepressants. Sigma 
receptors modulate monoamine signaling, as well as glutamatergic signaling, in addition to pathways 
relevant to neurite outgrowth and synapse formation, all mechanisms hypothesized to be factors in the 
actions of antidepressant medications.  
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The precise mechanisms by which sigma receptor ligands and sigma receptors themselves alter 
depressive phenotypes is currently unknown. It is known that sigma receptors alter many intercellular 
pathways related to the etiology of depression (Fishback et al., 2010b). The ways in which sigma 
receptors are known to modulate pathways relevant to depression are depicted in Figure 1.1.  
In depth discussion of each and every proposed mechanism by which sigma receptors can modulate 
these pathways would be extensive and beyond the scope of the current dissertation. Additionally, it is 
the focus of several well written reviews that are currently published (Fishback et al., 2010b; Hayashi et 
al., 2011; Stahl, 2005; Su and Hayashi, 2003; Takebayashi et al., 2004; Tsai et al., 2009). The section 
below thus discusses the relationship between glutamatergic signaling and sigma receptors exclusively, 
as it relevant to work contained in the proceeding sections of this dissertation.  
 
1.5. Sigma Receptors and Glutamatergic Signaling 
 Glutamatergic responses mediated through NMDA receptors are modulated by sigma receptor 
ligands. Specifically, sigma receptor activation results in an enhancement of NMDA neurotransmission 
(Bergeron et al., 1993; Bermack et al., 2002; Bermack and Debonnel, 2005; Iyengar et al., 1990; Monnet 
et al., 1992a; Monnet et al., 1996). Sigma-1 receptor activation also potentiates glutamatergic responses 
in hippocampal neurons in vivo (Bergeron et al., 1995; Bergeron et al., 1993; Monnet et al., 1992b; 
Monnet et al., 1990). More recently, a potential mechanism by which this effect occurs was discovered. 
It is now known that sigma receptor antagonists such as (+)-pentazocine exert this effect by shunting 
small conductance Ca2+-activated K+ channels (SK channels) (Martina et al., 2007). The ultimate effect of 
shunting SK channels is an enhancement of Ca2+ influx through NMDA receptors, thereby potentiating 
NMDA responses (Martina et al., 2007). This effect is illustrated in Figure 1.1. 
 Another way in which sigma receptor modulation may alter glutamatergic signaling that is 
relavant to the etiology of depression is through alterations in NMDA receptor expression. The sigma 
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receptor agonist SA4503 has been shown to reverse a decrease in the expression of NR1 sububits of 
NMDA receptors in animals that have undergone an olfactory bulbectomy (OB), a procedure that 
simulates many aspects of clinical depression in rodent models (Fishback et al., 2010b; Wang et al., 
2007a). It should be noted that SA4503 displays significant antidepressant-like efffects in rodent models 
and the increase in NR1 subunits was blocked by administration of NE-100, a sigma receptor antagonist 
(Skuza and Rogoz, 2002; Wang et al., 2007a).  
 It is clear that sigma receptor modulation can alter glutamatergic neurotransmission; however, 
the exact implications of this are currently unknown and the ability of sigma receptors and their ligands 
to modulate glutamatergic signaling represents one potential mechanism by which sigma receptor 
ligands exert antidepressant-like effects.  
 
1.6. Ketamine and Depression 
As discussed above, there are several issues with currently utilized antidepressants. One of  
the largest problems is a significant delay in time (approximately 2-4 weeks) between treatment 
initiation and any antidepressant efficacy of currently utilized pharmacotherapies. This has led to 
significant research resources being aimed at finding antidepressant therapies with alternative 
mechanisms of action that may have rapid antidepressant effects while also targeting the approximately 
30-50% of patients who fail to fail to respond to classical therapies. 
Recent studies have begun to investigate the antidepressant-like properties of ketamine 
 through a variety of approaches (aan het Rot et al., 2010; Berman et al., 2000; Diazgranados et al., 
2010a; Diazgranados et al., 2010b; Kollmar et al., 2008; Li et al., 2010b; Machado-Vieira et al., 2009; Paul 
et al., 2009; Popik et al., 2008; Price et al., 2009; Zarate et al., 2006). Ketamine is an NMDA receptor 
antagonist and dissociative anesthetic, that has been shown to display rapid acting antidepressant 
activity in human clinical populations in several small cohort trials (aan het Rot et al., 2010; Berman et 
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al., 2000; Diazgranados et al., 2010a; Diazgranados et al., 2010b; Zarate et al., 2006). These studies are 
especially significant because they focus on utilizing ketamine for patients with treatment resistant 
major depressive disorder who have clinically failed on currently available therapeutics (aan het Rot et 
al., 2010; Diazgranados et al., 2010b; Zarate et al., 2006). In treatment resistant patients, therapeutic 
effects were observed within hours after ketamine administration, with antidepressant effects of the 
treatment persisting for up to seven days (Zarate et al., 2006).  
It is believed that modulation of glutamatergic signaling through NMDA and α-amino-3-(3 
hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA) receptors is responsible for the antidepressant 
actions of ketamine (Maeng et al., 2008). It is hypothesized that increased AMPA signaling may underlie 
the antidepressant effects of ketamine, as treatment with the AMPA antagonist 2,3-dioxo-6-nitro-
1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX) has been shown to block the 
antidepressant-like actions of ketamine in the FST and the tail suspension test (TST) in rodents (Koike et 
al., 2011; Maeng et al., 2008). A more specific mechanism however has been proposed that focuses on a 
rapid increase in brain-derived neurotrophic factor (BDNF), mediated through eukaryotic elongation 
factor 2 (eEF2) kinase signaling through a modulation of NMDA receptors at rest by ketamine as a 
mechanism behind the antidepressant actions of the drug (Autry et al., 2011; Kavalali and Monteggia, 
2012).  
 
1.7. Ketamine and Sigma Receptors 
In addition to binding NMDA receptors and modulating glutamatergic signaling, ketamine  
interacts with several other protein targets, including sigma receptors (Hustveit et al., 1995; Seeman et 
al., 2009). As discussed above, sigma receptor ligands have been shown to display antidepressant-like 
effects in animal models and antidepressant actions in human trials. The determination as to whether 
the antidepressant actions of ketamine are related to its interaction with sigma receptors, however, has 
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yet to be made. The following chapter focuses on this interaction with the goal of determining if the 
antidepressant-like effects of ketamine involve sigma receptor modulation. The following three specific 
aims were proposed in order to evaluate the involvement of sigma receptors in the antidepressant-like 
effects of ketamine: 
1. Identify the sigma receptor subtypes for which ketamine displays appreciable 
affinity 
2. Determine the ability of ketamine to potentiate NGF-induced neurite outgrowth in 
vitro, and the role of sigma receptors in this effect.  
3. Confirm that ketamine elicits antidepressant-like effects in the FST and determine 
the role of sigma receptors in these effects.  
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Chapter 2 
 
Evaluation of sigma receptors in the antidepressant-like effects of 
ketamine in vitro and in vivo 
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2.1. Introduction 
Depression afflicts up to 20% of the world’s population during the course of their lives and is 
currently one of the top ten causes for morbidity and mortality (Berton and Nestler, 2006; Nestler et al., 
2002a). Approximately 30% of patients do not respond to available pharmaceutical agents for treating 
depression (Nestler et al., 2002b), and patients who do respond positively typically see changes only 
after weeks of treatment (Frazer and Benmansour, 2002). It has been reported that between 1992 and 
2001, there was a 47% increase in emergency department visits due to suicide attempts and self-
inflicted injuries in the United States (Larkin et al., 2008). Currently, healthcare professionals lack the 
necessary pharmacotherapies to adequately treat these patients in a timely and sufficient manner. A 
rapid acting antidepressant would therefore be of great utility to physicians, especially in emergency 
situations.     
 Recent studies have begun to investigate the antidepressant-like properties of ketamine 
through a variety of approaches (aan het Rot et al., 2010; Berman et al., 2000; Diazgranados et al., 
2010a; Diazgranados et al., 2010b; Kollmar et al., 2008; Li et al., 2010b; Machado-Vieira et al., 2009; Paul 
et al., 2009; Popik et al., 2008; Price et al., 2009; Zarate et al., 2006). Ketamine is an N-methyl-D-
aspartate (NMDA) receptor antagonist and dissociative anesthetic, that has been shown to display rapid 
acting antidepressant activity in human clinical populations in several small cohort trials (aan het Rot et 
al., 2010; Berman et al., 2000; Diazgranados et al., 2010a; Diazgranados et al., 2010b; Zarate et al., 
2006). These studies are especially significant because they focus on utilizing ketamine for patients with 
treatment resistant major depressive disorder who have failed on currently available therapeutics (aan 
het Rot et al., 2010; Diazgranados et al., 2010b; Zarate et al., 2006). In treatment resistant patients, 
therapeutic effects were observed within hours after ketamine administration, with effects lasting for 
up to seven days (Zarate et al., 2006). This has led to the belief that ketamine and similar compounds, 
such as dextromethorphan, may act as rapid acting antidepressants through the modulation of 
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glutamatergic signaling (Krystal, 2007; Lauterbach, 2011; Machado-Vieira et al., 2009; Maeng and 
Zarate, 2007). 
 In addition to binding NMDA receptors and modulating glutamatergic signaling, ketamine 
interacts with several other protein targets, including sigma receptors (Hustveit et al., 1995; Seeman et 
al., 2009). Sigma receptors are modulatory proteins, of which two known subtypes exist, sigma-1 and 
sigma-2. Sigma-1 receptors are 223 amino acid proteins found at the mitochondrial-associated 
endoplasmic reticulum membrane (MAM) and can translocate to the plasma membrane. Additionally, 
sigma-1 receptors can exhibit chaperone activity and modulate inositol triphosphate (IP3) receptor 
function, thereby effecting calcium signaling (Hayashi and Su, 2007b; Su et al., 2010b). Contrary to 
sigma-1 receptors, sigma-2 receptors remain poorly understood. They are smaller (18-22 kDa) than 
sigma-1 receptors and have been implicated in the regulation of cell proliferation and cell viability 
(Hellewell et al., 1994; Vilner and Bowen, 1993; Vilner et al., 1995). 
Sigma receptors are considered to be protein targets for existing and novel antidepressant drugs 
(Fishback et al., 2010a; Hayashi and Su, 2008; Kulkarni and Dhir, 2009b). Currently utilized 
antidepressants such as selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors 
and tricyclic antidepressants bind to sigma receptors (Narita, 1996; Schmidt, 1989; Villard, 2011). In 
addition, various sigma receptor agonists display antidepressant-like activity in experimental animals 
(Matsuno et al., 1996; Pande et al., 1999; Skuza, 2003; Skuza and Rogoz, 2002, 2003; Ukai et al., 1998; 
Volz and Stoll, 2004; Wang et al., 2007b). There is also clinical trial data supporting sigma receptors as a 
viable antidepressant target, as the sigma receptor ligand igmesine hydrochloride has been shown to be 
as effective as the commonly prescribed SSRI fluoxetine at ameliorating depression symptoms 
(Pharmaprojects, 2004).  
It is interesting to note that compared to conventional antidepressant drugs, the prototypic 
sigma receptor agonist (+)-pentazocine can elicit neuroadaptations in serotonergic neurons in the dorsal 
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raphe nucleus that are measureable within two days of treatment compared to the two-week delay 
typical of marketed antidepressants (Bermack and Debonnel, 2001). This suggests that it may be 
possible to mediate fast acting antidepressant effects through sigma receptors. 
In addition, sigma receptors modulate several signaling pathways and ion channels thought to 
be major elements in the etiology of depression (Fishback et al., 2010a; Hayashi and Su, 2008; Kulkarni 
and Dhir, 2009c). Sigma receptor modulation of these signaling pathways has also been shown to 
potentiate nerve growth factor (NGF)-induced neurite outgrowth in vitro, indicative of their potential to 
effect neuroplasticity and display antidepressant-like activity (Ishima et al., 2008; Nishimura et al., 2008; 
Takebayashi et al., 2002). Currently marketed antidepressant drugs can potentiate NGF-induced neurite 
outgrowth (Takebayashi et al., 2004), and it is believed that the delay in clinical efficacy of 
antidepressant medications may be related to the time required for neuronal remodeling to occur 
(Castren and Rantamaki, 2010; Duman et al., 1999; Duman et al., 2001). 
Together, data in the literature suggest that sigma receptors may be capable of mediating the 
fast acting as well as delayed actions of antidepressant drugs. Therefore, to evaluate the potential 
involvement of sigma receptors in the antidepressant actions of ketamine, three types of studies were 
undertaken. First, the affinity of ketamine for each of the sigma receptor subtypes was determined. 
Second, the ability of ketamine to potentiate NGF-induced neurite outgrowth in rat pheochromocytoma 
(PC12) cells was determined, alone and in combination with a sigma receptor antagonist. Third, the 
involvement of sigma receptors in the in vivo antidepressant-like effects of ketamine using the forced 
swim test was also evaluated.  
 
2.2. Materials and Methods  
 
2.2.1. Animals  
17 
 
Male, Swiss Webster mice (24-32g; Harlan, Frederick, MD) were housed with food and water ad 
libitum, with a 12:12 hr light-dark cycle. All animals were housed in groups of five for at least one week 
prior to initiation of experiments at West Virginia University. All procedures were conducted as 
approved by the Institutional Animal Care and Use Committee at West Virginia University. The total 
number of animals utilized for the experiments was 210. 
 
2.2.2. Drugs and compounds 
Racemic ketamine was purchased from Sigma (St. Louis, MO). Imipramine hydrochloride was 
also obtained from Sigma (St. Louis, MO). Both BD1047 (N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-
(dimethylamino)ethylamine dihydrobromide) and NE-100 (N,N-dipropyl-2-(4-methoxy-3-(2-
phenylethoxy)phenyl)ethylamine hydrochloride) were purchased from Tocris (Ellisville, MO). 
Radioligands were sourced from PerkinElmer (Shelton, CT). All other chemicals and reagents were 
purchased from commercial suppliers (Sigma-Aldrich, St. Louis, MO).  
 
2.2.3. In vitro competition binding assays 
Rat liver P2 membrane (~350 µg protein) was used for all sigma receptor binding assays. 
Membrane homogenates were diluted in 50 mM Tris-HCL buffer, pH 8.0, and incubated in a total 
volume of 500 µL with radioligand at 25oC in 96 well plates. The incubation time was 120 min for both 
sigma-1 and sigma-2 assays. Sigma-1 receptors were labeled with 5 nM [3H](+)-pentazocine and sigma-2 
receptors were labeled with 3 nM [3H]di-o-tolylguanidine (DTG) in the presence of 300 nM (+)-
pentazocine to block sigma-1receptors. Nonspecific binding was determined by the addition of 
haloperidol to a final concentration of 50 µM (blanks). Ten concentrations of each test ligand were run 
in duplicates and each assay repeated three times. Following incubation and subsequent equilibrium, 
the samples were harvested, washed three times, and filtered through Unifilter GF/B filter plates (Perkin 
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Elmer 50-905-1601, Shelton, CT) previously soaked in 0.5% polyethyleneimine. Bound radioactivity was 
counted using a Microbeta2 2450 Microplate Counter (Perkin Elmer, Waltham, MA).  
 
2.2.4. Neurite outgrowth assays 
Neurite outgrowth assays were performed as previously described with minor changes 
(Takebayashi et al., 2002). Briefly, PC12 cells were purchased from American Type Culture Collection 
(Manassas, VA) and grown in complete medium: RPMI1640 with 10% horse serum, 5% fetal bovine 
serum, penicillin/streptomycin, all purchased from Invitrogen (Carlsbad, CA). Cells were passaged by 
dissociation from culture flasks with cold Ca2+ and Mg2+ free DPBS and resuspended in RPMI1640 with 
5% fetal bovine serum to 1.0x104 cells/mL. For NGF titration experiments, NGF (Promega, Madison, WI) 
was added to final concentrations of 0.156, 0.3125, 0.625, 1.25, 2.5, 5.0, 10.0 and 20.0 ng/mL. For 
further neurite outgrowth experiments, NGF was added to a final concentration of 0.625 ng/mL. Cells 
were plated at 1 mL/well in 24 well plates precoated with poly-D-lysine (PDL) and laminin (BD Falcon, 
San Jose, CA) at 1 μg per cm2. Plates were then incubated at 37oC for 36 to 48 hours. Images were 
captured to contain approximately 100 cells per field, with 3 images per well and were run in at least 
triplicate. 
 
2.2.5. Locomotor measurements 
 Locomotor activity was measured utilizing an automated activity monitoring system (San Diego 
Instruments, San Diego, CA). Prior to locomotor activity measurements, animals were acclimated to the 
testing facility for at least 30 min and acclimated to the testing chambers for an additional 30 min. Each 
testing chamber consisted of a plexiglass housing and a 16 x 16 photobeam array to detect lateral 
movements with a separate 16 photobeam array to detect rearing activity. Subsequent to the 
acclimation period, animals were treated and placed back in their respective chambers. Pretreatments 
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were done 15 min prior to treatments with saline or ketamine. Locomotor activity was then quantified 
over a 30 min period. Ambulatory, fine and rearing movements were quantified in order to measure 
total locomotor activity. For some animals, immediately after the locomotor activity measurements, the 
mice were tested in the forced swim test (see section 2.6.).  
 For time course experiments, subsequent to the acclimation periods, animals were treated (i.p.) 
with either saline (0.1 mL/10 g) or ketamine (40 mg/kg) and placed back into the locomotor chambers. 
Total locomotor activity was quantified over 30 min. At 24, 48 and 72 hours animals underwent 
acclimation periods to both the facility and the testing chambers, then received saline injections and 
locomotor activity was quantified for a total of 30 min. Immediately after each of the locomotor 
measurements, the animals were subject to the forced swim test (see section 2.2.7.). 
 
2.2.6. Forced swim test: acute measurements 
Mice were acclimated to the testing facility for 30 min prior to initiation of experiments. To 
evaluate the antidepressant-like effects of the compounds, mice received intraperitoneal (i.p.) injections 
with one of the following treatments: imipramine (10-30 mg/kg, N =30), ketamine (10-40 mg/kg, N = 
30), BD1047 (5-20 mg/kg, N = 30), BD1047 (5-20 mg/kg) + ketamine (40 mg/kg, N =30), NE-100 (1-5 
mg/kg, N = 30), NE-100 (1-5 mg/kg) + ketamine (40 mg/kg, N =30) or saline (0.1 mL/10 g, N = 10). 
Pretreatments were administered 15 min prior to receiving ketamine (40 mg/kg, i.p.). Thirty min after 
receiving their respective treatments, animals were placed in individual cylinders of water (10 cm deep) 
for a total of 6 min. The initial two min was an acclimation period and not scored. During the remaining 
four min, immobility time was quantified using ANY-Maze Version 4.63 video tracking software 
(Stoelting Co., Wood Dale, IL). Immobility was defined as no activity other than that required to maintain 
the animal’s head above the surface of the water. ANY-Maze software settings were as follows: 
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accustomization period = 120 sec, test duration = 240 sec, minimum immobility time = 2000 ms, and 
immobility sensitivity = 75%.  
 
2.2.7. Forced swim test: time course experiments 
Mice were acclimated to the testing facility for 30 min prior to initiation of experiments. Mice 
were administered (i.p.) either saline (0.1 mL/10 g, N = 10) or ketamine (40 mg/kg, N = 10) on Day 1 of 
the experiment. Thirty min after receiving their respective treatments, animals underwent the forced 
swim test, as described above. All animals then received injections of saline (i.p.) at 24, 48 and 72 hours 
after the first administration, and underwent the forced swim test as described above at these time 
points.  
 
2.2.8. Data analysis 
Data from all experiments were analyzed using GraphPad Prism 4.0 (San Diego, CA). Data from 
the competition binding studies were analyzed using a nonlinear regression to determine the 
concentration of test ligand that inhibits 50% of the specific binding of the radioligand (IC50 value). Ki 
values were calculated using the Cheng-Prusoff equation (Cheng and Prusoff, 1973). The functional data 
were analyzed by either one-way analysis of variance (ANOVA) followed when applicable by post hoc 
Dunnett’s or Tukey’s multiple comparison tests, two-way ANOVA followed by Bonferroni’s post hoc 
analysis, or unpaired two-tailed t-test. Data are represented as mean ± S.E.M. P < 0.05 was considered 
statistically significant for all data analyzed.  
 
2.3. Results  
 
2.3.1. Competition binding assays 
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 As shown in Table 2.1, ketamine had micromolar affinity for sigma-1 and sigma-2 receptors. 
Imipramine, a tricyclic antidepressant, exhibited moderate nanomolar affinity for sigma-1 and sigma-2 
receptors. NE-100 and BD1047, two sigma receptor antagonists, bound to sigma-1 and sigma-2 
receptors with nanomolar affinities.  
 
Compound sigma-1 Ki sigma-2 Ki 
(±)-Ketamine 139.60 ± 6.13 µM 26.30 ± 2.98 µM 
Imipramine 332.10 ± 30.20 nM 327.20 ± 33.30 nM 
NE-100 7.20 ± 0.94 nM 45.10 ± 4.05 nM 
BD1047 2.88 ± 0.03 nM 26.40 ± 2.63 nM 
 
Table 2.1. Affinities of various compounds for sigma receptors (both subtypes) used for both forced 
swim test and PC12 neurite outgrowth paradigms.  
 
2.3.2. Neurite outgrowth assays 
Maximal induction of neurite outgrowth was observed at a final concentration of 10 ng/mL of 
NGF (25.44 ± 1.81%). Therefore, for subsequent experiments, a final concentration of 0.625 ng/mL (5.65 
± 1.09%) was used, as this concentration did not significantly increase neurite outgrowth when 
compared to the lowest concentration tested (F(7,64) = 51.56, P < 0.0001, q = 1.87, n.s.), and was low 
enough to allow for visualization of the potentiation of neurite outgrowth by compounds of interest 
(data not shown).                  
When the tricyclic antidepressant imipramine was tested for its ability to potentiate NGF-
induced neurite outgrowth, a one-way ANOVA showed that the changes were significant (F(6,56) = 
35.05, P < 0.0001). Furthermore, post hoc tests revealed that imipramine potentiated NGF-induced 
neurite outgrowth at the following concentrations: 10 nM (q = 3.04, P < 0.05), 100 nM (q = 7.00, P < 
0.01), 1 μM (q = 12.09, P < 0.01) and 10 μM (q = 4.56, P < 0.01) (Figure 2.1.A.).  
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Figure 2.1. Effects of imipramine (0-10,000 nM; A), ketamine (0-10,000 nM) B), and NE-100 (0-1,000 nM) 
C) on NGF-induced neurite outgrowth. Data shown are expressed as mean ± S.E.M. * P<0.05, **P<0.01, 
***P<0.001; one way ANOVA followed by post hoc Dunnett’s tests. 
 
Ketamine also significantly potentiated NGF-induced neurite outgrowth (F(7,64) = 28.82, P < 
0.0001). Ketamine significantly potentiated NGF-induced neurite outgrowth compared to vehicle 
controls at the following concentrations: 0.01 nM (q = 4.12, P < 0.01), 0.1 nM (q = 6.36, P < 0.01), 1 nM 
(q = 11.41, P < 0.01), 10 nM (q = 10.55, P < 0.01), 100 nM (q = 9.49, P < 0.01), 1 μM (q = 9.21, P < 0.01) 
and 10 μM (q = 8.23, P < 0.01) (Figure 2.1.B.).  
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The sigma receptor antagonist, NE-100, exerted modest, but statistically significant, effects on 
NGF-induced neurite outgrowth on its own (F(6,56) = 3.35, P < 0.01). NGF alone (0.625 ng/mL) 
stimulated neurite outgrowth in 5.70 ± 0.68% of cells, as opposed to 4.10 ± 0.44, 3.50 ± 0.29, 3.70 ± 0.21 
and 4.20 ± 0.25% with NE-100 treatment of 1, 10, 100 and 1000 nM, respectively. These changes in the 
percentage of NGF-induced neurite outgrowth as a result of NE-100 treatment, although minimal, were 
found to be significant when compared to vehicle controls: 1 nM (q = 2.85, P < 0.05), 10 nM (q = 3.89, P 
< 0.01) and 100 nM (q = 3.46, P < 0.01) (Figure 2.1.C.).  
NE-100 also significantly decreased imipramine’s potentiation of NGF-induced neurite 
outgrowth as shown by two-way ANOVA (F(6,204) = 10.61, P < 0.0001; Figure 2A). Bonferroni’s post hoc 
tests revealed that NE-100 treatment attenuated the ability of imipramine (100 nM) to increase neurite 
outgrowth at all concentrations tested: 10 nM (t = 6.98, P <0.001), 100 nM (t = 7.13, P < 0.001) and 1000 
nM (t = 9.72, P < 0.001). NE-100 also significantly attenuated the effects of imipramine (1 μM) on neurite 
outgrowth at concentrations of 10 nM (t = 7.34, P < 0.001), 100 nM (t = 8.81, P < 0.001) and 1 μM (t = 
12.04, P < 0.001) (Figure 2.2.A.). 
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Figure 2.2. Effects of NE-100 (0-1000 nM) on NGF-induced neurite outgrowth potentiated by imipramine 
(100 and 1,000 nM) A) and ketamine (100 and 1000 nM) B). Data shown are expressed as mean ± S.E.M. 
***P<0.001, ###P<0.001; one way ANOVA followed by post hoc Tukey’s tests. 
 
NE-100 (10 nM – 1 μM) had similar effects on the ability of ketamine to potentiate NGF-induced 
neurite outgrowth (F(6,204) = 21.46, P < 0.0001). Post hoc Bonferroni’s tests revealed that 10 nM, 100 
nM and 1 μM NE-100 significantly attenuated the ability of ketamine (100 nM) to potentiate NGF-
induced neurite outgrowth (t = 10.83, P < 0.001; t = 13.86, P < 0.001; t = 15.38, P < 0.001, respectively) 
(Figure 2.2.B.). The effects of NE-100 pretreatment on the ability of ketamine (1 μM) to potentiate NGF-
induced neurite outgrowth were similar to that of ketamine (100 nM) at 10 nM (t = 7.94, P < 0.001), 100 
nM (t = 11.80, P < 0.001) and 1000 nM (t = 13.15, P < 0.001).  
 
2.3.3. Locomotor activity 
 Acute saline treatment resulted in a total locomotor activity count of 1621 ± 275 during the 30 
min testing period. Acute ketamine 40 mg/kg treatment did not significantly alter locomotor activity 
compared to saline (1859 ± 215 counts, t = 0.68, n.s.) (data not shown). NE-100 alone displayed no 
significant effects on locomotor activity at any of the doses tested (F(3,36) = 0.06, n.s.). NE-100 (1, 2.5 or 
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5 mg/kg) in combination with ketamine 40 mg/kg did not significantly alter locomotor activity compared 
to saline (2464 ± 438 counts, q = 2.32, n.s.; 2877 ± 421 counts, q = 3.45, n.s.; 2919 ± 412 counts, q = 3.57, 
n.s., respectively) or ketamine 40 mg/kg alone (q = 1.66, n.s.; q = 2.80, n.s.; q = 2.91, n.s., respectively).   
 When the effect of a single dose of ketamine (40 mg/kg) on locomotor activity over an extended 
time period was evaluated, it did not significantly alter locomotor activity when compared to saline at 
0.5, 24, 48 or 72 hours (1859 ± 215 vs. 1621 ± 275 counts, q = 0.95, n.s.; 583 ± 148 vs. 1332 ± 387 counts, 
q = 2.98, n.s.; 533 ± 115 vs. 850 ± 233 counts, q = 1.26, n.s.; 1137 ± 100 vs. 1657 ± 366 counts, q = 2.07, 
n.s., respectively) (data not shown).  
 
2.3.4. Forced swim test 
Saline administration exhibited an immobility time in the forced swim test of 107.4 ± 6.1 sec. 
The tricyclic antidepressant drug imipramine significantly decreased immobility time in the forced swim 
test (F(3,36) = 8.08, P < 0.0005). Post hoc Dunnett’s tests revealed that imipramine 20 and 30 mg/kg 
significantly decreased immobility time when compared to saline (33.1 ± 15.8 sec, q = 4.07, P < 0.01; 
31.7 ± 6.9 sec, q = 4.08, P < 0.01, respectively) (Figure 2.3.A.). Ketamine administration also significantly 
reduced immobility time (F(3,36) = 8.73, P < 0.0005), with ketamine 40 mg/kg displaying a marked 
decrease in immobility time compared to saline (42.4 ± 11.9 sec, q = 4.98, P < 0.01)  (Figure 2.3.B.).  
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Figure 2.3. Antidepressant-like effects of imipramine (0-30 mg/kg, i.p.) A), ketamine (0-40 mg/kg, i.p.) B), 
NE-100 (0-5 mg/kg, i.p.) C), and BD1047 (0-20 mg/kg, i.p.) D) in the mouse forced swim test. The tests 
started 30 min after an injection of saline or one of the four drugs. Data shown are expressed as mean ± 
S.E.M. (N = 10). **P<0.01; one way ANOVA followed by post hoc Dunnett’s tests. 
 
Two different sigma receptor antagonists, NE-100 (Figure 2.3.C.) and BD1047 (Figure 2.3.D.), 
displayed no significant effects in the forced swim test (F(3,36) = 1.42, n.s.; F(3,36) = 2.85, n.s., 
respectively).  
BD1047 5, 10 or 20 mg/kg pretreatment was unable to attenuate the antidepressant-like effects 
of ketamine 40 mg/kg when analyzed by post hoc Tukey’s multiple comparison tests (q  = 1.22, n.s.; q = 
0.86, n.s.; q = 1.77, n.s., respectively) (Figure 2.4.A.). Similarly, as shown in Figure 2.4.B., NE-100 
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pretreatment was unable to attenuate the antidepressant-like effects of ketamine 40 mg/kg at any of 
the following doses: 1 mg/kg (q = 0.45, n.s.), 2.5 mg/kg (q = 0.80, n.s.) or 5 mg/kg (q = 0.69, n.s.).  
 
 
Figure 2.4. Antidepressant-like effects of BD1047 (0-20 mg/kg, i.p.) + Ketamine (40 mg/kg, i.p.) A) and 
NE-100 (0-5 mg/kg, i.p.) + Ketamine (40 mg/kg, i.p.) B) in the mouse forced swim test. The mice were 
injected ketamine 15 min after the BD1047 or NE-100 pretreatment. The tests were started 30 min after 
the injection of ketamine or saline. Data shown are expressed as mean ± S.E.M. (N = 10). *P<0.05, 
**P<0.01; one way ANOVA followed by post hoc Tukey’s tests. 
 
2.3.5. Time course of the antidepressant-like effects of ketamine 
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One-way ANOVA revealed that a single administration of ketamine 40 mg/kg produced effects in 
the repeated forced swim test (F(7,72) = 7.18, P < 0.0001). Post hoc Dunnett’s analysis revealed that 
ketamine 40 mg/kg significantly decreased immobility time 30 min after administration compared to 
saline administration (32.1 ± 8.9 sec, q = 2.89, P < 0.05). However, this effect was not present 24, 48 or 
72 hours post-administration (91.0 ± 10.8 sec, q = 0.39, n.s.; 124.4 ± 14.5 sec, q = 2.25, n.s.; 130.7 ± 13.1 
sec, q = 2.61, n.s., respectively) (Figure 2.5.).  
 
Figure 2.5. Time course of antidepressant-like effects of ketamine (40 mg/kg, i.p.) in the mouse forced 
swim test. The test started 0.5, 24, 48 and 72 h after the injection of saline or ketamine. Data shown are 
expressed as mean ± S.E.M. (N = 10). *P<0.05; one way ANOVA followed by post hoc Dunnett’s tests. 
 
 
2.4. Discussion  
 This study is the first to provide binding affinities of ketamine for both sigma receptor subtypes, 
in addition to determining the implications of this interaction on the antidepressant-like effects of 
ketamine in vitro and in vivo.  
 Ketamine binds to both subtypes of sigma receptors in the micromolar range. In addition to 
sigma receptors and NMDA receptors, ketamine has been shown to interact with HCN1 channels, 
dopamine D2 receptors, and opioid receptors (Chen, 2009; Hirota et al., 1999; Hustveit et al., 1995; 
Seeman et al., 2009). This pattern of binding suggests that ketamine may produce direct effects through 
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sigma receptors, but that other mechanisms of action are also likely to contribute. Further, it is possible 
that the cumulative actions of ketamine through multiple targets in the body may be modified 
downstream through sigma receptor-mediated interventions given the modulatory role of sigma 
receptors in cellular functions (Hayashi et al., 2000b; Hayashi and Su, 2007a; Nishimura et al., 2008). 
This is also the first report of ketamine potentiating NGF-induced neurite outgrowth in PC12 
cells, an effect that is mitigated through administration of a sigma receptor antagonist. Recent studies 
have demonstrated that sigma receptor agonists potentiate NGF-induced neurite outgrowth in this 
cellular model, whereas antagonists or inverse agonists have no effect or decrease NGF-induced neurite 
outgrowth (Hashimoto et al., 2007a; Kishimoto, 2010; Nishimura et al., 2008; Takebayashi et al., 2002; 
Villard, 2011). In addition, several currently utilized antidepressants that bind to sigma receptors have 
been shown to potentiate NGF-induced neurite outgrowth (Hashimoto et al., 2007a; Nishimura et al., 
2008; Takebayashi et al., 2002). The ability of ketamine to potentiate NGF-induced neurite outgrowth 
suggests that, similar to other antidepressant drugs, it can stimulate neuronal remodeling and this effect 
may underlie the observed therapeutic effects. With conventional antidepressant drugs, this remodeling 
is thought to be associated with the delay in therapeutic efficacy and may thus correspond to the 
persistent antidepressant effects observed with ketamine, even after the drug has been eliminated from 
the body (Berman et al., 2000; Duman et al., 1997; Duman et al., 1999; Zarate et al., 2006).   
Ketamine appears to exert its potentiating effects on NGF-induced neurite outgrowth by 
interacting with sigma receptors, thereby modulating pathways relevant to neuroplasticity. Agonist 
activity at sigma receptors would explain the ability of ketamine to potentiate NGF-induced neurite 
outgrowth and also explain the ability of NE-100 to dose-dependently attenuate this effect. Further 
supporting the theory of direct interactions between ketamine and sigma receptors, are results from 
imaging studies displaying competition binding between racemic ketamine and a [11C] labeled sigma 
receptor PET ligand, SA5845 in numerous brain regions in primates (Kortekaas et al., 2008).  
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In addition, sigma receptors may play a modulatory role in signaling pathways activated by 
ketamine administration that are relevant to neurite outgrowth. It has been shown that activation of 
sigma receptors can potentiate signaling through ERK/MAPK and IP3/Akt pathways, both of which are 
implicated in neurite outgrowth (Nishimura et al., 2008). Sigma-1 receptors have been shown to 
stabilize IP3 receptors at the MAM and ultimately increase Ca
2+ release through this stabilization 
(Hayashi et al., 2000a; Hayashi and Su, 2007b; Su et al., 2010b). The ability of sigma-1 receptors to 
stabilize IP3 receptors may result in increased Ca
2+ efflux from IP3 receptors and result in the potentiation 
of signaling pathways required for neurite outgrowth in this cellular model (Nishimura et al., 2008). 
Recently, it was reported that the antidepressant effects of ketamine involve mammalian target of 
rapamycin (mTor) signaling through ERK and Akt pathways (Li et al., 2010b). It was shown that ketamine 
increased the population of mushroom spines and increased spine density in medial prefrontal cortex 
(mPFC) pyramidal neurons, and this was attenuated by infusion of an mTor inhibitor, rapamycin (Li et al., 
2010b). Sigma receptor ligands have been shown to regulate Akt signaling, leading to the modulation of 
NGF-induced neurite outgrowth (Li et al., 2010a; Nishimura et al., 2008). This could be another possible 
explanation as to how the sigma receptor antagonist NE-100 is modulating the effects of ketamine on 
NGF-induced neurite outgrowth. The determination as to whether ketamine is acting as a sigma agonist 
through direct interactions with the receptor and/or whether sigma receptors are modulating pathways 
relevant to ketamine’s effects on neurite outgrowth in PC12 cells has yet to be made.  
It has been speculated that the antidepressant effects of ketamine are mediated by increases in 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) influx (Li et al., 2010b; Maeng et al., 
2008). Treatment with 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX), an 
AMPA antagonist, completely blocked the induction of the phosphorylation of Akt and ERK in response 
to ketamine treatment in the mPFC (Li et al., 2010b). The effects of AMPA signaling on the 
antidepressant effects of ketamine have also been shown to be important in behavioral paradigms. 
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Results linking the antidepressant-like effects of ketamine to AMPA receptors, by using NBQX to 
attenuate the antidepressant-like effects of ketamine in the forced swim test have been reported 
(Maeng et al., 2008). Rapamycin has also been shown to attenuate the antidepressant-like effects 
ketamine in the forced swim test (Li et al., 2010b).  
The current study used the forced swim test to show that the behavioral antidepressant-like 
effects of ketamine are not mediated by its interaction with sigma receptors. This conclusion is 
substantiated by the use of two well-established sigma receptor antagonists that were unable to 
attenuate the antidepressant-like effects of ketamine at any dose tested in this paradigm. In contrast, 
these antagonists have been reported to attenuate the antidepressant-like actions of sigma receptor 
agonists in the forced swim test (Wang et al., 2007b). It is believed that the antidepressant effects of 
sigmareceptor agonists are primarily the result of their interactions with sigma-1 receptors (Kulkarni and 
Dhir, 2009c). NE-100 and BD1047, two well accepted sigma-1 receptor antagonists which also exhibit 
significant affinity and putative antagonist effects at sigma-2 receptors (McCracken et al., 1999; Vilner 
and Bowen, 2000), were shown in the current study to not attenuate the antidepressant-like effects of 
ketamine. It therefore appears that increases in AMPA signaling are required for the acute 
antidepressant-like behavioral effects of ketamine, and these signaling events occur through sigma 
receptor independent mechanisms, which include alterations in mTOR (Li et al., 2010b).  
Our study also further validates that the forced swim test is a valuable tool for the study of the 
antidepressant-like actions of ketamine, and it has been reported in rats that these effects are not 
confounded by general increases in activity levels (Engin et al., 2009). It has also been shown that acute 
treatment with ketamine (50 mg/kg) does not increase exploratory or general locomotor activity (Popik 
et al., 2008). The current study provides further evidence that the antidepressant-like effects of 
ketamine in animal models such as the forced swim test are not confounded by alterations in locomotor 
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activity. It should also be noted that in this study, a single administration of ketamine did not alter 
locomotor activity when compared to saline for up to 72 hours.  
 In the current study, we found no evidence of persistent antidepressant-like effects by a single 
administration of ketamine in repeated trials of the forced swim test. These results are similar in nature 
to a previous report (Popik et al., 2008), and another recent study has shown that in CD-1 and Balb/cJ 
mice, ketamine displays no long-term antidepressant-like actions one week after administration in the 
forced swim test (Bechtholt-Gompf, 2011). However, there is variation between reported studies with 
regard to the persistent effects of ketamine in animal models of antidepressant-like behaviors. It has 
been reported that two weeks after administration, the antidepressant-like effects of ketamine were 
still present in the forced swim test (Maeng et al., 2008), and another group has also previously 
published results showing that an anesthetic dose of ketamine (160 mg/kg) was able to decrease 
immobility time in the forced swim test 10 days post-administration (Yilmaz et al., 2002). The 
methodologies used to determine whether ketamine had sustained antidepressant-like effects in each 
of these studies were drastically different and potentially led to the differences seen in previously 
reported studies (Maeng et al., 2008; Popik et al., 2008; Yilmaz et al., 2002).  
 The behavioral results of antidepressant-like effects presented in this report were obtained 
through the use of a single assay, the forced swim test. Therefore, it will be important in future studies 
to validate the pattern of effects presented here using other behavioral paradigms such as learned 
helplessness, chronic mild stress, tail suspension tests and social defeat stress models (Martin and 
Brown, 2010; Yan et al., 2010). Although the effects of ketamine treatment in a variety of these models 
have begun to be determined, the role that sigma receptors play in these effects has yet to be studied 
(Koike et al., 2011; Li et al., 2011). In addition, the role of gender and other physiologic characteristics in 
many of these behavioral models of depression and antidepressant-like effects is yet unknown (Martin 
and Brown, 2010).   
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 In conclusion, the data presented here show for the first time that ketamine potentiates NGF-
induced neurite outgrowth in an in vitro model and provides evidence that this effect occurs through a 
sigma receptor dependent mechanism. Additional studies to understand the molecular signaling events 
by which these effects occur are warranted and may shed light on the mechanism by which ketamine 
displays antidepressant actions.  
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ABSTRACT 
The Involvement of Sigma Receptor Modulation in the Neurotoxic Actions of Methamphetamine 
 
Matthew J. Robson 
Methamphetamine (METH) is an illicit, addictive psyhostimulant and chronic use of the drug is known to 
result in striatal neurotoxicity that has been linked to cognitive deficits and an increased risk of 
developing Parkinson’s disease. The precise molecular mechanisms by which these effects occur have 
yet to be fully delineated, however it is known that METH results in the induction of endoplasmic 
reticulum (ER) stress, reactive gliosis and neuroinflammation in regions subject to the neurotoxic actions 
of the drug. In addition to interacting with monoaminergic targets with the CNS, METH binds to both 
subtypes of sigma receptors at physiologic concentrations and sigma receptor antagonists have been 
shown to attenuate many behavioral and physiologic effects of METH in vivo, including neurotoxicity. 
Additionally, sigma receptor antagonists have been shown to block the toxic effects of the drug in vitro. 
The determination as to whether sigma receptor modulation alters METH-induced ER stress, reactive 
gliosis or neuroinflammation however has yet to be made. The purpose of the studies contained herein 
were therefore to determine if sigma receptor ligands mitigate the effects of METH on ER stress, 
reactive gliosis and neuroinflammation using various in vitro and in vivo models. METH treatment 
resulted in a significant upregulation of PERK-mediated ER stress specific genes including atf3, atf4, chop 
and gadd34 after 6, 12 and 24 hrs using an in vitro model of METH neurotoxicity, an effect that was 
unable to be mitigated by treatment with SN79, a sigma receptor antagonist. In vivo studies revealed 
that the ability of sigma receptor antagonists to attenuate METH-induced dopaminergic neurotoxicity is 
correlated with a mitigation of METH-induced hyperthermia. Additionally, METH treatment was found 
to result in striatal glial cell activation and neuroinflammation in male, Swiss Webster mice, effects that 
were blocked by SN79 treatment. Results from the current studies provide evidence that sigma receptor 
antagonists such as SN79 are modulating neuroinflammation stemming from METH, thereby conveying 
protective effects against METH-induced neurotoxicity. 
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Chapter 3 
Introduction 
Methamphetamine Abuse and Neurotoxicity 
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3.1. Drug Abuse 
In the United States alone, drug abuse is responsible for billions of dollars in costs associated 
with treatments for addiction, as well as various medical complications that develop as a result of acute 
and chronic substance abuse (Policy, 2004). In addition, incarceration and health care costs associated 
with emergency department admissions from drug overdose are problematic (Rich et al., 2011). 
Compounding this problem, several classes of currently abused substances lack FDA-approved 
pharmacotherapies to treat the addiction, overdose and toxic effects associated with their usage (Jupp 
and Lawrence, 2010). New strategies and ultimately, therapies developed for treating the effects of 
drugs of abuse are essential. Classical targets, including the dopaminergic system, have not yielded 
clinically viable treatments capable of ameliorating the acute physiological or the rewarding effects of 
drugs such as cocaine and METH, which target these systems (Jupp and Lawrence, 2010). These results 
have led to the current state which involves a myriad of research dedicated toward the discovery and 
development of novel strategies for the treatment of substance abuse. 
 
3.2. Sigma Receptors and Drug Abuse 
Sigma receptors have recently become compelling targets for the development of novel 
therapeutics aimed at treating the effects of a variety of abused substances. Of the two subtypes, sigma-
1 and sigma-2, which are described in detail in other articles in this volume, sigma-1 receptors have 
garnered increasing attention as accumulating knowledge about their functions have emerged. Sigma-1 
receptors are expressed in several regions of the brain that have implications in drug abuse and 
addiction (i.e. limbic regions such as the hippocampus and striatal regions such as the caudate, 
putamen, nucleus accumbens and amygdala) (Alonso et al., 2000; Phan, 2000). 
Sigma receptors were initially theorized to be novel targets for treating addiction disorders after 
it was shown that various drugs of abuse interact with these receptors at physiologically relevant 
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concentrations. Drugs of abuse previously reported to interact directly with both subtypes of sigma 
receptors include: cocaine and certain metabolites of cocaine; METH; 3,4-
methylenedioxymethamphetamine (MDMA) and phencyclidine (PCP) (de Costa et al., 1989; de Costa et 
al., 1992; Liu et al., 2005; Matsumoto et al., 2001a; Sharkey et al., 1988; Weber et al., 1986). In addition 
to direct interactions with sigma-1 receptors, the modulation of neurotransmitter systems and signaling 
pathways relevant to the actions of many of the above drugs of abuse are believed to involve sigma-1 
receptors (Gonzalez-Alvear and Werling, 1994, 1995; Gonzalez and Werling, 1997; Gudelsky, 1995; 
Kobayashi et al., 1997; Su and Hayashi, 2003; Weatherspoon et al., 1996). Sigma-1 receptors also have 
profound effects on drug-induced gene expression, including genes that are related to the behavioral 
effects of abused substances (Hayashi and Su, 2005; Liu et al., 2005; Liu and Matsumoto, 2008) and 
learning and memory processes (Yang et al., 2009). The evidence that sigma-1 receptors can modulate 
diverse processes necessary for the effects of a variety of drugs of abuse makes them viable targets for 
the development of novel drugs aimed at treating the negative side effects of several drugs of abuse, 
including addiction. 
 
3.3. Methamphetamine (METH) 
 METH is an addictive psychostimulant that targets monoaminergic systems within the central 
nervous system (CNS). It is a very widely abused substance worldwide with an estimated 25 million users 
and is currently the second most abused substance in the world, behind only Cannabis (Cadet and 
Krasnova, 2009; Rawson and Condon, 2007). Inexpensive production, long half-life and low cost are all 
associated with its popularity among users (Cadet and Krasnova, 2009). Emergency room admissions 
stemming from METH usage have also risen in previous years. In the period from 1992 to 2002, METH 
related ER admissions rose from 10 to 52 per 100,000 people (Roehr, 2005). Clearly, METH abuse and 
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overdose is a significant public health problem, one in which there are currently no pharmacologic 
treatments approved by the FDA (Jupp and Lawrence, 2010).  
 METH abuse is associated with several negative effects including tachycardia, increased blood 
pressure, hyperthermia, stroke, insomnia, anxiety, hallucinations, paranoia, memory loss, depression, 
dental decay, psychosis, weight loss, and with extended usage significant neurotoxicity (Romanelli and 
Smith, 2006). Two of these side effects, hyperthermia and neurotoxicity are particularly problematic. 
METH overdose can result in life threatening hyperthermia that raises core body temperature in excess 
of 41oC and can result in renal and liver damage (Cadet and Krasnova, 2009; Romanelli and Smith, 2006). 
The neurodegenerative effects of chronic METH abuse are hypothesized to be responsible for deficits in 
attention, memory and executive functioning in METH addicts (Gonzalez et al., 2007; Gonzalez et al., 
2004; Hart et al., 2012; Woods et al., 2005). Additionally, it has been hypothesized for some time that 
chronic METH usage leading to neurotoxicity may result in an increased risk of developing Parkinson’s 
disease (Guilarte, 2001; Volkow et al., 2001b). Recently, it was found that METH abusers do indeed have 
an increased risk of developing Parkinson’s disease later in life as opposed to non-METH using controls 
(Callaghan et al., 2010; Callaghan et al., 2012; Kuehn, 2011). With the numbers of METH abusers 
worldwide, the increased risk of developing Parkinson’s disease in these individuals is a significant public 
health concern. Exacerbating this problem is the current lack of any approved pharmacotherapies aimed 
at treating METH-induced neurotoxicity.   
 The hypothesis that METH-induced neurotoxicity may lead to an increased risk of developing 
Parkinson’s disease stemmed from studies showing that METH-induced neuronal damage affects 
dopaminergic nerve terminals in related regions of the brain as Parkinson’s disease. Imaging studies 
have been utilized to show a reduction in dopamine transporters (DAT) in the cortex and striatum of 
chronic METH users, indicative of nerve terminal damage (Sekine et al., 2001; Sekine et al., 2003; 
Volkow et al., 2001a; Volkow et al., 2001b). Additionally, a reduction in serotonin transporters (SERT) in 
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humans has also been reported in the cortex, indicative of damage to serotonergic nerve terminals 
(Sekine et al., 2006).  
 Damage to dopaminergic and serotonergic nerve terminals by METH has been shown in rodent 
models by using a variety of administration regimens (Albers and Sonsalla, 1995; Bowyer et al., 1994; 
Brunswick et al., 1992; Krasnova et al., 2010; Matsumoto et al., 2008; Schwendt et al., 2009; Seminerio 
et al., 2011). Additionally, a myriad of potential therapies aimed at counteracting these effects have also 
been used in rodents and have been reviewed elsewhere (Escubedo et al., 2009; Krasnova and Cadet, 
2009; Panenka et al., 2012; Rodvelt and Miller, 2010).  
 
3.4. METH-Induced Neurotoxicity: Potential Mechanisms 
 The nerve terminal damage elicited by METH is believed to occur through a variety of cellular 
and molecular mechanisms involving various cell types within the CNS. Figure 3.1 depicts a simplified 
dopaminergic nerve terminal with highlighted mechanisms by which METH is believed to result in 
neurotoxicity. Some of the mechanisms by which METH is believed to result in neurotoxicity are listed 
below:  
 1. Dopamine and serotonin release: Excess release of these two neurotransmitters (primarily 
dopamine) is believed to be the initiating event leading to neurotoxicity elicited by METH (Riddle et al., 
2006; Stephans and Yamamoto, 1994). This excess release can lead to post-synaptic signaling involved in 
cellular toxicity (Cadet and Krasnova, 2009; Gross et al., 2011). Additionally, excess dopamine is known 
to result in reactive forms of dopamine called dopamine quinones (DAQ) that are believed to be major 
contributors to METH-induced neurotoxicity (Kuhn et al., 2006; LaVoie and Hastings, 1999a, b; Miyazaki 
and Asanuma, 2009). 
 2. Excitotoxicity: Glutamatergic excitotoxicity is also implicated in the neurotoxic actions of 
METH. The exact mechanism by which occurs is currently unknown, however it is known that METH 
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results in glutamate release in the CNS and glutamate antagonists have been previously shown to 
mitigate some of the neurotoxic actions of METH (Battaglia et al., 2002; Cadet and Krasnova, 2009; 
Sonsalla et al., 1989; Tata and Yamamoto, 2008). Increases in glutamate may originate from many 
sources including the modulation of glutamate uptake by astrocytes (Coulter and Eid, 2012), as METH is 
known to affect astrocyte function (see below). Glutamate is hypothesized to result in nitric oxide 
formation as a result of METH, an effect that can result in neuronal damage (Cadet and Krasnova, 2009).  
 3. Glial cell activation: METH treatment also results in the activation of glial cells within the CNS, 
including microglial cells and astrocytes (Cadet and Krasnova, 2009). METH has been shown to result in 
microglial activation in human abusers and several groups have published reports providing evidence 
that METH results in the activation of astrocytes and microglial cells in preclinical models (Kelly et al., 
2012; Sekine et al., 2008; Thomas et al., 2004a; Thomas et al., 2004c). It is also hypothesized that glial 
cell activation results in cytokine and ROS/RNS release that mediates several aspects of toxicity 
associated with METH (Cadet and Krasnova, 2009; Goncalves et al., 2008; Hebert and O'Callaghan, 2000; 
Kelly et al., 2012; Ladenheim et al., 2000; Nakajima et al., 2004).  
 4. Death pathway activation: METH has been shown to activate both caspase-dependent and 
caspase-independent death cascades involving the both the ER and mitochondria (Cadet et al., 2007; 
Deng et al., 2001; Imam et al., 2001; Jayanthi et al., 2001; Jayanthi et al., 2005; Jayanthi et al., 2004). 
Alterations in proteins related to mitochondrial death pathways as a result of METH have been shown, 
including reductions in Bcl-2 (an antiapoptotic protein), and increases in BAX and BID (inducers of 
apoptosis) (Cadet and Krasnova, 2009). Additionally, METH results in increases in Fas/FasL cell death 
signaling through caspase-3, an effect implicated in the toxic actions of the drug in striatal neurons 
(Jayanthi et al., 2005). 
 5. ER stress: ER stress elicited by METH has been reported in brain regions affected by the 
neurotoxic actions of the drug (Jayanthi et al., 2009). METH treatment results in the activation of 
41 
 
pathways involved in ER stress induction and ER stress-induced cell death and these effects have been 
reported to be dependent on dopaminergic signaling (Beauvais et al., 2011; Jayanthi et al., 2004; 
Jayanthi et al., 2009).   
 6. Neuroinflammation: Neuroinflammation, resulting from the activation of glial cells, is 
hypothesized to be involved in the ability of METH to cause neurotoxicity (Cadet and Krasnova, 2009). 
Pro-inflammatory cytokines released from activated microglial cells as a result of METH are believed to 
be contributors to the drug’s effects on dopaminergic nerve terminals within the striatum (Kelly et al., 
2012). Specifically, a lack of Interleukin-6 (IL-6) has been shown to be protective against METH-induced 
neurotoxicity (Ladenheim et al., 2000).  
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Figure 3.1. Proposed mechanisms of METH-induced dopaminergic neurotoxicity. METH is believed to 
result in toxicity through a variety of cellular mechanisms. These include excess dopamine (DA) 
converting to dopamine quinones (DAQ) and reactive dopamine species, gene expression alterations 
related to cellular toxicity, glutamatergic excitotoxicity, caspase cleavage and apoptosis signaling, ER 
stress induction,  glial cell activation and subsequent release of pro-inflammatory cytokines from 
activated microglia.  
 
3.5. Sigma Receptors and METH 
One potentially promising target for the production of therapies aimed at counteracting the 
effects of METH, including neurotoxicity are sigma receptors. Evidence that sigma receptors play a role 
in the actions of METH began to emerge nearly 20 years ago (Ujike et al., 1992b). METH interacts 
directly with both subtypes of sigma receptors and is known to display a 22-fold preference for sigma-1 
receptors over sigma-2 receptors (Ki 2.16 ± 0.25 µM and 46.67 ± 10.34 µM for sigma-1 and sigma-2 
receptors, respectively) (Nguyen et al., 2005). Nguyen et al. also showed that interactions between 
METH and sigma-1 receptors are competitive in nature by using the selective sigma-1 receptor ligand 
[3H](+)-pentazocine in saturation binding experiments conducted in rat brain homogenates (Nguyen et 
al., 2005). These studies, showing a direct interaction between METH and sigma-1 receptors, raised the 
possibility that METH exerts effects through direct interactions with sigma-1 receptors.  
In addition to evidence for competitive interactions, accumulated data over the years suggests 
that the interaction of METH with sigma-1 receptors is complex. METH is believed to act as a sigma-1 
receptor agonist and data supporting this comes from reports of the ability of sigma-1 receptor 
antagonists and antisense oligonucleotides to attenuate many effects of the drug (Matsumoto et al., 
2008; Nguyen et al., 2005). However, the binding of classical sigma-1 receptor agonists to sigma-1 
receptors results in the dissociation of the chaperone protein BiP and sigma-1 receptors at the MAM 
(Hayashi and Su, 2007b). METH produces effects that are atypical of classical sigma-1 receptor agonists 
in this assay (Hayashi and Su, 2007b), although the underlying reason for this difference is currently 
unknown. In addition, pharmacological dose response characterizations show that sigma-1 receptor 
antagonists lower the maximal effect of the dose response curve for METH in behavioral studies 
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(Nguyen et al., 2005), a pattern that is indicative of non-competitive interactions at the receptor. 
Together, the data suggest that although METH can interact competitively with the classical sigma-1 
agonist binding site, its effects subsequent to binding are atypical of a classical agonist at sigma-1 
receptors.  
Therefore, it is noteworthy that sigma-1 receptors are involved in a variety of processes that 
may modulate responses to METH away from the binding site. First, sigma receptors modulate 
dopamine synthesis, release and uptake (Basianetto et al., 1995; Booth and Baldessarini, 1991; 
Gonzalez-Alvear and Werling, 1994; Weatherspoon et al., 1996; Weiser et al., 1995). Specifically, the 
sigma-1 receptor agonist (+)-pentazocine increases dopamine synthesis in rat striatum, and this effect is 
prevented with the sigma receptor antagonist 1-(4-fluorophenyl)-4-[4-(5-fluoropyrimidin-2-yl)piperazin-
1-yl]butan-1-ol (BMY-14802) (Booth and Baldessarini, 1991). Moreover, the activation of sigma-1 
receptors results in increased dopaminergic neurotransmission in the striatum (Gonzalez-Alvear and 
Werling, 1994; Gonzalez and Werling, 1997). Another modality by which sigma-1 receptors may 
modulate responses to METH is through the alteration of cellular signaling. Sigma-1 receptors modulate 
a variety of signaling pathways including interactions with protein partners, modulation of ion channel 
function and alterations in signaling cascades relevant to neurotransmission (Su and Hayashi, 2003; Su 
et al., 2010a). Therefore, direct interactions with the sigma-1 receptor, altering dopaminergic 
neurotransmission and modulating signaling relevant to neurotransmission are three distinct modalities 
by which sigma-1 receptor ligands may affect the actions of METH. 
 The expression levels of sigma-1 receptors themselves are also altered after repeated METH 
administration. Increases in sigma-1 receptors, labeled with [3H](+)-pentazocine, in the substantia nigra, 
cerebellum and the frontal cortex, result from repeated METH treatment (Itzhak, 1993). In addition, 
increases in sigma-1 receptor expression have been shown in response to self-administration of METH in 
rats (Hayashi et al., 2010; Stefanski et al., 2004). These results are believed to be indicative of sigma-1 
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receptors playing a distinctive role in the learning and conditioning responses associated with METH 
self-administration (Hayashi et al., 2010).  
 Much less is known about the specific roles of sigma-2 receptors in the actions of METH. This is 
primarily due to the current lack of molecular tools and truly selective ligands targeting sigma-2 
receptors. It is hypothesized however that sigma-2 receptors are involved in many cellular responses 
relevant to the actions of METH, including neurotoxicity (Kaushal and Matsumoto, 2011). It is known 
that sigma-2 receptor activation can result in apoptosis through the modulation of Ca2+ levels from both 
the ER and mitochondria (Cassano et al., 2009; Vilner and Bowen, 2000). Apoptosis elicited by sigma-2 
activation can occur through caspase dependent and/or caspase independent processes (Bowen, 2000; 
Crawford and Bowen, 2002), both of which are implicated in the neurotoxic actions of METH (Cadet and 
Krasnova, 2009).  
 
3.6. Sigma Receptor Ligands as Potential Treatments for Negative Side Effects of METH 
Sigma receptor antagonists have been used in various animal models to mitigate many of the 
negative effects of METH. A synopsis of these results is included below and focuses on physiologic, 
behavioral and toxicity studies involving a variety of sigma receptor ligands and molecular techniques 
specifically targeting sigma-1 receptors. 
 
3.6.1. Locomotor activity studies 
 METH treatment results in acute increases in locomotor stimulatory behavior in rodents and 
these effects are attenuated with pretreatment of the sigma receptor antagonists BD1047 and BD1063 
(Nguyen et al., 2005). Evidence implicating an involvement of sigma-1 receptors in these effects arose 
from genetic knockdown studies. A 40% reduction in sigma-1 receptor expression has been reported in 
the CNS of rodents using antisense oligonucleotides to block the translation of sigma-1 receptors 
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(Matsumoto et al., 2001b), resulting in a marked decrease in METH-induced increases in locomotor 
activity, without affecting basal locomotor activity compared to naïve and mismatch controls (Nguyen et 
al., 2005). Contradictory to these results however, knockout of sigma-1 receptor expression does not 
ameliorate METH-induced hyperactivity (Fontanilla et al., 2009). Sigma-1 knockout mice in these studies 
displayed METH-induced increases in locomotor activity similar to METH treated wild type mice 
(Fontanilla et al., 2009). It is possible that in sigma-1 receptor knockout animals, sigma-2 receptors 
substitute some functionality for sigma-1 receptors and this is the rationale behind the discrepancy in 
results between the knockdown and knockout studies.  
In contrast to the actions of antagonists, SA4503, a selective sigma-1 receptor agonist has 
varying dose-dependent effects on METH-induced locomotor activity, as it can both potentiate and 
attenuate METH-induced increases in locomotor activity (Rodvelt et al., 2011b). SA4503, at a dose of 1 
mg/kg, potentiated METH-induced increases in locomotor activity, whereas 10 and 30 mg/kg 
pretreatments were shown to attenuate METH-induced hyperactivity. It should be noted, however, that 
30 mg/kg also displayed sedative effects on its own (Rodvelt et al., 2011b). Other sigma-1 receptor 
agonists have been shown to not affect basal locomotor activity; therefore, the pattern of data suggests 
that SA4503 may be exerting effects through non-sigma-1 receptor sites at higher dosages (Okuyama et 
al., 1996; Xu and Domino, 1997). Combined, these results provide evidence that sigma-1 receptor 
ligands alter METH-induced locomotor activity, with antagonism generally providing protective effects.    
 
3.6.2. Drug discrimination paradigms  
Sigma receptor ligands have been shown to alter a variety of other METH-induced behaviors in 
addition to hyperactivity. SA4503 potentiates the ability of METH to substitute for cocaine in a drug 
discrimination paradigm in Sprague-Dawley rats (Rodvelt et al., 2011a). The potentiation by SA4503 
resulted in a shift of the dose response curve to the left and an increase in the ED50 of METH in this 
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behavioral paradigm by nearly 200% (Rodvelt et al., 2011a). Interesting to note, is that in this same 
study, d-amphetamine, an amphetamine with low affinity for sigma-1 receptors, also substitutes for 
cocaine; however, these effects are unable to be potentiated with concomitant administration of 
SA4503 (Rodvelt et al., 2011a). These results are indicative of sigma-1 receptor agonism resulting in a 
potentiation of the METH discriminative stimulus response. These results appear to involve sigma-1 
receptors as SA4503 was unable to potentiate the responses to an amphetamine that displays relatively 
little affinity for these receptors. These studies thus provide evidence that sigma-1 receptors are 
involved in the behavioral effects of METH beyond that of locomotor activity.    
SA4503 has also been shown not to substitute for METH in a drug discrimination paradigm using 
rats trained to discriminate between saline and METH (Rodvelt et al., 2011b). However, when rats were 
pretreated with the sigma-1 receptor agonist SA4503 at a dose of 1 mg/kg, there was a significant 
increase in the discriminatory effects of METH in these animals (Rodvelt et al., 2011b). This effect is not 
present when d-amphetamine was used in place of METH, providing further evidence that sigma-1 
receptors are indeed responsible for this effect (Rodvelt et al., 2011b). SA4503 appears to display mixed 
effects in many behavioral paradigms relevant to the actions of METH. Although SA4503 potentiates 
METH discrimination in animals trained to discriminate between saline and cocaine and in animals 
trained to discriminate between saline and METH, it lacks the ability to substitute for METH on its own 
(Rodvelt et al., 2011b). It therefore appears that activation of sigma-1 receptors alone is not sufficient in 
and of itself to substitute for METH and it may be through a modulation of signaling that SA4503 
potentiates these responses.     
 
3.6.3. Behavioral sensitization 
Mixed sigma-1/2 receptor ligands such as (R)-(+)-1-(4-chlorophenyl)-3-[4-(2-methoxyethyl) 
piperazin-1-yl]methyl-2-pyrrolidinone L-tartrate (MS-377), BMY 14802 and 3-(4-(4-cyclohexylpiperazin-
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1-yl)pentyl)-6-flourobenzo[d]thiazol-2(3H)-one (AZ66) have been shown to prevent behavioral 
sensitization induced by METH (Seminerio et al., 2012b; Takahashi et al., 2000; Ujike et al., 1992b). 
Behavioral sensitization is an in vivo experimental paradigm that uses locomotor activity as a 
quantifiable measure of neuroplastic changes in response to repeated treatments of a drug (Chen et al., 
2009; Kalivas and Nakamura, 1999). These studies have provided evidence that sigma receptors are 
involved in the neurological changes associated with the sensitization to METH, however the exact 
mechanisms by which this occurs is currently unclear.  
 
3.6.4. Hyperthermia 
In addition to mitigating METH-induced locomotor activity, sigma receptor antagonists have 
been shown to attenuate the acute physiologic effects of METH. Mixed sigma-1/2 receptor antagonists 
such as AC927, CM156 and SN79 attenuate the hyperthermia elicited by METH, at doses that do not 
alter basal body temperature on their own (Kaushal et al., 2011d; Kaushal et al., 2011f; Seminerio et al., 
2011). Since METH-induced hyperthermia is one of the principal causes of death in METH overdose 
(Bowyer et al., 1994), therapies that can attenuate these potentially fatal increases in body temperature 
have high clinical significance.  
 
3.6.4. Neurotoxicity 
A variety of mixed sigma-1/sigma-2 antagonists have been shown to attenuate markers of 
METH-induced neurotoxicity in animal models. Pretreatment with mixed sigma-1/2 receptor antagonists 
such as AC927, CM156, AZ66 and SN79 mitigate decreases in striatal dopamine and/or serotonin levels, 
as well as reductions in striatal DAT and/or SERT expression, resulting from a neurotoxic regimen of 
METH (Kaushal and Matsumoto, 2011; Kaushal et al., 2012b; Matsumoto et al., 2008; Robson et al., 
2012; Seminerio et al., 2012a; Seminerio et al., 2011). Prior to these studies, BMY 14802, a sigma-1/2 
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receptor antagonist, was shown to attenuate METH-induced dopaminergic neurotoxicity; the effects of 
BMY14802 were initially attributed to its interactions with the dopaminergic system, and it was not until 
the aforementioned data using more selective compounds that the protective effects could be 
attributed to sigma receptors (Terleckyj and Sonsalla, 1994).  
Sigma Receptor Ligand Chemical Structure Chemical Name 
 
AC927 
1-(2-phenethyl)piperidine oxalate 
 
CM156  
3-(4-(4-cyclohexylpiperazin-1-
yl)butyl)benzo[d]thiazole-2(3H)-thione 
 
 
AZ66  
3-(4-(4-cyclohexylpiperazin-1-yl)pentyl)-6-
fluorobenzo[d]thiazol-2(3H)-one 
 
SN79  
6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-
1-yl)butyl)benzo[d]oxazol-2(3H)-one 
Table 3.1. Chemical structures of sigma receptor ligands known to mitigate the neurotoxic effects of 
METH 
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Currently, it is unclear what molecular effects are responsible for the ability of sigma receptor 
antagonists to mitigate the neurotoxic actions of METH. Many of the cellular effects of sigma receptors 
remain a mystery and little work has currently been conducted aimed at determining the molecular 
mechanisms by which sigma receptor antagonists mitigate many of the effects of METH. The purpose of 
the studies included in the remainder of this dissertation are aimed at beginning to delineate the 
mechanisms by which sigma receptor antagonists convey neuroprotective effects against METH using a 
combination of in vivo and in vitro models. The three specific aims of this section are therefore: 
1. Determine if the ability of sigma receptor antagonists to mitigate METH-induced 
dopaminergic neurotoxicity is correlated to their ability to mitigate METH-induced 
hyperthermia.  
2. Determine if a protective sigma receptor antagonist modulates METH-induced PERK-
mediated ER stress in an in vitro model.  
3. Determine if a protective sigma receptor antagonist mitigates METH-induced 
neuroinflammation and glial cell activation in vivo.  
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Chapter 4 
Sigma receptor antagonist attenuation of METH-induced neurotoxicity is 
correlated to body temperature modulation 
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4.1. Introduction 
METH is an addictive psychostimulant whose use results in acute elevations in core body 
temperature (Krasnova and Cadet, 2009). Chronic usage of the drug has been shown to cause 
neurotoxic effects in specific regions of the brain, most notably the striatum in human subjects and 
animal models (Bowyer et al., 1994; Kaushal et al., 2011f; Volkow et al., 2001a). Moreover, METH has 
recently been connected to an increased risk of developing Parkinson’s disease in chronic users 
(Callaghan et al., 2012). METH is currently listed as the second most abused illicit substance worldwide 
and there are no FDA approved pharmacotherapies for treating METH addiction or its other negative 
consequences (Rawson and Condon, 2007).  
 METH is believed to exert its effects through interactions with monoamine transporters and 
vesicular monoamine transporters at nerve terminals (Krasnova and Cadet, 2009). However, recent 
studies suggest METH may produce some of its effects through sigma receptors as pretreatment with 
sigma receptor antagonists attenuates METH-induced hyperthermia and provides neuroprotective 
effects in animal models of METH-induced neurotoxicity (Kaushal et al., 2011f; Matsumoto et al., 2008; 
Seminerio et al., 2011). METH interacts with both subtypes of sigma receptors, denoted sigma-1 and 
sigma-2, at physiologically relevant concentrations (Nguyen et al., 2005). In addition, sigma receptor 
ligands have been shown to modulate dopamine release and signaling pathways relevant to the 
behavioral and physiologic actions of METH (Gonzalez-Alvear and Werling, 1994; Liu et al., 2001).  
 It is believed that METH-induced hyperthermia is a contributing factor to METH-induced 
neurotoxicity (Kiyatkin and Sharma, 2009). There are several agents, however, that have been shown in 
rodent models to ameliorate the neurotoxic effects of METH without a concomitant attenuation of 
hyperthermia (Chipana et al., 2008; Escubedo et al., 2009; Tsuji et al., 2009). It remains unknown 
whether sigma receptor antagonists attenuate METH-induced neurotoxicity without mitigating METH-
induced increases in core body temperature. In two distinct batches of animals, pretreatment with two 
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separate sigma receptor antagonists failed to attenuate METH-induced hyperthermia. These results 
represent deviations from the normal pattern of data previously reported (Kaushal et al., 2011f; 
Matsumoto et al., 2008; Seminerio et al., 2011). Although the specific cause of this deviation remains 
unknown, it afforded the opportunity to determine the relationship between the ability of sigma 
receptor antagonists to attenuate METH-induced hyperthermia and their ability to attenuate METH-
induced dopaminergic neurotoxicity. The purpose of the current study was therefore to determine if 
sigma receptor antagonists are able to mitigate METH-induced dopaminergic neurotoxicity without a 
concomitant attenuation of METH-induced hyperthermia.  
 
4.2. Materials and Methods  
 
4.2.1. Drugs and reagents  
Methamphetamine was purchased from Sigma-Aldrich (St. Louis, MO). N-phenethylpiperidine 
oxalate (AC927) was synthesized by converting the free base N-phenethylpiperidine (Sigma-Aldrich, Inc., 
St. Louis, MO) to the oxalate salt (Maeda et al., 2002). 3-(4-(4-Cyclohexylpiperazin-1-yl)pentyl)-6-
flourobenzo[d]thiazol-2(3H)-one (AZ66) was synthesized as previously described (Seminerio et al., 
2012b). Dopamine Research EIA kits were purchased from Rocky Mountain Diagnostics (Colorado 
Springs, CO).  
 
4.2.2. Animals 
Male, Swiss Webster mice (24-28 g, Harlan, Indianapolis, IN; Frederick, MD) were used for all 
experiments. Animals were housed in groups of five with a 12:12-h light/dark cycle and food/water ad 
libitum. All experiments were performed as approved by the Institutional Animal Care and Use 
Committee at the West Virginia University Health Sciences Center.  
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4.2.3. Treatment procedure 
Mice underwent a repeated dosing experimental paradigm that has previously been shown to 
cause significant dopaminergic neurotoxicity in response to METH in vivo (Kaushal et al., 2011f). All 
treatments and procedures were conducted in the same way. Mice were transported from the animal 
housing facility to the testing area (laboratory) where they were acclimated for at least 1 h prior to 
initiation of experiments. Additionally, all experimental procedures were conducted between the hours 
of 9 AM and 6 PM. The doses for METH (5 mg/kg, i.p.) and the sigma receptor antagonists (10 mg/kg, 
i.p.) were selected based on earlier dose response characterizations (Matsumoto et al., 2008). Mice 
were randomly assigned to one of the following experimental groups: Saline+ Saline; Saline + METH; 
AC927 + Saline; AC927 + METH or AZ66 + Saline; AZ66 + METH. Saline or sigma receptor antagonist 
pretreatments occurred 15 min prior to treatments with either saline or METH. Mice received their 
designated treatment combination a total of four times, once every two hours. Core body temperature 
was recorded one hour after each treatment combination. Recordings were made with a Thermalert TH-
S monitor (Physitemp Instruments Inc., Clifton, NJ). Mice were held at the base of the tail and a probe 
(RET-3) inserted approximately 2.5 cm past the rectum into the colon for 8–10 s until a rectal 
temperature was maintained for 3–4 s. All experiments were conducted at room temperature (20oC). 
 
4.2.4. Striatal dopamine measurements 
Dopamine ELISA kits (Rocky Mountain Diagnostics, Colorado Springs, CO) were used to quantify 
dopamine in the striatum. Briefly, animals were decapitated one week after undergoing treatment. 
Bilateral striatum samples were dissected and immediately flash frozen in liquid nitrogen and stored at -
80oC. Dopamine was measured according to manufacturer’s protocols as previously reported (Kaushal et 
al., 2011f; Matsumoto et al., 2008). METH-induced reductions in striatal dopamine content were used as 
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a marker of METH-induced dopaminergic neurotoxicity in the current study because it correlates well 
with other established markers, such as reductions in striatal dopamine transporter expression and 
tyrosine hydroxylase activity (Albers and Sonsalla, 1995; Kaushal et al., 2011f).  
 
4.2.5. Data analysis  
Body temperature recordings were analyzed using a two-way repeated measures ANOVA 
followed by post-hoc Bonferroni’s analyses. Striatal dopamine measurements were analyzed using a 
one-way ANOVA, followed by post-hoc Tukey’s multiple comparison’s tests. A correlation of average 
body temperatures during the course of the experiment to striatal dopamine content was conducted 
using Pearson’s correlation analysis. All analyses were conducted using GraphPad Prism 5.0 (San Diego, 
CA). P < 0.05 was considered significant for all statistical analyses.  
 
4.3. Results 
A total of four distinct experiments were conducted: two utilizing pretreatments of either saline 
or AC927 (experiments 1A and 1B), and two which utilized pretreatments of either saline or AZ66 
(experiments 2A and 2B). In experiment 1A using AC927, two-way repeated measures ANOVA revealed 
significant differences in core body temperatures at different time points between groups (p < 0.01). 
Post-hoc Bonferroni’s analysis revealed that METH treatment resulted in an increase in core body 
temperature compared to saline-treated animals at time points 2, 3 and 4 (t = 4.22, p < 0.001; t = 6.13, p 
< 0.001; t = 4.95, p < 0.001, respectively). Pretreatment with AC927 in experiment 1A resulted in the 
mitigation of METH-induced hyperthermia at time points 2, 3 and 4 (t = 3.49, p < 0.01; t = 6.02, p < 
0.001; t = 4.61, p < 0.001, respectively) (Figure 4.1.A.). 
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Figure 4.1. Male, Swiss Webster mice were treated with saline (Sal), AC927 (10 mg/kg, i.p.) or AZ66 (10 
mg/kg, i.p.) followed 15 min later with either saline or methamphetamine (METH, 5 mg/kg, i.p.). Each 
mouse received their designated treatment combination at two hr intervals a total of four times. Body 
temperature (BT) was measured one hour after each of the four treatments. (A) METH treatment results 
in a significant increase in core body temperature, attenuated by pretreatment with the sigma receptor 
antagonist AC927 (experiment 1A). *** p < 0.001 vs. Sal/Sal; ## p <0.01, ### p < 0.0001 vs. Sal/METH. 
(B) In a secondary experiment (experiment 1B) pretreatment with AC927 failed to attenuate METH-
induced hyperthermia at any timepoint. ** p < 0.01, *** p <0.001 vs. Sal/Sal. (C) AZ66 pretreatment 
mitigates METH-induced hyperthermia (experiment 2A). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. Sal/Sal; 
# p < 0.05, ## p < 0.01, ### p < 0.001 vs. Sal/METH. (D) AZ66 failed to mitigate METH-induced core body 
temperature increases in a secondary experiment (experiment 2B). ** p < 0.01, *** p < 0.001 vs. Sal/Sal. 
 
 In experiment 1B, it was once again found that METH treatment alone resulted in a significant 
increase in core body temperature as compared to animals receiving saline at time points 2, 3 and 4 (t = 
3.87, p < 0.01; t = 4.00, p < 0.001; t = 5.74, p < 0.001, respectively). Pretreatment in experiment 1B with 
AC927, contrary to experiment 1A, failed to block METH-induced hyperthermia at any time point tested 
(n.s.) (Figure 4.1.B.). One-way ANOVA revealed differences between groups in striatal dopamine content 
in AC927 experiments 1A and 1B (F (4,35) = 14.02, p < 0.0001). Post-hoc analyses with Tukey’s multiple 
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comparison tests revealed that METH treatment resulted in a significant reduction in striatal dopamine 
content as compared to saline (q = 8.87, p < 0.001). Pretreatment with AC927 that mitigated the 
hyperthermic effects of METH was found to attenuate METH-induced striatal dopamine reductions (q = 
6.64, p < 0.001). AC927 pretreatment that failed to attenuate METH-induced hyperthermia was unable 
to mitigate METH-induced striatal dopamine reductions (q = 2.43, n.s.) (Figure 4.2.A.). Further analysis of 
these effects was conducted using a Pearson’s correlation of average core body temperature over the 
course of the experiments and striatal dopamine content. It was found that the average body 
temperature of animals was correlated to striatal dopamine content one week post-treatment (r = -0.66, 
p < 0.0001, r2 = 0.43) (Figure 4.3.A.).  
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Figure 4.2. Male, Swiss Webster mice were treated with saline (Sal), AC927 (10 mg/kg, i.p.) or AZ66 (10 
mg/kg, i.p.) followed 15 min later with either saline or methamphetamine (METH, 5 mg/kg, i.p.). Each 
mouse received their designated treatment combination at two hr intervals a total of four times. Striatal 
tissues were collected from the mice one week post-treatment and dopamine (DA) levels measured. (A) 
AC927 pretreatment that blocks METH-induced hyperthermia (experiment 1A) attenuates METH-
induced dopaminergic toxicity. AC927 that fails to block METH-induced hyperthermia (experiment 1B) 
also fails to mitigate dopaminergic toxicity elicited by METH. *p < 0.05, *** p < 0.001 vs. Sal/Sal; ### p < 
0.001 vs. Sal/METH.  (B) Similar to pretreatment with AC927, AZ66 pretreatment that mitigates the 
hyperthermic effects of METH also blocks METH-induced dopaminergic deficits (experiment 2A). Failure 
to block METH-induced hyperthermia with AZ66 results in a failure to attenuate METH-induced 
dopaminergic deficits (experiment 2B). *p < 0.05, ** p < 0.01 vs. Sal/Sal; ### p < 0.001 vs. Sal/METH. 
 
Two separate experiments utilizing the sigma receptor antagonist AZ66 were also conducted. 
Two-way repeated measures ANOVA revealed differences in core body temperature between groups at 
different time points in experiment 2A utilizing AZ66 (p < 0.0001). Bonferroni’s post-hoc analysis 
revealed that METH treatment significantly increased core body temperature, compared to saline 
treatment at time points 2, 3 and 4 in experiment 2A (t = 5.62, p < 0.001; t = 5.85, p < 0.001; t = 8.23, p < 
0.001, respectively). Pretreatment with AZ66 mitigated METH-induced hyperthermia at all three time 
points (t = 4.98, p < 0.001; t = 7.75, p < 0.001; t = 9.25, p < 0.001; for time points 2, 3 and 4, 
respectively). Additionally, time point 1 significantly differed between these two groups (t = 3.56, p < 
0.01) (Figure 4.1.C.).  
In a second experiment involving AZ66 (experiment 2B), two-way repeated measures ANOVA 
revealed significant differences between groups and different time points (p < 0.0001). Similar to 
experiment 2A, METH treatment resulted in a significant increase in core body temperature as 
compared to saline treatment at time points 2, 3 and 4 (t = 3.66, p < 0.01; t = 4.29, p < 0.001; t = 5.95, p 
< 0.001; respectively). Unlike experiment 2A however, AZ66 pretreatment was found to not attenuate 
METH-induced hyperthermia at any time point tested (n.s.) (Figure 4.1.D.).  
One-way ANOVA revealed significant differences between AZ66 experimental groups 2A and 2B 
in striatal dopamine content (F (4,35) = 16.46, p < 0.0001). Post-hoc Tukey’s analysis revealed that METH 
treatment resulted in a significant reduction in striatal dopamine content as compared to saline treated 
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animals (q = 5.28, p < 0.01). In experiment 2A in which AZ66 mitigated METH-induced hyperthermia, it 
also significantly attenuated the METH-induced reduction in striatal dopamine content (q = 8.12, p < 
0.001). However, in experiment 2B, in which AZ66 pretreatment failed to mitigate METH-induced 
hyperthermia, it also failed to block METH-induced reductions in striatal dopamine content (n.s.) (Figure 
2B). A Pearson’s correlation revealed that the average core body temperature of animals in these two 
experiments was significantly correlated to striatal dopamine content measured one week post 
treatment (r = -0.52, p < 0.001, r2 = 0.27) (Figure 4.3.B.).  
 
Figure 4.3. The ability of sigma receptor antagonists to attenuate METH-induced dopaminergic toxicity is 
correlated to core body temperature. (A) Average body temperatures (Avg BT) of animals during 
experiments utilizing AC927 (experiments 1A and 1B) as compared to striatal dopamine (DA) levels (p < 
0.0001). (B) Average body temperatures (Avg BT) of animals during experiments utilizing AZ66 
(experiments 2A and 2B) as compared to striatal dopamine (DA) content (p < 0.001). 
 
4.4. Discussion 
 This study confirms how large a role core body temperature modulation plays in the ability of 
sigma receptor antagonists to mitigate METH-induced neurotoxicity. Our data unequivocally 
demonstrates that the blockade of METH-induced hyperthermia by sigma receptor antagonists is 
correlated with their ability to attenuate METH-induced dopaminergic neurotoxicity. Moreover, this 
report shows that failure of a sigma receptor antagonist to attenuate METH-induced hyperthermia also 
fails to mitigate the dopaminergic deficit elicited by METH in vivo.  
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The relationship between METH-induced hyperthermia and neurotoxicity has been studied 
extensively in rodent models (Bowyer et al., 1994; Bowyer et al., 1992). High ambient temperatures 
have been shown to exacerbate the neurotoxic effects of METH, and reducing ambient temperatures 
has been shown to reduce the neurotoxic effects of the drug (Bowyer et al., 1994). The precise 
mechanisms by which this occurs are currently unknown and the protective effects do not appear to be 
specifically driven by core body temperature modulation (Albers and Sonsalla, 1995; Bowyer et al., 
1992). Pharmacological reduction of core body temperature with resperine, for example, has been 
shown to not mitigate the neurotoxic effects of METH (Albers and Sonsalla, 1995). Additionally, some 
pharmacologic tools which fail to attenuate METH-induced hyperthermia have been shown to mitigate 
the effects of METH on markers of neurotoxicity (Chipana et al., 2008; Tsuji et al., 2009).  
 Mechanisms by which METH is thought to cause hyperthermia include increased reactive 
oxygen and nitrogen species (ROS/RNS) production, dopamine quinone production, and increased 
release of proinflammatory cytokines that have pyrogenic activity (Krasnova and Cadet, 2009). 
Interestingly, AC927 has been shown to attenuate METH-induced ROS/RNS generation, dopamine 
release and cellular toxicity in vitro (Kaushal et al., 2012a). The ability of selective sigma receptor 
antagonists such as AC927 to modulate dopamine release and therefore signaling events and possible 
reactive dopamine species formation may play a large role in their ability to modulate hyperthermic and 
neurotoxic responses to METH. The ability of selective sigma receptor antagonists such as AC927 and 
AZ66, to modulate these effects in vivo has yet to be determined; however it appears that sigma 
receptor ligands do have the ability to modulate many processes relevant to both the hyperthermic and 
neurotoxic effects of METH.  
While the data supports the idea that in order for sigma receptor antagonists to mitigate 
dopaminergic deficits associated with METH, they must block the hyperthermic effects elicited by METH, 
further studies are needed to conclusively determine if the mitigation of METH-induced hyperthermia is 
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truly a requirement for the blockade of dopaminergic neurotoxicity by sigma receptor antagonists or 
whether sigma receptor antagonists modulate common mediators that drive both hyperthermia and 
neurotoxicity. Experiments in which modulation of ambient temperature is used to study these effects 
have thus far been inconclusive because METH-induced lethality in the positive control group is a major 
limiting factor in rodent models (Bowyer et al., 1994; Seminerio et al., 2011).  
In an alternative approach, an in vitro model of METH-induced neurotoxicity showed that when 
temperature was held constant, sigma receptor antagonists maintain their ability to attenuate the 
cytotoxicity caused by METH (Kaushal et al., 2011a; Kaushal et al., 2011b). Moreover, at higher in vitro 
temperatures, METH-induced cytotoxicity worsened, with sigma receptor antagonists still being able to 
attenuate these responses (Kaushal et al., 2011b). These in vitro studies demonstrate that sigma 
receptor antagonists are capable of mitigating METH-induced cytotoxicity at normal as well as elevated 
ambient temperatures in cell culture (Kaushal et al., 2011b), suggesting that the neuroprotective effects 
of the compounds are not dependent on temperature. This raises the possibility that under in vivo 
conditions, the apparent dependence of the ability of sigma receptor antagonists to mitigate METH-
induced neurotoxicity may stem from sigma-mediated attenuation of mediators common to both 
hyperthermia and neurotoxicity. 
It should be noted that the underlying cause of the differences in response between the 
responsive (experiments 1A and 2A) and unresponsive (experiments 1B and 2B) groups remain 
unknown, with the testing of the groups occurring weeks to months apart. Ambient temperature 
alterations have been shown to alter dopaminergic neurotoxicity in response to neurotoxic METH 
treatment regimens in rodents (Bowyer et al., 1992). Ambient temperature and other environmental 
variables, however, were accounted for in the above described experiments, and no unusual variations 
could be documented. Although all the animals were of the same outbred strain, from the same vendor, 
it is possible that an unidentified genetic variation may have existed between the batches of mice. 
61 
 
Although nothing is known about variations in sigma-2 receptors, splice variants and polymorphisms in 
sigma-1 receptors have been reported, with some ramifications for function (Shioda et al., 2012). 
However, such variations would be expected to be distributed across different batches of mice, rather 
than affecting entire batches as was observed herein.  
Due to the serendipitous nature of this study, only one measure of dopaminergic neurotoxicity 
was used in the current report. However, it should be emphasized that numerous studies have 
confirmed concomitant changes in other markers of dopaminergic neurotoxicity along with changes in 
striatal dopamine levels under conditions similar to those used in the present study (Bowyer et al., 1994; 
Kaushal et al., 2011f). In addition, AC927 has previously been shown to attenuate METH-induced 
decreases in striatal dopamine content, dopamine transporters and striatal serotonin content and 
serotonin transporters in vivo (Matsumoto et al., 2008; Seminerio et al., 2011), suggesting that the 
alterations in striatal dopamine levels measured herein serve as a reasonable marker of METH-induced 
dopaminergic neurotoxicity. The determination as to whether similar trends exist with regards to METH-
induced serotonergic neurotoxicity and other markers of central nervous system toxicity has yet to be 
made.  
In conclusion, the ability of sigma receptor antagonists to mitigate METH-induced neurotoxicity 
is closely associated with their ability to attenuate the hyperthermic effects of METH in vivo. Additional 
studies are warranted to further define the exact role of hyperthermia in the neurotoxic actions of 
METH. Moreover, further investigations are needed to identify the mechanisms through which sigma 
receptor antagonists reduce the hyperthermic and neurotoxic effects of METH, and to determine 
whether the ability of sigma receptor antagonists to mitigate METH-induced neurotoxicity is dependent 
on the modulation of body temperature.     
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4.5. Contributions 
 Matthew Robson, Michael Seminerio, Ph.D. and Jamaluddin Shaikh, Ph.D. conducted in vivo 
body temperature experiments and striatal dopamine measurements.  
 
 
This chapter has previously been published as: 
Robson MJ, Seminerio MJ, McCurdy CR, Coop A, Matsumoto RR. Sigma receptor antagonist 
attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature 
modulation. Pharmacological Reports. 2013. 65(2): 343-349 
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Chapter 5 
AC927 Pretreatment Mitigates METH-Induced Changes in Striatal  
Gene Expression 
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5.1. Introduction 
 METH treatment is known to result in neurotoxicity in striatal regions of the brain, a side effect 
for which there are currently no FDA approved pharmaceutical treatments (Volkow et al., 2001a; 
Volkow et al., 2001b). METH is known to exert several of its effects through the modulation of sigma 
receptors and sigma receptor antagonists have been shown to mitigate the behavioral and physiological 
effects of METH administration in rodent models, including METH-induced neurotoxicity (Matsumoto et 
al., 2008; Nguyen et al., 2005; Seminerio et al., 2011). The molecular mechanisms by which METH results 
in neurotoxicity are currently not entirely elucidated and hypothesized mechanisms are discussed in 
previous chapters. Furthermore, the precise molecular mechanisms by which sigma receptor 
antagonists mitigate the neurotoxic actions of METH are unclear.  
 It is known that METH administration results in changes in gene expression related to cellular 
toxicity in the striatum of rodents administered neurotoxic regimens of the drug (Jayanthi et al., 2001; 
Jayanthi et al., 2009; Kuhn et al., 2006; Thomas et al., 2004b). The determination as to whether sigma 
receptors have a role in METH-induced genetic alterations has yet to be made. Furthermore, the ability 
of sigma receptors to modulate gene expression related specifically to cellular toxicity associated with 
METH has yet to be studied. Therefore, the primary goal of the current study was to determine the 
genetic changes in the striatum that result from the administration of a METH regimen known to result 
in dopaminergic neurotoxicity, and which of these genetic alterations are modulated by pretreatment 
with a selective sigma receptor antagonist known to mitigate METH-induced dopaminergic 
neurotoxicity.  
5.2. Materials and Methods 
5.2.1. Drugs and Reagents 
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Methamphetamine was purchased from Sigma-Aldrich (St. Louis, MO). N-phenethylpiperidine 
oxalate (AC927) was synthesized by converting the free base N-phenethylpiperidine (Sigma-Aldrich, Inc., 
St. Louis, MO) to the oxalate salt (Maeda et al., 2002) 
5.2.2. Animals 
Male, Swiss Webster mice (24-28 g, Harlan, Indianapolis, IN; Frederick, MD) were used for all 
experiments. Animals were housed in groups of five with a 12:12-h light/dark cycle and food/water ad 
libitum. All experiments were performed as approved by the Institutional Animal Care and Use 
Committee at the West Virginia University Health Sciences Center.  
 
5.2.3. Drug Treatments 
Mice underwent a repeated dosing experimental paradigm that has previously been shown to 
cause significant dopaminergic neurotoxicity in response to METH in vivo (Kaushal et al., 2011f). All 
treatments and procedures were conducted in the same way. Mice were transported from the animal 
housing facility to the testing area (laboratory) where they were acclimated for at least 1 h prior to 
initiation of experiments. Additionally, all experimental procedures were conducted between the hours 
of 9 AM and 6 PM. The doses for METH (5 mg/kg, i.p.) and AC927 (10 mg/kg, i.p.) were selected based 
on earlier dose response characterizations (Matsumoto et al., 2008). Mice were randomly distributed for 
each experiment into one of four treatment groups: 1) Saline/Saline (0.1 ml/10 g body weight), 2) 
Saline/METH 5 mg/kg, 3) AC927 10 mg/kg/Saline, or 4) AC927 10 mg/kg/METH 5 mg/kg. The first 
compound listed in each pair (Saline or AC927) was administered intraperitoneally (i.p.) as a 
pretreatment 15 min prior to the second compound in each treatment group (Saline or METH, i.p.). Each 
animal underwent four pretreatments/treatments at 2 h intervals as previously described (Kaushal et 
al., 2012b). Animals were sacrificed 6 h post-treatment (time after last injection), brains removed and 
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bilateral striatum samples excised, flash frozen using liquid nitrogen and then stored at -80o C for future 
use.  
 
5.2.4. RNA Isolation and Microarray 
Total RNA was then extracted from flash frozen striatum samples using Trizol reagent 
(Invitrogen, Grand Island, NY) according to manufacturer’s instructions. The total RNA concentration for 
each sample was quantified by spectral absorption, and the purity of the sample checked to confirm 
that the 260/280 ratio was in the range of 1.8-2.1. Additionally, RNA was quantified using a Nanodrop 
(Fisher Scientific, Pittsburgh, PA). The RNA quality was checked on a Bioanalyzer (Agilent, Santa Clara, 
CA). Two hundred fifty ng of each RNA sample was processed using the Ambion WT Expression Kit 
(Grand Island, NY) according to the manufacturer’s instructions. The typical yield from a WT Expression 
Kit reaction was 6-9 μg of cDNA. The required amount of cDNA (5.5 μg) was processed for fragmentation 
and biotin labeling using the Gene Chip WT Terminal Labeling Kit (Affymetrix, Santa Clara, CA). The 
efficiency of each fragmentation reaction was checked via Agilent Bioanalyzer. The entire reaction of 
fragmented and biotin-labeled cDNA (50 μl) with added hybridization controls was hybridized to the 
mouse GeneChip 1.0 ST Exon Arrays (Affymetrix) at 45 C for 17 h in a GeneChip Hybridization Oven 640 
(Affymetrix).  Mouse GeneChip 1.0 ST Exon Arrays were stained using the FS 450_0001 protocol in a 
GeneChip Fluidics Station 450 (Affymetrix). Briefly, biotin-labeled cDNA was reacted using two rounds of 
washes with a solution containing a streptavidin-phycoerythrin complex, with an intermediate 
treatment of biotin-labeled anti-streptadvidin antibody to amplify the signal. Phycoerythrin labeling was 
detected within the Affymetrix GeneChip Scanner 3000 7G plus using 532 nm light and detected by a 
photomultiplier tube. Expression Consol software (Affymetrix) was used to check quality controls of 
hybridized chips. 
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5.2.5. Data Analysis 
 Microarray results were analyzed using ANOVA, in combination with either a fold change 
greater than 2 for all genes or a false discovery rate (FDR) correction. p < 0.05 was considered 
statistically significant for all studies contained within this chapter.  
 
5.3. Results 
5.3.1. p < 0.05 and fold change greater than 2 
Striatal gene changes elicited by METH treatment that were blocked by AC927 pretreatment through 
first analysis method are listed below. 
Gene Symbol Reference  
Sequence 
p-value(M 
vs. Sal) 
Fold-
Change(
M vs. Sal) 
p-value(AM 
vs. AC) 
Fold-
Change(AM 
vs. AC) 
Lilrb4 NM_013532 0.00180553 9.69286 0.0741054 2.76968 
Gfap NM_001131020 0.000949219 3.11686 0.0339675 1.7703 
Ch25h NM_009890 0.00626758 2.7104 0.11481 1.61622 
Slc14a1 NM_001171010 0.000116953 2.22542 0.00289043 1.62514 
Hectd2 NM_001163471 2.94E-05 2.14606 0.000123207 1.86743 
Rasl11b NM_026878 0.00141089 2.09226 0.0385694 1.4663 
Pde1a NM_001159582 0.0419207 2.08911 0.26192 1.44428 
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Nudt10 NM_001031664 0.000615864 2.06335 0.0439124 1.37452 
Cd44 NM_009851 6.81E-05 2.06329 0.00149471 1.57639 
Id2 NM_010496 0.000844173 2.04379 0.0441542 1.38998 
Olfr20 NM_146923 0.0298164 2.0244 0.711642 1.10785 
Stc1 NM_009285 0.00103342 -2.01013 0.0264272 -1.45948 
Olfr1480 NM_207575 0.00267988 -2.07149 0.35788 -1.18046 
Olfr1501 NM_146633 0.0377525 -2.14437 0.57827 -1.19457 
Ahcy NM_016661 0.00735228 -2.24096 0.365986 1.24225 
Slc39a1 NM_013901 0.0329088 -2.31698 0.943762 1.02404 
5930434B04Rik ENSMUST00000114005 0.00262656 -2.37444 0.444594 -1.17565 
Fthl17 NM_031261 0.02022 -2.78129 0.573186 1.23113 
Zfp617 NM_133358 0.0353633 -2.79772 0.896814 -1.05599 
Lce3b NM_025501 0.0197789 -3.02109 0.37619 1.4287 
Zc3h3 NM_172121 0.01694 -3.06143 0.686689 -1.16855 
Ttr NM_013697 0.0456178 -4.04402 0.755256 1.21 
 
Table 5.1. List of genes obtained through ANOVA and fold change greater than 2 analysis. Genes 
contained within table were shown to be modulated by METH treatment and these effects were 
mitigated by pretreatment with the protective sigma receptor antagonist AC927. Sal = Saline/Saline, M = 
Sal/METH 5 mg/kg, AC = AC927 10 mg/kg/ Sal, AM = AC927 10 mg/kg/ METH 5 mg/kg. 
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5.3.2. p < 0.05 and false discovery rate (FDR) correction analysis 
 Genetic changes that were blocked by AC927 treatment when analyzed using ANOVA and FDR 
correction are listed below.  
Gene Symbol 
 
Reference 
Sequence 
p-value (M 
vs. Sal) 
Fold-Change 
(M vs. Sal) 
p-value (AM 
vs. AC) 
Fold-Change 
(AM vs. AC) 
Osmr NM_011019 0.0001927 4.13795 0.00159139 2.78749 
Nptx1 NM_008730 0.00035427 2.38875 0.000797363 2.15714 
Slc14a1 NM_001171010 0.00011695 2.22542 0.00289043 1.62514 
Cd44 NM_009851 6.81E-05 2.06329 0.00149471 1.57639 
Hbegf NM_010415 0.00036405 1.99337 0.0006412 1.8827 
Adamts1 NM_009621 0.00035377 1.93685 0.000527136 1.8631 
Mtmr11 NM_181409 0.0003504 1.89723 0.000823128 1.75354 
Acvr2a NM_007396 5.50E-05 1.88613 0.000268993 1.65707 
Zfp131 NM_028245 8.51E-06 1.85103 0.000305029 1.45181 
Plek NM_019549 0.00026016 1.83277 0.00290717 1.51095 
Msn NM_010833 0.00033894 1.70161 0.014071 1.32184 
Pdzrn3 NM_018884 0.00013631 1.68695 0.00483103 1.34463 
Hsph1 NM_013559 0.00014295 1.6495 0.00640477 1.31097 
Khdrbs3 NM_010158 3.56E-05 1.62341 0.000277688 1.43521 
Tlr13 NM_205820 0.00030646 1.57293 0.000837112 1.4745 
Tubb6 NM_026473 0.0002387 1.56219 0.00030785 1.5366 
Scg2 NM_009129 0.00035852 1.53699 0.000758903 1.46687 
Cdh11 NM_009866 0.00024785 1.52405 0.000535637 1.45532 
70 
 
Slc35f5 NM_028787 0.00034225 1.51268 0.701781 1.028 
Cd68 NM_009853 4.71E-05 1.5039 0.000457272 1.34113 
Slc3a2 NM_001161413 3.19E-05 1.50293 0.00490767 1.20625 
Rheb NM_053075 0.00014106 1.49405 0.00693648 1.23805 
C1galt1 NM_052993 0.00023449 1.47929 0.00350786 1.28942 
Ptgfrn NM_011197 0.00021078 1.44497 0.00312876 1.27127 
Irf8 NM_008320 0.00036992 1.4294 0.00449511 1.26797 
Aox1 NM_009676 0.00034196 1.42651 0.00316922 1.28185 
Ppm1l NM_178726 0.00034436 1.3953 0.00211272 1.28392 
Npl NM_028749 0.00026462 1.38622 0.000305569 1.37667 
Zdhhc2 NM_178395 0.00016223 1.38348 0.0588858 1.11358 
Tmem87a NM_173734 0.00023935 1.37237 0.922154 -1.0051 
Atg2b NM_029654 0.00026218 1.35215 0.00555849 1.20101 
Grip1 NM_028736 0.00015675 1.30055 0.000197567 1.28927 
Rab3gap2 NM_001163754 0.00035057 1.28556 0.160574 1.06773 
Ptpn12 NM_011203 8.80E-05 1.27151 0.000258994 1.22809 
Stt3b NM_024222 2.53E-05 1.26962 0.00626664 1.10704 
Pfkp NM_019703 0.00018972 1.26258 0.0130746 1.12083 
Pdia4 NM_009787 0.00019396 1.26097 0.000795363 1.20601 
Stt3a NM_008408 0.00033717 1.22312 0.443214 -1.02762 
Eif3b NM_133916 0.00013736 1.21472 0.00415003 1.12003 
L3mbtl3 NM_172787 5.93E-05 1.17696 0.0201281 1.0634 
Mrps5 NM_029963 1.47E-05 1.09198 0.478552 -1.00707 
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Dennd1a NM_146122 0.00011191 -1.12406 0.140571 -1.02768 
Spen NM_019763 0.00013004 -1.12638 0.292816 1.01973 
Sf1 NM_001110791 0.000196 -1.12755 0.0128729 1.06099 
Shank3 NM_021423 0.00028295 -1.13448 0.608111 -1.01106 
Ampd2 NM_028779 0.00010417 -1.14633 0.0215159 -1.0565 
Rhot2 NM_145999 0.00013083 -1.15318 0.367114 -1.02008 
Dlgap3 NM_198618 0.00028162 -1.15459 0.0147093 1.07542 
Fads1 NM_146094 0.00013968 -1.15721 0.00293909 -1.0949 
Pqbp1 NM_019478 0.00028344 -1.16095 0.0053691 -1.09664 
Vegfb NM_011697 0.00021857 -1.16114 0.0655957 -1.05137 
Cabc1 NM_023341 0.00012736 -1.16304 0.000884201 -1.11951 
Mmab NM_029956 0.0001297 -1.16533 0.0034468 -1.09572 
Clptm1 NM_019649 7.95E-05 -1.16895 0.0111738 -1.07211 
Ranbp10 NM_145824 0.00036617 -1.18075 0.0267285 1.0794 
Srrm2 NM_175229 1.40E-05 -1.18108 0.023722 -1.05082 
Phf12 NM_174852 3.07E-05 -1.18255 0.014224 -1.06428 
Sphk2 NM_203280 0.00020608 -1.19402 0.211459 1.03826 
Bcorl1 NM_178782 0.00014795 -1.19507 0.000321274 -1.17235 
Gnb2 NM_010312 0.00023138 -1.19538 0.200889 -1.04024 
Ptpn5 NM_001163565 9.09E-05 -1.19737 0.836896 -1.00532 
Eps15l1 NM_007944 5.85E-05 -1.19764 0.00597495 -1.09097 
Hexdc NM_001001333 0.00013112 -1.20473 0.000636658 -1.15857 
1810031K17Rik BC013714 0.0003549 -1.20725 0.0120652 -1.10827 
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Slc25a37 NM_026331 0.00034177 -1.2161 0.00641494 -1.12782 
Mink1 NM_001045959 5.86E-05 -1.2188 0.0245697 -1.07379 
Mapk4 NM_172632 0.00035993 -1.22172 0.0265024 -1.09641 
Med16 NM_198107 0.00019771 -1.22888 0.086139 -1.06448 
Grin1 NM_001177656 3.37E-05 -1.23253 0.00689277 -1.09524 
Sh3bgrl3 NM_080559 0.00023163 -1.24354 0.9106 1.00401 
Lrch4 NM_146164 0.00024427 -1.24626 0.199928 -1.0504 
Mllt6 NM_139311 0.00026901 -1.25335 0.442613 -1.03002 
Smarcd1 NM_031842 1.96E-05 -1.25533 0.000648623 -1.14734 
Haghl NM_026897 0.00029796 -1.26519 0.000254525 -1.27226 
Rin1 NM_145495 5.43E-05 -1.2705 0.15695 -1.04936 
Epha6 NM_007938 1.42E-05 -1.27262 0.000795612 -1.14455 
Efnb2 NM_010111 0.00029619 -1.27495 0.0601893 -1.09132 
Lmo2 NM_008505 0.00014984 -1.28077 0.00505848 -1.15127 
Syt9 NM_021889 2.37E-06 -1.28587 0.000194487 -1.14722 
Icam5 NM_008319 3.70E-05 -1.28657 0.00715915 -1.1166 
Zmynd10 NM_053253 0.00022291 -1.28681 0.0841946 -1.08155 
Axin2 NM_015732 0.00027593 -1.28709 0.000528035 -1.25715 
Stxbp2 NM_011503 0.00018301 -1.29275 0.00418683 -1.16852 
Slc22a8 NM_031194 0.00015181 -1.29613 0.0420327 -1.09801 
Raver2 NM_183024 0.0001222 -1.29839 0.00531884 -1.15374 
Shkbp1 NM_138676 5.64E-05 -1.30145 0.415263 -1.02975 
Phyhip NM_145981 0.00019558 -1.30592 0.0194023 -1.12798 
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S1pr1 NM_007901 9.75E-05 -1.30978 0.000922063 -1.2127 
Cyp2j9 NM_028979 0.0003406 -1.31476 0.0143913 -1.1538 
Sez6 NM_021286 8.85E-05 -1.32525 0.0259069 -1.11188 
Hdac11 NM_144919 1.73E-05 -1.35094 0.00950187 -1.1188 
Reep6 NM_139292 0.00035315 -1.35192 0.0138459 -1.17327 
Rgs14 NM_016758 0.00017402 -1.35962 0.0114328 -1.16485 
Wasf1 NM_031877 9.53E-06 -1.36059 0.00145494 -1.15995 
Gm996 NM_001005424 0.00033003 -1.36086 0.00256347 -1.24889 
Zdhhc12 NM_025428 0.00020453 -1.36483 0.0323279 -1.13343 
Prodh NM_011172 0.00014486 -1.37179 0.00244581 -1.2259 
Scn4b NM_001013390 0.00023462 -1.37682 0.000852337 -1.30052 
Mfge8 NM_008594 2.08E-05 -1.37831 0.000692342 -1.21349 
Coro7 NM_030205 6.67E-05 -1.38432 0.00279585 -1.20125 
Sepw1 NM_009156 1.82E-05 -1.40384 0.0253801 -1.1086 
Dbn1 NM_001177371 2.11E-05 -1.40845 0.00858213 -1.14334 
Tmem180 NM_029186 0.00014683 -1.42698 0.000279983 -1.38194 
Usp2 NM_198092 0.00014512 -1.42989 0.00221837 -1.26405 
Gli3 NM_008130 0.00022823 -1.43065 0.556116 -1.03543 
4931432E15Rik AK016500 0.00024738 -1.44531 0.0204267 -1.18537 
Cbx4 NM_007625 8.89E-05 -1.45169 0.00311063 -1.23961 
Dbp NM_016974 6.72E-05 -1.46159 0.00904331 -1.18824 
Adora2a NM_009630 9.53E-05 -1.4806 0.000225044 -1.41427 
Scube3 NM_001004366 7.74E-05 -1.48138 0.000674508 -1.33039 
74 
 
Ido1 NM_008324 8.60E-05 -1.491 0.000193323 -1.42693 
2310034C09Rik NM_054100 0.00021332 -1.53469 0.0723369 -1.14898 
Prosapip1 NM_197945 4.22E-05 -1.54302 0.00484289 -1.23125 
Abca9 NM_147220 0.00014309 -1.55893 0.000478416 -1.44957 
Actn2 NM_033268 0.00028576 -1.60686 0.00746275 -1.31761 
Id4 NM_031166 4.63E-05 -1.63309 0.000237216 -1.47458 
Cml5 NM_023493 0.00010866 -1.70492 0.000352385 -1.56697 
Xkrx NM_183319 0.00029446 -1.78082 0.0107005 -1.36877 
Fzd2 NM_020510 9.62E-05 -1.98053 0.0703235 -1.22046 
 
Table 5.2. List of genes obtained through ANOVA and FDR correction analysis. Genes contained within 
table were shown to be modulated by METH treatment and these effects were mitigated by 
pretreatment with the protective sigma receptor antagonist AC927. Sal = Saline/Saline, M = Sal/METH 5 
mg/kg, AC = AC927 10 mg/kg/ Sal, AM = AC927 10 mg/kg/ METH 5 mg/kg. 
 
5.4. Discussion 
 Data contained within the current chapter provides evidence that treatment with the selective 
sigma receptor antagonist AC927 mitigates specific gene changes associated with neurotoxic METH 
treatment in a rodent model. These genetic changes may be associated with the ability of AC927 and 
other sigma receptor antagonists to mitigate dopaminergic neurotoxicity associated with METH 
treatment in rodents.  
 Some of the genes included within the current lists have previously been shown to be increased 
by METH treatment (Thomas et al., 2004b). Many of the genes are known to be associated with 
neuroinflammatory processes, including gfap, cd68, cd44, and osmr (Baker et al., 2008; Hebert and 
O'Callaghan, 2000; Nakashima et al., 1999). These results provide initial evidence that AC927 treatment 
75 
 
is associated with a reduction in neuroinflammation that is associated with neurotoxic METH treatment. 
A much more thorough and in depth collection of studies on the role of sigma receptor antagonists in 
mitigating METH-induced neuroinflammation is included in subsequent chapters of the current 
dissertation.  
It should be emphasized that many of the genes included in the current lists are related to 
processes other than neuroinflammation. An analysis determining the role of many of these genes in 
various pathways and cascades associated with neuronal injury has yet to be conducted and it is 
possible that many of the genes above are involved in pathways associated with neurotoxicity. 
Furthermore, a comparison with microarray studies previously conducted and published aimed at 
determining the role of sigma-1 receptors in modulating gene expression has yet to be conducted (Tsai 
et al., 2012). A full comparison of gene alterations between this previous study and the current data set 
may provide further insight into which of the gene changes present within the current data set are 
mediated specifically through sigma-1 receptor modulation or whether sigma-2 receptors appear to be 
involved in modulating METH-induced genetic changes (Tsai et al., 2012).  
Additionally, data contained within this chapter is representative of one time point after the 
administration of drug treatments. The genetic alterations determined within the current data set may 
not be representative of different time points after drug treatments and subsequent time courses 
should be run for further characterization of genetic changes that may be associated with the ability of 
sigma receptor antagonists to mitigate the neurotoxic effects of METH.  
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5.5. Contributions 
 Matthew Robson conducted all in vivo experiments and RNA isolations. Wioletta Szeszel-
Fedorowicz, Ph.D. conducted the microarray experiments and Donquan Chen, Ph.D. analyzed all 
microarray data.  
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Chapter 6 
METH causes PERK-mediated endoplasmic reticulum stress in NG108-15 cells 
through a mechanism independent of sigma receptors 
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6.1. Introduction 
Chronic METH usage is associated with neurotoxicity in specific regions of the brain such as the 
striatum (Volkow et al., 2001b; Wang et al., 2004). These toxic consequences are believed to result in 
functional cognitive deficits and an increased risk of developing Parkinson’s disease (Callaghan et al., 
2010; Callaghan et al., 2012; Volkow et al., 2001b). Additionally, it has been shown that patients with 
greater nerve terminal degeneration have higher rates of relapse (Wang et al., 2012). Compounding 
these problems is the current paucity of viable pharmacotherapies aimed at treating the neurotoxic 
effects of METH usage.  
The precise molecular mechanisms by which METH results in neurotoxicity are still being fully 
elucidated. One hypothesis is that signaling cascades associated with mitochondrial and endoplasmic 
reticulum (ER) function become disrupted and result in the initiation of signaling associated with cellular 
toxicity (Jayanthi et al., 2004; Krasnova and Cadet, 2009). Excesses of unfolded proteins, reactive oxygen 
species and reactive nitrogen species (ROS/RNS) and/or disruptions in inter-ER Ca2+ levels can disrupt ER 
function and result in the induction of ER stress signaling (Tabas and Ron, 2011).  
The initiation of ER stress results in signaling through three distinct pathways, namely the 
activating transcription factor 6 (ATF6), inositol-requiring enzyme 1α (IRE-1α) and PKR-like ER kinase 
(PERK) pathways (Ron and Walter, 2007; Walter and Ron, 2011). The induction of these pathways results 
in gene and protein expression alterations aimed at counteracting the ER stressor, whereas severe or 
prolonged ER stress results in the induction of apoptosis and cell death (Tabas and Ron, 2011). The PERK 
pathway is of particular importance as it mediates several crucial aspects of ER stress (Figure 5.1.).  
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Figure 6.1. PERK-mediated ER stress pathway. Unfolded protein load and other ER perturbations result 
in the homodimerization of PERK at the ER membrane. Phosphorylated PERK, then phosphorylates 
eIF2α, halting translation and activating ATF4 to cause the transcriptional upregulation of genes aimed 
at counteracting the perturbations present within the ER. If ER stressor persists, CHOP signaling can 
result in the activation of pathways relevant to apoptosis. 
 
Initially, homodimerization and phosphorylation of PERK halts protein translation within the cell 
through the phosphorylation of eukaryotic initiation factor-2α (eIF2α) to counteract unfolded protein 
load within the ER (Walter and Ron, 2011). Secondly, transcriptional upregulation of transcription 
factors such as activating transcription factor 3 (ATF3) and activating transcription factor 4 (ATF4) induce 
the upregulation of genes aimed at counteracting increases in unfolded protein load (Walter and Ron, 
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2011). Additionally, PERK activation of ATF4 is a requirement for the upregulation of C/EBP homologous 
protein (CHOP) (Szegezdi et al., 2006). CHOP is believed to be a primary mediator of ER stress-induced 
apoptosis and has been implicated as a mediator of dopaminergic neurotoxicity (Gorman et al., 2012; 
Silva et al., 2005).  
The induction of ER stress by METH has been reported in regions of the brain affected by METH 
neurotoxicity (Beauvais et al., 2011; Hayashi et al., 2010; Jayanthi et al., 2009). Specifically, the 
upregulation of genes involved in PERK-mediated ER stress signaling such as atf3, atf4, chop and protein 
phosphatase 1 regulatory subunit 15A (gadd34) was found along with a concomitant increase in CHOP 
protein levels (Beauvais et al., 2011). Importantly, it appears that CHOP upregulation is correlated with 
the neurotoxic actions of METH, as METH fails to upregulate CHOP in the absence of neurotoxicity 
(Takeichi et al., 2012). These results provide evidence that the induction of PERK-mediated ER stress 
may be associated with the neurotoxic actions of METH in vivo; however, systematic studies linking 
PERK-mediated ER stress to the neurotoxic actions of METH are currently lacking.  
Sigma receptors have been proposed as potential targets for therapies aimed at treating the 
neurotoxic effects of METH. Sigma receptor antagonists, including 6-acetyl-3-(4-(4-(4-
fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), have been shown to attenuate 
METH-induced neurotoxicity in vivo and in vitro by an as of yet unknown signaling mechanism (Kaushal 
et al., 2012a; Kaushal et al., 2012b; Matsumoto et al., 2008). Currently, there are two known subtypes of 
sigma receptors, denoted sigma-1 and sigma-2. Sigma-1 receptors are ligand-activated ER chaperone 
proteins that reside at the mitochondrial associated ER membrane (Hayashi and Su, 2007b). 
Overexpression and knockdown of sigma-1 receptors has been shown to modulate cellular responses to 
ER stress in vitro, including phosphorylation levels of PERK elicited by an ER stressor (Hayashi and Su, 
2007b).  
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The ability of sigma-1 receptors to modulate ER stress responses led us to hypothesize that the 
ability of sigma receptor antagonists to mitigate METH-induced cellular toxicity may be due to an ability 
to modulate PERK-mediated ER stress elicited by the drug. The purpose of the current study was 
therefore to determine if METH causes PERK-mediated ER stress in an in vitro model of METH 
neurotoxicity and to determine if pretreatment with the prototypic sigma receptor antagonist, SN79 
mitigates METH-induced PERK-mediated ER stress.  
 
6.2. Materials and Methods 
 
6.2.1. Reagents and chemicals  
Phosphate-buffered saline (PBS), Dulbecco’s modified Eagle’s medium (DMEM), 
penicillin/streptomycin solution, hypoxanthine/aminopterin/thymidine (HAT) and TRIzol lysis reagent 
were obtained from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS), dimethylsulfoxide (DMSO), 
methamphetamine-HCl, Trizma base, glycine, sodium dodecyl sulfate (SDS) and tris-buffered saline (TBS) 
with Tween 20 were obtained from Sigma-Aldrich Chemicals (St. Louis, MO). Isopropanol and methanol 
were purchased from Fisher Scientific (Pittsburgh, PA). SN79 was synthesized in the laboratory of Dr. 
Christopher R. McCurdy (University of Mississippi), as previously described (Kaushal et al., 2011e).  
 
6.2.2. Cell culture 
The neuroblastoma X glioma hybridoma NG108-15 cell line was obtained from American Type 
Culture Collection (Manassas, VA) and cultured as previously described (Kaushal et al., 2012a). Briefly, 
cells were maintained in 75 cm2 (T75) culture flasks (Costar; Corning Life Sciences, Lowell, MA) at 37oC in 
high glucose DMEM with 10% FBS, penicillin/streptomycin and HAT in a humidified incubator containing 
5% CO2. Cells were plated and grown in complete medium in 12-well CellBind tissue culture plates 
82 
 
(Costar; Corning Life Sciences) for all quantitative real-time polymerase chain reaction (PCR) studies and 
6-well CellBind tissue culture plates for protein level analysis. Cells were allowed to become 
approximately 80% confluent and medium was replaced with differentiation medium (DMEM containing 
0.5% FBS, penicillin/streptomycin, HAT and 1% DMSO) and cells were allowed to differentiate for an 
additional 3-4 days prior to undergoing respective treatments.  
 
6.2.3. Real-time PCR  
Differentiated NG108-15 cells cultured as described above underwent respective treatments 
and RNA isolations were conducted by removing media and adding TRIzol cell lysis reagent to extract 
total RNA according to manufacturer’s instructions (Invitrogen, Carlsbad, CA). For antagonist 
experiments, cells were treated with either vehicle (media) or SN79 (100 nM) 15 min prior to adding 
METH (1000 μM). The METH concentration was determined from previous toxicity experiments using 
differentiated NG108-15 cells (Kaushal et al., 2012a) and current dose response studies specifically 
related to ER stress. SN79 concentration (100 nM final concentration) was selected based on  prior 
experiments utilizing this compound and cell line in which SN79 was shown to block cellular toxicity to 
METH at a large range of concentrations in differentiated NG108-15 cells (Kaushal et al., 2011c).    
The quality and quantity of RNA was assessed using a spectrophotometer (Biochrom, 
Cambridge, UK). To synthesize cDNA, 1 μg of RNA was used in conjunction with high capacity 
Superscript-H cDNA reverse transcription kits (Applied Biosystems, Foster City, CA). Respective cDNA 
was then used as a template for TaqMan quantitative real-time PCR with oligonucleotide primer sets 
specific for 18S rRNA (Hs99999901_s1) as an endogenous control and ATF3 (Mm00476032_m1), ATF4 
(Mm00515324_m1), CHOP (Mm00492097_m1) and GADD34 (Mm01205601_g1) (Applied Biosystems, 
Foster City, CA) as PERK-mediated ER stress gene targets. All samples were run using TaqMan real-time 
PCR universal master mixture (Applied Biosystems) for a total of 45 cycles using a StepOnePlus real-time 
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PCR system (Applied Biosystems). The difference in cycles to threshold for each sample as compared to 
the respective 18S endogenous control for each sample was recorded. Threshold was set at 0.2 for all 
gene probes tested. The change in the difference in cycles to threshold method (ΔΔCT  method) was used 
to calculate relative quantities of each gene in each respective sample obtained from NG108-15 cells. 
  
6.2.4. Western blots  
Differentiated NG108-15 cells cultured and treated as described above underwent protein 
isolations using TRIzol cell lysis reagent according to manufacturer’s instructions (Invitrogen). The 
protein concentration of each sample was measured using a Coomassie Plus Bradford Assay Kit (Pierce, 
Rockford, IL) which is based upon a modified form of the Bradford assay (Bradford, 1976). Samples were 
run using 30 μg of protein/well using Tris-HCl 12% pre-cast 15-well gels (Bio-Rad, Hercules, CA) in 
combination with 5X Lammeli sample buffer. Gels were run using a mini-PROTEAN system (Bio-Rad) and 
gels were equilibrated for 15 min in Towbin’s buffer prior to transfer to polyvinylidene fluoride (PVDF) 
membranes (Bio-Rad) using semi-dry electrophoretic transfer cells (Bio-Rad). Membranes were blocked 
using 5% fat-free milk/TBS-T for 2 h at room temperature. Membranes were incubated with primary 
CHOP antibody (Cell Signaling, Danvers, MA) at a concentration of 1:1,000 overnight at 4oC. Anti-rabbit 
IgG horseradish peroxidase (HRP)-linked antibody (Cell Signaling) was used at a concentration of 1:2,000 
with gentle shaking for 2 h. Imaging was conducted using LumiGLO chemiluminescent substrate (Cell 
Signaling) according to manufacturer’s instructions. HRP-conjugated β-actin rabbit mAB (Cell Signaling) 
was used as an endogenous control for all respective samples at a concentration of 1:10,000 and 
incubated for a period of 1 h. Molecular weight determination was conducted using a biotinylated 
protein ladder (Cell Signaling). Images were converted to 8-bit and analyzed using densitometry with 
background subtraction and normalized to β-actin using ImageJ software (NIH; 
http://rsbweb.nih.gov/ij/).  
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6.2.5. Statistical analysis  
Statistical analysis consisted of one-way or two-way analysis of variance (ANOVA), followed by 
post hoc Tukey’s or Bonferroni’s test where applicable using GraphPad Prism 5 (GraphPad Software, San 
Diego, CA). 
 
6.3. Results 
 
6.3.1. METH treatment results in transcriptional upregulation of PERK-mediated ER stress genes 
 METH treatment dose-dependently increased the expression of PERK-mediated ER stress genes 
at all three time points tested (6, 12, and 24 h). Two-way ANOVA revealed that METH treatment 
resulted in a dose dependent difference in atf3 mRNA expression (p < 0.0001). Post hoc Bonferroni’s 
analysis revealed that METH treatment increased atf3 expression at 6 h, at concentrations of 300 and 
1000 μM (t = 4.41, p < 0.001 and t = 7.58, p < 0.001, respectively). Additionally, atf3 mRNA expression 
was elevated at 12 and 24 h post-treatment at these two concentrations (t = 3.18, p < 0.05,  t = 4.17, p < 
0.01 and t = 5.19, p < 0.001, t = 6.27, p < 0.001 for 300 and 1000 μM at 12 and 24 h, respectively) (Figure 
6.2.A.).  
METH treatment also resulted in significant dose and time dependent increases in atf4 mRNA 
expression. Two-way ANOVA revealed significant differences in atf4 expression as a result of 
concentration, time and their interaction (p < 0.0001, p < 0.001 and p < 0.05, respectively). Bonferroni’s 
post hoc tests revealed that METH treatment, at concentrations of 300 and 1000 μM, significantly 
increased atf4 mRNA expression at 6 h (t = 3.99, p < 0.01 and t = 9.33, p < 0.001, respectively), as 
compared to vehicle-treated controls. In addition, METH 1000 μM resulted in significant increases in 
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atf4 mRNA expression 12 and 24 h post-treatment (Figure 6.2.B.) (t = 4.27, p < 0.001 and t = 8.50, p < 
0.001, respectively).  
 
 
Figure 6.2. METH treatment causes an upregulation of genes involved in PERK ER stress in NG108-15 
cells. (A) METH increases atf3 mRNA expression at 6, 12 and 24 hrs post treatment (*p < 0.05, **p < 
0.01, ***p < 0.001; vs. vehicle control). (B) METH treatment causes a significant upregulation of atf4 
mRNA expression at 6, 12 and 24 hrs post-treatment (**p < 0.01, ***p < 0.001; vs. vehicle control). (C) 
METH treatment results in significant upregulation of chop, a gene implicated in ER stress-induced 
apoptosis at all three time points as compared to vehicle treated controls (*p < 0.05, ***p < 0.001). (D) 
gadd34 expression, another PERK-mediated ER stress gene, was upregulated by METH 6, 12 and 24 hrs 
post-treatment (*p < 0.05, ***p < 0.001; vs. vehicle control). 
 
METH treatment also increased the expression of chop, a downstream mediator of the PERK ER 
stress pathway. Two-way ANOVA revealed a significant dose and time effect of METH treatment on chop 
expression, as well as their interaction (p < 0.0001, p < 0.01 and p < 0.001, respectively). Bonferroni’s 
post hoc analysis revealed that METH treatment at concentrations of 300 and 1000 μM increased chop 
mRNA expression 6 and 24 h post-treatment as compared to vehicle controls (t = 3.22, p < 0.05 and t = 
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8.20, p < 0.001 at 6 h and t = 3.06, p < 0.05 and t = 12.69, p < 0.001 at 24 h for 300 and 1000 μM, 
respectively). Twelve hours post-treatment with METH (1000 μM) resulted in a significant increase in 
chop mRNA expression (t = 4.80, p < 0.001) (Figure 6.2.C.).  
Additionally, gadd34 mRNA expression was determined at various time points after METH 
treatment. Two-way ANOVA revealed a significant dose, time and interaction effect of METH treatment 
on gadd34 expression (p < 0.0001, p < 0.01 and p < 0.05, respectively). Similar to METH-induced 
increases in chop expression, METH was found to increase gadd34 mRNA expression 6 h post-treatment, 
at concentrations of 300 and 1000 μM (Bonferroni’s post hoc tests, t = 2.94, p < 0.05 and t = 6.56, p < 
0.001). Additionally, these concentrations increased gadd34 expression 24 h post-METH treatment (t = 
3.20, p < 0.05 and t = 10.00, p < 0.001 for 300 and 1000 μM, respectively). The 1000 μM concentration 
of METH also increased gadd34 mRNA expression 12 h post-treatment (t = 4.68, p < 0.001) (Figure 
6.2.D.).  
 
6.3.2. METH treatment increases CHOP protein expression  
Due to its involvement in toxicity elicited by PERK ER stress pathway activation, CHOP was 
selected for further protein level analysis of PERK-mediated ER stress activation by METH in NG108-15 
cells. One-way ANOVA revealed a significant effect of METH treatment on CHOP expression (F[3,23] = 
5.98, p < 0.01). Post hoc Dunnett’s multiple comparison tests revealed that METH (1000 μM) 24 h post-
treatment resulted in a significant increase in CHOP protein levels (q = 3.94, p < 0.01) (Figure 6.3.).  
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Figure 6.3. METH treatment results in a dose dependent increase in CHOP protein expression 24 h post-
treatment (**p < 0.01; vs. vehicle control). 
 
5.3.3. SN79 + METH and the expression of PERK-mediated ER stress genes 
 A single timepoint of 6 h was selected for use in experiments described below utilizing SN79, as 
METH (1000 μM) alone was found to significantly increase expression levels of PERK-mediated ER stress 
genes at this early timepoint. Additionally, we have previously shown that at a later timepoint of 24 h, 
METH (1000 μM) results in significant cellular toxicity, an effect mitigated by treatment with SN79 (100 
nM) (Kaushal et al., 2012a; Kaushal et al., 2011c; Kaushal et al., 2012b). Despite an ability to mitigate the 
neurotoxic effects of METH in both in vivo and in vitro models (Kaushal et al., 2011c; Kaushal et al., 
2012b), SN79 treatment was found to have little effect on METH-induced PERK-mediated ER stress. One-
way ANOVA revealed significant differences between treatment groups in atf3 expression (F[3,23] = 
8.98, p < 0.001). As depicted in Figure 6.4.A, METH (1000 μM) treatment resulted in a significant 
increase in atf3 mRNA expression 6 h post-treatment (Tukey’s test, q = 4.39, p < 0.05). SN79 (100 nM) 
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pretreatment had no effect on METH-induced increases in atf3 expression (n.s.), although cells treated 
with SN79 in combination with METH did significantly differ from vehicle treated controls (q = 5.96, p < 
0.01). Additionally, SN79 displayed no effects on its own (n.s.) (Figure 6.4.A.).  
 SN79 treatment also had no effect on METH-induced chop mRNA expression. One-way ANOVA 
revealed significant differences between treatment groups (F[3,23] = 14.22, p < 0.0001). METH 
treatment (1000 μM) increased chop mRNA expression, as compared to vehicle-treated controls 
(Tukey’s test, q = 4.95, p < 0.05). SN79 treatment had no effect on METH-induced increases in chop 
mRNA expression (n.s.). Treatment with SN79 alone had no significant effects on chop mRNA expression 
as compared to vehicle-treated controls (n.s.) (Figure 6.4.B.).  
 One-way ANOVA revealed significant differences between treatment groups in gadd34 mRNA 
expression (F[3,23] = 13.89, p < 0.0001). Post hoc analysis found that METH treatment (1000 μM) 
increased gadd34 expression as compared to vehicle-treated controls (q = 5.19, p < 0.01). SN79 in 
combination with METH increased expression of gadd34 mRNA, as compared to vehicle-treated controls 
(q = 8.10, p < 0.001); however, SN79 treatment had no effect on METH-induced increases in gadd34 
expression (n.s.) (Figure 6.4.C.).  
 Interestingly, SN79 pretreatment increased atf4 mRNA expression as compared to METH alone 
or vehicle-treated cells. One-way ANOVA revealed significant differences between treatment groups 6 h 
post-treatment in atf4 expression (F[3,22] = 13.59, p < 0.0001). SN79 in combination with METH 
significantly increased atf4 expression, as compared to vehicle alone and METH alone treated cells 
(Tukey’s multiple comparison tests, q = 8.29, p < 0.001 and q = 4.57, p < 0.05, respectively). METH 
treatment (1000 μM) was unable to significantly increase atf4 expression 6 h post-treatment as 
compared to vehicle controls, although this effect was trending towards statistical significance (q = 3.91, 
n.s.) (Figure 6.4.D.).  
89 
 
 
Figure 6.4. SN79 treatment in combination with METH upregulates atf4 mRNA expression while having 
no effect on METH-induced upregulations of other PERK-mediated ER stress genes (A) SN79 treatment 
fails to alter METH-induced increases in atf3 mRNA expression 6 h post-treatment (*p < 0.05, **p < 0.01; 
vs. vehicle control). (B) METH-induced increases in chop expression are not altered by SN79 treatment 
(*p < 0.05, **p < 0.01; vs. vehicle control). (C) Similarly, METH-induced increases in gadd34 expression 
are unaltered by SN79 treatment (**p < 0.01, ***p < 0.001; vs. vehicle control). (D) SN79 pretreatment 
significantly increases atf4 expression in NG108-15 cells, as compared to METH alone (***p < 0.001; vs. 
vehicle control; #p < 0.05; vs. METH 1000 μM). 
 
5.3.4. SN79 + METH CHOP protein expression 
 To evaluate potential regulation of CHOP by SN79 at the translational level, NG108-15 cells 
were treated with either vehicle, METH (1000 μM), SN79 (100 nM) or SN79 + METH for a period of 24 h. 
One-way ANOVA found significant differences between treatment groups in CHOP protein expression 
(F[3,23] = 47.34, p < 0.0001). Similar to experiments described above and as shown in Fig. 6.4., METH 
increased CHOP expression 24 h post-treatment as compared to vehicle controls (Tukey’s test, q = 13.09, 
p < 0.001). SN79 pretreatment however, was unable to mitigate METH-induced increases in CHOP 
expression (n.s.) (Figure 6.5.).  
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Figure 6.5. Treatment with the sigma receptor antagonist SN79 does not alter METH-induced increases 
in CHOP expression.  METH (1000 μM) treatment results in a significant upregulation of CHOP 24 h post-
treatment in NG108-15 cells. SN79 pretreatment is unable to significantly alter METH-induced increases 
in CHOP expression (***p < 0.001, vs. vehicle control; n.s., SN79 + METH vs. METH). 
 
6.4. Discussion 
The current study shows that METH exposure results in PERK-mediated ER stress in an in vitro 
model of METH neurotoxicity. METH increases mRNA expression of atf3, atf4, chop and gadd34, with all 
four previously implicated in PERK-mediated ER stress signaling. Additionally, METH increases the 
expression of CHOP, a protein involved in apoptosis elicited by prolonged ER stress. Furthermore, these 
effects occur on a time and concentration scale corresponding to earlier reported apoptosis by METH in 
NG108-15 cells (Kaushal et al., 2012a). Together, the data indicate that METH elicits a substantial 
increase in PERK-mediated ER stress signaling leading to enhanced CHOP expression, and subsequent ER 
stress-induced apoptosis.   
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The initiation of PERK ER stress initially represents a protective measure as cells attempt to cope 
with increases in unfolded protein loads, changes in ER Ca2+ levels, or altered redox status (Lai et al., 
2007; Walter and Ron, 2011). However, prolonged stimulation initiates pro-apoptotic signaling by 
upregulating proteins such as CHOP. It is known that for CHOP protein to be upregulated, the ATF4 arm 
of the PERK ER stress pathway must be active (Szegezdi et al., 2006). Furthermore, in the latent, 
apoptotic phases of ER stress, the PERK arm involving CHOP is active (Lin et al., 2007).  
A role for CHOP in ER stress-induced apoptosis is supported by several earlier studies. Knockout 
of CHOP in mouse fibroblasts reduces ER stress-induced apoptosis (Zinszner et al., 1998). CHOP 
knockout also significantly reduces apoptosis of dopaminergic neurons in 6-hydroxydopamine (6-OHDA) 
treated rats (Silva et al., 2005). In neuronal cells in vitro, PERK-mediated ER stress increases ATF4-
mediated CHOP expression and apoptosis (Galehdar et al., 2010). Thus, the ability of METH to act 
through PERK-mediated ER stress signaling for a prolonged period at concentrations that result in 
apoptosis provides evidence that METH exerts toxic responses through this ER stress signaling cascade.  
Further implicating PERK-mediated ER stress in the toxic effects of METH, PERK-mediated ER 
stress occurs in the striatum of rats whom have undergone a neurotoxic dosing paradigm of the drug 
(Beauvais et al., 2011; Jayanthi et al., 2009). These changes are correlated with the neurotoxic actions of 
the drug, as CHOP upregulation by METH occurs only in the presence of neurotoxicity (Takeichi et al., 
2012). For example, low-dose METH pretreatments that mitigate METH-induced neurotoxicity (as 
measured by tyrosine hydroxylase levels) also block increases in CHOP expression (Takeichi et al., 2012). 
In vitro, one prior report has shown an induction of CHOP expression by METH in CATH.a cells, a 
dopaminergic cell line, after exposure for at least 24 h (Irie et al., 2011). This report however, examined 
only CHOP expression and neglected other participating members of the PERK-mediated ER stress 
pathway. The current study extends and confirms these earlier observations by showing induction of 
multiple components of PERK ER stress by METH in a cell line on a time scale similar to that obtained 
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through in vivo studies utilizing rodents (Beauvais et al., 2011) and time and concentration scale 
corresponding to toxicity elicited by METH in vitro (Kaushal et al., 2012a).  
CHOP is not the sole member of the PERK ER stress pathway implicated in ER stress apoptosis. 
The induction of GADD34 is another way in which METH may regulate ER stress-induced apoptosis, as 
overexpression of GADD34 can initiate and potentiate apoptosis (Adler et al., 1999). It is possible that 
METH-induced increases in GADD34 expression increases unfolded protein load by dephosphorylating 
eIF2α, thereby reinstating translation and increasing apoptosis (Marciniak et al., 2004; Tsaytler et al., 
2011).  
The convergence of downstream mediators related to PERK-mediated ER stress signaling such as 
CHOP and GADD34 and apoptosis signaling cascades may be a significant contributing factor in the 
ability of METH to cause apoptosis. Increases in CHOP expression can decrease the anti-apoptotic 
protein Bcl-2 (McCullough et al., 2001). Interestingly, METH can also alter Bcl-2/BAX protein ratios in 
regions of the brain affected by its neurotoxic actions (Beauvais et al., 2011; Imam et al., 2001; Jayanthi 
et al., 2001). The upregulation of PERK-mediated ER stress in these brain regions by METH may alter the 
ratios of anti-apoptotic and apoptotic proteins, thereby leading to neurotoxicity.   
 The induction of PERK-mediated ER stress in vivo appears dependent on dopaminergic signaling 
as pretreatment with the D1 receptor antagonist SCH23390 attenuates gene upregulation of atf3, atf4, 
chop and gadd34 by METH in the striatum (Beauvais et al., 2011). Additionally, pretreatment with the 
D2 receptor antagonist raclopride exerts moderate inhibitory effects on METH-induced increases in 
CHOP expression in the striatum, further implicating dopamine receptor signaling in these effects 
(Beauvais et al., 2011). Sigma-1 receptors have been shown to modulate dopamine D1 signaling in 
response to psychostimulant-mediated activation; however, the role of this interaction in mediating 
cellular stress responses has yet to be determined (Navarro et al., 2010).  
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Thus, the second aim of the current study was to determine if ER stress elicited by METH is 
invoked through signaling involving sigma receptors. Previous work shows that sigma receptor 
antagonists mitigate METH-induced neurotoxicity in vivo and in vitro through an unknown signaling 
mechanism. SN79, the prototypic sigma receptor antagonist utilized in the current study, has previously 
been shown to mitigate METH-induced apoptosis, necrosis, caspase activation and ROS/RNS generation 
in NG108-15 cells (Kaushal et al., 2011c). We hypothesized that the neuroprotective effects of sigma 
receptor antagonists against METH may also result from the modulation of ER stress signaling. 
Interestingly, pretreatment with SN79 increases atf4 mRNA expression as compared to METH alone; 
however, SN79 has no effect on expression levels of other PERK ER stress genes under similar 
conditions. The inability of a sigma receptor antagonist to modulate PERK-mediated ER stress elicited by 
METH is surprising. Overexpression of sigma-1 receptors has previously been shown to attenuate PERK 
phosphorylation, indicative of an upstream blockade of PERK-mediated ER stress, in response to the ER 
stressor thapsigargin in CHO cells (Hayashi and Su, 2007b). Thapsigargin functions, however, by 
depleting ER Ca2+ stores and it may be possible that METH results in ER stress solely by altering the level 
of unfolded proteins within the ER irrespective of ER Ca2+ levels. This is one potential explanation for the 
disparities between data presented here utilizing METH and reports using thapsigargin to induce PERK-
mediated ER stress.  
Interestingly, the increase in atf4 mRNA expression as compared to METH alone could be a way 
for sigma receptor ligands to modulate PERK-mediated ER stress. This increase led us to believe that 
CHOP protein expression might be elevated at later time points. However, there was no difference in 
CHOP protein expression in METH samples pretreated with SN79 or those with vehicle. It is currently 
unclear why this occurred; however, ATF4 has recently been shown to play a crucial role in several 
aspects of cellular energy regulation. ATF4 is believed to be involved in lipid metabolism, responses to 
amino acid deprivation, and glucose metabolism in addition to its roles in ER stress (Seo et al., 2009; Siu 
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et al., 2002; Wang et al., 2010). It is hypothesized that sigma-1 receptors, when activated, are able to 
increase energy production by modulating Ca2+ flux into mitochondria thereby altering cellular energy 
production (Hayashi et al., 2009). It is thus possible that sigma receptor modulation of atf4 expression 
alters cellular energetics and conveys protection against the toxic effects of METH.  
In conclusion, the current study provides the first evidence that METH causes PERK-mediated ER 
stress an in vitro model of METH neurotoxicity. Sigma receptor modulation can have many effects on 
cellular signaling and death cascades (Meunier and Hayashi, 2010; Su and Hayashi, 2003; Su et al., 
2010a), but does not appear to affect PERK-mediated ER stress by METH. Further studies to delineate 
the molecular mechanisms by which sigma antagonists mitigate the neurotoxic actions of METH and to 
evaluate the role of PERK-mediated ER stress in the toxic actions of METH are warranted. 
 
6.5. Contributions 
 Matthew Robson conducted and analyzed all experiments contained within Chapter 5. 
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Chapter 7 
SN79, a sigma receptor ligand, blocks METH-induced microglial activation and 
cytokine upregulation 
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7.1. Introduction  
 METH is an addictive psychostimulant that is currently the second most abused illicit substance 
in the world behind only Cannabis (Romanelli and Smith, 2006). METH exerts many of its behavioral and 
physiologic effects by modulating monoaminergic systems within the central nervous system (CNS). 
METH abuse has several associated side effects including mood disturbances, anxiety, severe dental 
problems and notably, neurotoxicity (Romanelli and Smith, 2006). Chronic METH usage has been shown 
in humans to result in dopaminergic damage in the striatum, an effect correlated to relapse rates during 
clinical addiction treatment (Volkow et al., 2001a; Volkow et al., 2001b; Wang et al., 2012). Recently, 
chronic abusers of METH were also found to have a greater risk of developing Parkinson’s disease later 
in life, which is believed to stem from the neurotoxic consequences of the drug (Callaghan et al., 2010; 
Callaghan et al., 2012).  
 The precise mechanisms by which METH elicits neurotoxic effects are still being elucidated. 
There are several contributing factors that have been implicated in these effects, such as increased 
reactive oxygen and nitrogen species (ROS/RNS) generation, dopamine quinone formation, caspase and 
cell death signaling cascade activation, endoplasmic reticulum (ER) stress induction, and glutamatergic 
excitotoxicity (Cadet and Krasnova, 2009; Krasnova and Cadet, 2009). Additionally, microglial activation 
has been implicated in the neurotoxic effects of METH (Escubedo et al., 1998; Kelly et al., 2012; Kuhn et 
al., 2006; Thomas et al., 2004a; Yue et al., 2012).  
 Microglia are the resident macrophages of the CNS that function in maintaining homeostasis by 
sensing deviations from the normal brain environment. Upon activation by perturbations of their 
surrounding environment, microglia can undergo transformation to different response phenotypes, 
similar to peripheral macrophages (Perry et al., 2010; Saijo and Glass, 2011). These have classically been 
categorized as M1- and M2-type macrophage/microglia, with M1 microglia being associated with 
inflammation and degeneration and M2 being associated with regeneration or anti-inflammatory 
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processes (Czeh et al., 2011; Mosser and Edwards, 2008). The classical activation of microglia (M1) is 
associated with an upregulation of a variety of cell surface proteins, release of pro-inflammatory 
cytokines, generation of ROS/RNS, and subsequent neuronal damage (Czeh et al., 2011; Mosser and 
Edwards, 2008; Perry et al., 2010), all of which have been shown to be increased in response to 
neurotoxic regimens of METH (Escubedo et al., 1998; Kuhn et al., 2006; O'Callaghan et al., 2008; Thomas 
et al., 2004a; Thomas et al., 2004c).  
 The activation of microglia by METH has been demonstrated in both human studies and 
preclinical rodent models (Sekine et al., 2008; Thomas et al., 2004a; Thomas et al., 2004c). Microglial 
activation by METH occurs in regions of the brain affected by the neurotoxic actions of the drug and 
these effects have been shown to be persistent and long lasting even after extended abstinence from 
the drug (Sekine et al., 2008). The ability of microglia to produce cytokines and reactive species that can 
compromise synaptic transmission and neuronal function make them logical contributors to METH 
neurotoxicity and intriguing targets for drug development. 
 Among the pro-inflammatory cytokines, members of the interleukin-6 (IL-6) family are of 
particular relevance in the context of METH neurotoxicity. It is believed that the release of cytokines 
(including IL-6-type cytokines) by activated microglia is relevant to the effects of several 
neurodegenerative disorders, representing mechanistic overlap between these diseases and the 
neurotoxic actions of METH (Cadet and Krasnova, 2009; Smith et al., 2012b). The upregulation of IL-6 
and other members of this cytokine family have been shown in brain regions affected by the neurotoxic 
actions of METH (Goncalves et al., 2008; Kelly et al., 2012). Moreover, it has previously been shown that 
mice lacking IL-6 are protected against the neurotoxic actions of METH (Ladenheim et al., 2000), 
supporting a role of IL-6 in the neurotoxic actions of the drug. Furthermore, it is believed that molecular 
signaling cascades activated by IL-6-type cytokine signaling are involved in glial cell activation by METH 
(Hebert and O'Callaghan, 2000).    
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Presently, there are no FDA approved medications aimed at treating any of the negative side 
effects of METH abuse, including neurotoxicity. Many potentially promising preclinical treatments have 
failed to provide clinically effective pharmacotherapies, including those targeting monoaminergic 
systems. Sigma receptors have recently emerged as potential targets for the production of novel 
therapeutics aimed at treating many of the negative effects associated with METH usage, including 
neurotoxicity (Robson et al., 2012; Rodvelt and Miller, 2010). There are currently two known subtypes of 
sigma receptors, denoted sigma-1 and sigma-2, and sigma receptor antagonists have been shown to 
mitigate METH-induced behavioral effects and hyperthermia in rodents (Matsumoto et al., 2008; 
Nguyen et al., 2005). Additionally, sigma receptor antagonists block METH-induced reductions in striatal 
dopamine and serotonin and their respective transporters in preclinical models of METH-induced 
neurotoxicity (Kaushal et al., 2012b; Seminerio et al., 2011). The ability of sigma receptor antagonists to 
mitigate the effects of METH on neuronal cells is well documented; however, it is currently unclear if 
sigma receptor antagonists also block METH-induced microglial activation.  
Sigma receptors are found in microglial cells and sigma receptor ligands have been shown to 
modulate microglial activation in vitro and in vivo (Cuevas et al., 2011; Hall et al., 2009). Sigma receptor 
ligands have been shown to modulate several aspects of microglial activation including migration and 
cytokine release in response to various activators such as adenosine triphosphate (ATP) and 
lipopolysaccharide (LPS) (Cuevas et al., 2011; Hall et al., 2009). The sigma receptor ligand SR 31747 has 
also been reported to block peripheral increases in IL-6 expression in response to peripheral LPS and 
Staphylococcal enterotoxin B administration, although data from the CNS is currently lacking (Bourrie et 
al., 1996; Derocq et al., 1995). These studies provide evidence that sigma receptor ligands are capable of 
modulating the functionality of immune cells, including those present within the CNS. The purpose of 
the current study was therefore to determine if the putative sigma receptor antagonist and drug 
development candidate, 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one 
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(SN79), mitigates microglial activation and cytokine upregulation elicited by METH in the striatum in a 
preclinical model of METH-induced neurotoxicity.  
 
7.2. Materials and Methods 
 
7.2.1. Drugs and chemicals  
(+)-Methamphetamine hydrochloride was obtained from Sigma Aldrich (St. Louis, MO). SN79 
was synthesized as previously described (Kaushal et al., 2011e) and provided by Dr. Christopher R. 
McCurdy (University of Mississippi, University, MS). All administered drugs were dissolved in sterile 
saline solution (0.1 ml/10 g body weight) (Teknova, Fisher Scientific, Pittsburgh, PA). All other chemicals 
were obtained from Sigma Aldrich (St. Louis, MO) unless otherwise specified.  
 
7.2.2. Animals  
Male, Swiss Wesbter mice (24-28 g; Harlan, Indianapolis, IN) were utilized for all experiments. 
Mice were housed in groups of five, on a 12:12 h light/dark cycle with food and water ad libitum. Mice 
were randomly assigned to their respective treatment groups for all experiments. Experiments were 
performed as approved by the Animal Care and Use Committee at West Virginia University.  
 
7.2.3. Repeated dosing paradigm 
 Mice were randomly distributed for each experiment into one of four treatment groups: 1) 
Saline/Saline (0.1 ml/10 g body weight), 2) Saline/METH 5 mg/kg, 3) SN79 3 mg/kg/Saline, or 4) SN79 3 
mg/kg/METH 5 mg/kg. The first compound listed in each pair (Saline or SN79) was administered as a 
pretreatment 15 min prior to the second compound in each treatment group (Saline or METH). Each 
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animal underwent four pretreatments/treatments at 2 h intervals as previously described (Kaushal et 
al., 2012b). All injections were administered intraperitoneally. 
Core body temperature was measured 1 h after each treatment using a probe (Thermalert TH-S 
Monitor, Physitemp Instruments Inc., Clifton, NJ) inserted approximately 2.5 cm past the rectum into 
the colon. Body temperature was recorded after a stable temperature had been reached approximately 
10 s post-probe insertion.  
The METH dose (5 mg/kg x 4) was selected based upon previous dose response experiments 
assessing dopaminergic neurotoxicity in this specific model, where it has consistently been shown to 
result in significant dopaminergic deficits in the striatum (Matsumoto et al., 2008; Seminerio et al., 
2012a). Similarly, the SN79 dose (3 mg/kg x 4) was selected due to previously reported dose response 
experiments assessing the ability of this compound to mitigate the striatal dopaminergic deficits elicited 
by METH (Kaushal et al., 2012b).  
At various timepoints post-treatment (as measured from the last injection) bilateral striatum 
samples were collected, flash frozen in liquid nitrogen and stored at -80o C for later use. Samples for 
protein level analysis were collected 72 h post-treatment and were collected after transcardial perfusion 
with phosphate buffered saline (PBS) followed by 4% paraformaldehyde. Time points were selected 
based upon time course experiments contained within this report (microglial markers and cytokine 
expression levels) and previous data reporting the timeline of METH-induced dopaminergic 
neurotoxicity and microglial activation in rodent models (Escubedo et al., 2005; Escubedo et al., 1998; 
Kita et al., 2000; Thomas et al., 2004c).   
 
7.2.4. Quantitative real-time PCR  
Total RNA was extracted from flash frozen striatum samples using Trizol reagent (Invitrogen, 
Grand Island, NY) according to manufacturer’s instructions. The total RNA concentration for each sample 
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was quantified by spectral absorption, and the purity of the sample checked to confirm that the 260/280 
ratio was in the range of 1.8-2.1. Samples of cDNA were prepared by reverse transcription using a high 
capacity reverse transcription kit (Applied Biosystems, Foster City, CA). Each sample reaction included 
MultiScribe TM Reverse Transcriptase and random primers, with thermal cycler conditions set as 
follows: step 1 at 25° C for 10 min, step 2 at 37° C for 120 min, step 3 at 85° C for 5 s, and step 4 at 4° C 
for 10 min.  
For the PCR amplification, TaqMan® Universal PCR Master Mix and the following probes were 
obtained from Applied Biosystems (Foster City, CA): 18s (Hs99999901_s1) for use as an endogenous 
control gene, IL6 (Mm00446190_m1), OSM (Mm0119366_m1), CD68 (Mm03047343_m1) and LIF 
(Mm00434762_g1). The reaction mixture was prepared according to the manufacturer’s instructions, 
with the following thermal cycling conditions: initial holding at 50° C for 2 min which is required for 
optimal AmpErase® UNG activity, followed by a first denaturing step at 95° C for 10 min, then 45 cycles 
at 95° C for 15 s, and at 60° C for 1 min. The data from the real-time PCR measurements were calculated 
using the ΔΔCt method. The threshold value was set at 0.2 and the threshold cycle (Ct value) of each 
gene was normalized to 18s rRNA. 
 
7.2.5. Immunohistochemistry 
 At 72 h post-treatment (after the last injection), animals were anesthetized and immediately 
perfused transcardially with PBS followed by 4% paraformaldehyde. The entire brain was removed and 
immediately placed in 4% paraformaldehyde for 24 h. Following fixation, the brains were processed 
using a Tissue-Tek VIP 5 automatic tissue processor (Sakura Finetek, Torrance, CA) and then embedded 
in paraffin with a Tissue-Tek TEC 5 embedding console system (Sakura Finetek). Embedded tissues were 
sliced in 6 m sections using a Leica RM2235 microtome (Leica Microsystems, Buffalo Grove, IL), and 
slices mounted on glass slides for staining. All slides were heat-fixed and deparaffinized via a series of 
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xylene and alcohol washes prior to immunohistochemical procedures. Classical (M1) and alternative 
(M2) labeling of microglia was conducted as previously described (Niino et al., 2010; Zhang et al., 2012). 
Briefly, tissues were incubated first in mouse anti-rat CD68 antibody (AbD Serotec, Kidlington, UK) at a 
dilution of 1:100 in 4% horse serum in Dulbecco’s phosphate buffered saline (DPBS) overnight. Sections 
were washed 3x in DPBS and then incubated in a biotinylated anti-mouse IgG secondary antibody 
(Vector Laboratories, Burlingame, CA) diluted at 1:10,000 in 4% horse serum in DPBS for 4 h. Following 
incubation with a secondary antibody, alkaline phosphatase (Life Technology, Carlsbad, CA) diluted at 
1:100 in Tris-bovine serum albumin (BSA) was applied for 1 h. Following the incubation with alkaline 
phosphatase, the tissues were rinsed 3x in DPBS and then Fast Blue BB salt (Santa Cruz Biotechnology, 
Santa Cruz, CA) for 5 min. Tissues were again rinsed 3x in DPBS prior to incubation in mouse anti-rat 
CD163 (AbD serotec, Kidlington, UK) at a dilution of 1:100 in 4% horse serum in DPBS overnight. 
Following incubation with the primary antibody, the tissues were washed 3x in DPBS and then incubated 
in a biotinylated anti-mouse IgG secondary antibody (Vector Laboratories, Burlingame, CA) diluted at 
1:10,000 in 4% horse serum in DPBS for 4 h. Following incubation with the secondary antibody, the 
tissues were then incubated in avidin D-horseradish peroxidase (HRP) (Vector Laboratories, Burlingame, 
CA) diluted at 1:1,000 in DPBS for 1 h. The chromagen solution, diaminobenzidine (DAB) (Vector 
Laboratories, Burlingame, CA), was applied for 5 min per manufacturer’s instructions. The tissues 
underwent a final wash in xylene and were mounted using an antifade agent and cover slipped. The 
slides were sealed with acrylic and stored in the dark in a laboratory refrigerator. Staining for IBA-1, 
another marker of microglial activation, followed a similar approach but utilized anti–IBA-1 polyclonal 
antibody raised in rabbit (Wako, Richmond, VA). Sections were developed using Nova Red (Vector 
Laboratories, Burlingame, CA). 
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7.2.6. Statistical analysis  
Statistical analyses were conducted using analysis of variance (ANOVA). For significant effects, 
pairwise comparisons followed using post hoc Bonferroni’s or Tukey’s multiple comparisons tests. P < 
0.05 was considered statistically significant. 
 
7.3. Results 
 
7.3.1. Body temperature modulation  
 Dosing regimens of METH previously found to be neurotoxic (Matsumoto et al., 2008; Seminerio 
et al., 2012a) significantly increased core body temperature in mice, as compared to saline-treated 
controls. Two-way repeated measures ANOVA revealed significant differences between treatment 
groups and time, as well as their interaction (p < 0.0001, p < 0.0001 and p < 0.0001, respectively). 
Bonferroni’s post hoc analyses revealed that METH (5 mg/kg x 4) treatment significantly increased body 
temperature as compared to saline at time points 2, 3 and 4 (t = 5.16, p < 0.001, t = 9.45, p < 0.001 and t 
= 10.39, p < 0.001, respectively) (Fig. 7.1.). SN79 pretreatment was also found to significantly attenuate 
METH-induced changes in body temperature at all four time points (1: t = 7.28, p < 0.001; 2: t = 8.50, p < 
0.001; 3: t = 8.93, p < 0.001 and 4: t = 10.38, p < 0.001), while having no effects on its own as compared 
to saline-treated animals (n.s. for time points 1, 2, 3 and 4) (Fig. 7.1.).  
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Figure 7.1. Repeated methamphetamine (METH, 5 mg/kg x 4) treatment increased core body 
temperature as compared to saline (Sal), an effect mitigated by SN79 (3 mg/kg x 4) pretreatment. SN79 
treatment also displayed no effects on basal body temperature alone. Two-way repeated measures 
ANOVA, followed by post hoc Bonferroni’s multiple comparison tests; *** p<0.001, Sal/Sal vs. Sal/METH; 
### p<0.001, Sal/METH vs. SN79/METH. BT=body temperature. 
 
7.3.2. Markers of microglial activation 
 CD68 expression is a commonly used marker of microglial activation due to CNS insult 
(Komohara et al., 2011; Li et al., 2009; Nagai et al., 2005). Two-way ANOVA revealed significant 
differences in striatal cd68 mRNA expression between treatment groups, time, and their interaction (p < 
0.0001 for treatment, time, and their interaction). Post hoc Bonferroni’s analyses revealed that METH (5 
mg/kg x 4) caused a significant increase in striatal cd68 expression at 3, 6, 12 and 24 h post-treatment as 
compared to saline alone (t = 3.15, p < 0.05, t = 4.37, p < 0.001, t = 8.58, p < 0.001 and t = 13.06, p < 
0.001, respectively) (Fig. 7.2.).  
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Figure 7.2. Methamphetamine treatment (METH, 5 mg/kg x 4) time-dependently increased cd68 mRNA 
expression in the striatum, indicative of microglial cell activation. Two-way ANOVA, followed by 
Bonferroni’s post hoc analysis; * p<0.05, *** p<0.001, Saline vs. METH. 
 
At 24 h post-treatment, a time point when the highest METH effects were observed, significant 
differences between treatment groups in cd68 mRNA expression were found (one-way ANOVA; F[3,39] 
= 37.84, p < 0.0001). Post hoc analysis confirmed that similar to the time course study, METH (5 mg/kg x 
4) treatment resulted in a significant increase in striatal cd68 expression as compared to saline alone (q 
= 13.63, p < 0.001). This METH-induced change in cd68 expression was significantly attenuated by SN79 
pretreatment (3 mg/kg x 4) (q = 9.11, p < 0.001), though the blockade was incomplete since SN79 
pretreatment prior to METH still resulted in an elevated expression of cd68 as compared to saline-
treated controls (q = 4.51, p < 0.05). In the absence of METH, SN79 treatment alone resulted in no 
significant changes in striatal cd68 mRNA expression (n.s.) (Fig. 7.3.A.).  
 To further confirm that SN79 mitigated processes related to METH-induced microglial activation, 
protein expression levels were determined for both CD68 and the commonly used microglial marker 
IBA-1 using immunohistochemistry at a later time point of 72 h post-treatment. One-way ANOVA 
revealed significant differences between treatment groups in CD68 protein expression at 72 h (F[3,19] = 
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24.17, p < 0.0001). Tukey’s post hoc analysis revealed that METH treatment significantly increased 
striatal CD68 protein expression as compared to saline (q = 9.70, p < 0.001). In accordance with the 
mRNA expression studies, SN79 pretreatment attenuated the striatal CD68 protein increases elicited by 
METH (q = 9.67, p < 0.001), while having no effect on its own (n.s.) (Fig. 7.3.B.).  
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Figure 7.3. SN79 (3 mg/kg x 4) pretreatment attenuated methamphetamine (METH, 5 mg/kg x 4)-
induced increases in striatal CD68 mRNA and protein expression, indicative of a reduction in microglial 
activation. (A) SN79 treatment resulted in the blockade of METH-induced cd68 expression in the 
striatum 24 h post treatment. (B) SN79 pretreatment also blocked protein level increases in CD68 
elicited by METH treatment at 72 h. (C) Representative images of CD68 expression for each respective 
group. Black arrows depict microglia expressing high levels of CD68. 20X magnification. [One-way 
ANOVA, followed by post hoc Tukey’s multiple comparison tests; * p<0.05, *** p<0.001, Sal/Sal vs. 
respective group; ### p<0.001, Sal/METH vs. SN79/METH] Sal = saline. 
 
Similar to the pattern of effects observed for CD68 protein, SN79 pretreatment also blocked 
METH-induced increases in striatal IBA-1 protein expression, providing confirmation of a reduction in 
another marker of microglial activation. One-way ANOVA revealed significant differences between 
groups in IBA-1 expression (F[3,19] = 150.00, p < 0.0001). Post hoc analyses showed that METH 
treatment increased IBA-1 expression as compared to saline-treated controls at 72 h (q = 26.35, p < 
0.001), which was blocked by SN79 pretreatment (q = 24.40, p < 0.001). Interestingly, SN79 alone 
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resulted in a slight, yet statistically significant, paradoxical increase in IBA-1 expression compared to 
saline-treated controls (q = 4.41, p < 0.05) (Fig. 7.4.).  
 
 
Figure 7.4. SN79 (3 mg/kg x 4) blocked methamphetamine (METH, 5 mg/kg x 4)-induced increases in the 
microglial marker IBA-1 72 h post treatment, confirming an attenuation of METH-induced microglial 
activation. (A) SN79 treatment blocked METH-induced increases in striatal IBA-1 expression at 72 h. (B) 
Representative images of striatal IBA-1 expression for each respective group. Black arrows represent 
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microglia with high levels of IBA-1 expression. 20X magnification. [One-way ANOVA, followed by post 
hoc Tukey’s analysis; * p<0.05, *** p<0.001, Sal/Sal vs. respective group; ### p<0.001, Sal/METH vs. 
SN79/METH] Sal = saline. 
 
 Immunohistochemical studies to determine the type of microglia (M1 or M2) that were being 
activated by METH within the striatum revealed a strong, preferential effect on M1 microglia. While 
METH treatment resulted in a significant increase in M1-type microglia (denoted by solely expressing 
CD68; as shown in Fig. 7.3.B.), it did not increase nor decrease levels of M2-type microglia in the 
striatum (denoted by co-expression of CD68 and CD163; one-way ANOVA, n.s.). Additionally, SN79 
treatment had no effect on M2-type microglia in the striatum, either alone or in the presence of METH 
(n.s.) (Fig. 7.5.). 
 
 
 
Figure 7.5. None of the drug treatments had a significant effect on levels of M2-type microglia present 
in the striatum 72 h post treatment (n.s.). Sal = saline, METH = methamphetamine (5 mg/kg x 4), SN79 = 
SN79 (3 mg/kg x 4). 
 
 7.3.3. IL-6 family inflammatory cytokine mRNA expression  
 Along with the activation of pro-inflammatory M1 microglia, METH increased the mRNA 
expression of il-6, osm and lif, three IL-6 family cytokines within the striatum in a time-dependent 
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manner. Two-way ANOVA revealed differences in il-6 expression between treatment groups (p < 
0.0001). Post hoc analyses revealed that METH significantly increased il-6 mRNA expression at 1.5, 3, 6, 
12 and 24 h (t = 3.69, p < 0.01, t = 5.87, p < 0.001, t = 4.94, p < 0.001, t = 6.25, p < 0.001 and t = 3.09, p < 
0.05, respectively) (Fig. 7.6.A.).  
 Two-way ANOVA also revealed significant differences between treatment groups, time, and 
their interaction in striatal osm mRNA expression (p < 0.0001, p < 0.05 and p < 0.05, respectively). Post 
hoc tests revealed that METH significantly increased osm expression as compared to saline treatment at 
1.5, 3, 6 and 12 h post- treatment (t = 5.68, p < 0.001, t = 6.41, p < 0.001, t = 5.86, p < 0.001 and t = 5.4, 
p < 0.001, respectively) (Fig. 7.6.B.).  
 A significant difference was also found in striatal lif expression as a result of METH treatment, 
with two-way ANOVA showing a significant difference between treatment groups, time, and their 
interaction (p < 0.0001, p < 0.01 and p < 0.01, respectively). Post hoc analyses confirmed that METH 
treatment significantly increased lif expression in the striatum at 1.5, 3, 6, and 12 h post treatment as 
compared to saline (t = 6.02, p < 0.001, t = 7.36, p < 0.001, t = 4.73, p < 0.001 and t = 3.11, p < 0.05, 
respectively) (Fig. 7.6.C.).  
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Figure 7.6. Methamphetamine treatment (METH, 5 mg/kg x 4) increased mRNA expression of 
interleukin-6 (IL-6) family cytokines in the striatum. (A) METH treatment resulted in significant increases 
in il-6 expression at all time points tested. (B) METH also increased striatal osm expression at 1.5, 3, 6 
and 12 h post treatment. (C) METH further increased lif expression in the striatum at 1.5, 3, 6 and 12 h 
post treatment. Two-way ANOVA, followed by post hoc Bonferroni’s analysis; * p<0.05, ** p<0.01, *** 
p<0.001, Saline vs. METH.  
 
 At 6 h post-treatment, a time point at which all three IL-6 family cytokines studied were 
significantly up-regulated by METH in the time course studies described above, pretreatment with SN79 
blocked these effects. One-way ANOVA revealed significant differences in striatal il-6 mRNA expression 
between the treatment groups at 6 h (F[3,38] = 21.16, p < 0.0001). Similar to the time course 
experiments described above, METH treatment increased striatal il-6 expression as compared to saline-
treated controls (q = 10.00, p < 0.001), an effect mitigated by SN79 pretreatment (q = 6.38, p < 0.001). 
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SN79 treatment alone was also found to have no effect on striatal il-6 mRNA expression (n.s.) (Fig. 
7.7.A.).  
 
Figure 7.7. SN79 pretreatment (3 mg/kg x 4) blocked methamphetamine (METH, 5 mg/kg x 4)-induced 
increases in mRNA expression of IL-6 family cytokines in the striatum 6 h post treatment. (A) SN79 
attenuated METH-induced increases in il-6 expression. (B) METH treatment significantly increased 
striatal osm expression, an effect mitigated by SN79 treatment. (C) SN79 attenuated METH-induced 
increases in lif expression. One-way ANOVA, followed by post hoc Tukey’s multiple comparison tests; 
*** p<0.001, Sal/Sal vs. Sal/METH; ## p<0.01, ### p<0.001, Sal/METH vs. SN79/METH. Sal = saline. 
 
Pretreatment with SN79 also mitigated METH-induced increases in osm expression in the 
striatum. One-way ANOVA showed significant differences in osm expression between treatment groups 
(F[3,38] = 19.48, p < 0.0001). Tukey’s post hoc analysis revealed that METH significantly increased osm 
mRNA expression as compared to saline controls (q = 9.45, p < 0.001). SN79 treatment attenuated 
METH-induced increases in osm expression (q = 5.57, p < 0.001), while having no effects on its own 
compared to saline-treated controls (n.s.) (Fig. 7.7.B.).  
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Additionally, SN79 attenuated METH-induced increases in lif expression in the striatum. One-
way ANOVA showed a difference between the treatment groups in striatal lif expression (F[3,38] = 
31.89, p < 0.0001), and post hoc analysis revealed that METH caused a significant increase in lif as 
compared to saline controls (q = 11.99, p < 0.001). SN79 blocked METH-induced increases in lif mRNA 
expression (q = 9.10, p < 0.001), while having no effects on its own (n.s.) (Fig. 7.7.C.).  
 
7.4. Discussion 
 Data from the current study provides evidence that sigma receptor antagonists, such as SN79, 
block METH-induced microglial activation. SN79 blocked METH-induced increases in mRNA and protein 
of the microglial markers CD68 and IBA-1. Additionally, SN79 treatment blocked METH-induced 
increases in the expression of pro-inflammatory IL-6 family cytokines in the striatum. The ability of SN79 
to block METH-induced microglial activation and increases in the expression of pro-inflammatory 
cytokines provides evidence that this may be a mechanism by which sigma receptor antagonists mitigate 
the neurotoxic effects of METH.  
 The characterization of microglial activation as a result of METH exposure in preclinical rodent 
models has provided evidence that microglial activation is associated with METH-induced neurotoxicity 
(Kelly et al., 2012; LaVoie et al., 2004; Thomas and Kuhn, 2005; Thomas et al., 2004c). METH activates 
microglia in a dose- and time-dependent manner coinciding with reductions in striatal dopamine levels 
elicited by exposure to the drug (Thomas et al., 2004c). Amphetamine-type drugs that do not cause 
neurotoxicity such as L-methamphetamine and fenfluramine, fail to activate microglia, providing further 
evidence that microglial activation is associated with neurotoxicity (Thomas et al., 2004a). Additionally, 
environmental manipulations that block METH-induced dopaminergic neurotoxicity such as reductions 
in ambient temperature also block METH-induced microglia activation (Thomas et al., 2004c). This same 
study, however, also ruled out hyperthermia as a causative factor in microglia activation as 
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hyperthermia elicited by simple ambient temperature increases or pharmacologic treatments other than 
METH were unable to cause microglial activation (Thomas et al., 2004c). These results thus imply that 
hyperthermia plays a significant contributory, but not causative, role in microglia activation by METH, 
and compounds such as SN79 may convey beneficial effects at least in part through the blockade of 
METH-induced hyperthermia. 
 Increases in pro-inflammatory cytokines in the striatum following a neurotoxic regimen of METH 
have been shown previously (Kelly et al., 2012; Kuhn et al., 2006). Recently, increases in striatal 
expression levels of IL-6 family pro-inflammatory cytokines such as OSM, LIF and IL-6 by METH exposure 
were reported (Kelly et al., 2012). Further support of a role for IL-6 and its family members in the 
neurotoxic effects of METH are studies showing a reduction in dopaminergic and serotonergic 
neurtoxicity by METH in IL-6 knockout mice (Ladenheim et al., 2000). These effects were found 
independently of any alterations in METH-induced hyperthermia between knockout animals and wild 
type controls, indicative of a specific effect of IL-6 reduction on neurotoxicity (Ladenheim et al., 2000). 
The activation of microglia with a concomitant increase in pro-inflammatory cytokines such as IL-6 is 
believed to result in neuronal toxicity through excitotoxicity, apoptosis, immune activation, and 
generation of ROS/RNS, all of which are hypothesized to contribute to the neurotoxic effects of METH 
(Cadet et al., 2003; Cadet and Krasnova, 2009; Smith et al., 2012b). Additionally, the extent of 
dopaminergic nerve terminal damage has recently been found to be linked to microglial activation, 
further inferring that microglial activation and neuroinflammation may play a prominent role in the 
ability of METH to elicit neurotoxic reponses (Kelly et al., 2012; Thomas and Kuhn, 2005).  
 The ability of sigma receptor antagonists such as SN79 to block microglial activation and 
increases in IL-6 family cytokine mRNA elicited by METH may be one mechanism by which they are able 
to mitigate the neurotoxic effects of METH. Sigma receptors themselves are known to be expressed in 
microglia and ligands targeting sigma receptors have been shown to modulate microglia function and 
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activation in in vitro and in vivo models (Ajmo et al., 2006; Hall et al., 2009; Ruscher et al., 2012). The 
precise mechanism by which this occurs is currently unknown; however, sigma receptor modulation 
alters intracellular Ca2+ levels that have been associated with microglial activation and migration in vitro 
(Cuevas et al., 2011; Hall et al., 2009). This effect does not appear to be subtype specific, as ligands 
targeting sigma-1 and sigma-2 receptors independently have been shown to modulate microglial 
responses to a variety of microglial activators such as ATP, uridine triphosphate (UTP), LPS and 
monocyte chemotactant protein-1 (Cuevas et al., 2011; Hall et al., 2009; Yao et al., 2010). The ability of 
sigma receptor ligands to alter intracellular Ca2+ levels within microglia, thereby altering activation and 
migration, may result in the attenuation of the production of pro-inflammatory cytokines in activated 
microglia and the subsequent neurotoxicity associated with METH treatment (Cuevas et al., 2011).  
Interestingly, METH-induced microglial activation has also been linked to behavioral effects 
associated with usage of the drug in addition to neurotoxicity. Minocycline is an anti-inflammatory agent 
known to affect microglia that has been shown in rodent models to block METH-induced increases in 
locomotor activity, development of behavioral sensitization, impairments in recognition memory and 
rewarding effects of the drug as assessed by a conditioned place preference paradigm (Hashimoto et al., 
2007b; Mizoguchi et al., 2008; Zhang et al., 2006). A recent case report has also provided clinical 
evidence that minocycline treatment was linked to a reduction in METH-induced psychosis in a patient 
experiencing hallucinations associated with chronic METH usage (Tanibuchi et al., 2010). These reports 
provide evidence of a link between microglial activation and the behavioral and neurotoxic effects of 
METH. Notably, sigma receptor antagonists have been shown in rodent models to block METH-induced 
increases in locomotor activity, development and expression of behavioral sensitization and 
impairments in recognition memory, in addition to blocking hyperthermia and neurotoxicity associated 
with the drug (Kaushal et al., 2012b; Kaushal et al., 2011f; Seminerio et al., 2012a; Seminerio et al., 
2011). The current report however, is the first showing that sigma receptor antagonists are able to 
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mitigate METH-induced microglial activation. It remains to be seen if the ability of sigma receptor 
antagonists to mitigate the aforementioned METH-induced behaviors is associated with modulation of 
microglial activity.  
 It has recently been hypothesized that compounds targeting glial cells may be effective clinical 
treatments for the abuse of psychostimulants, including METH (Cooper et al., 2012). Given the current 
lack of treatments aimed at reducing METH usage or the negative effects associated with chronic METH 
usage, the further study of compounds that modulate glial cell function is certainly warranted. 
Compounds such as SN79 may be promising candidates to treat the negative complications of 
psychostimulant abuse by acting through a variety of mechanisms including microglial activation. SN79 
has previously been shown to display pharmacokinetic parameters amenable to clinical usage, and is 
orally bioavailable (Kaushal et al., 2011e), making it a potentially viable compound for further drug 
development. Future studies aimed at further delineating the mechanisms by which sigma receptor 
antagonists mitigate the neurotoxic actions of METH and further exploring drug development of these 
compounds for clinical usage are warranted.  
 
7.5. Contributions 
 Matthew Robson conducted all in vivo studies, quantitative real-time PCR and analyzed all data. 
Immunohistochemistry was conducted by Ryan Turner and Zachary Naser and data was analyzed by 
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Chapter 8 
SN79, a sigma receptor ligand, attenuates methamphetamine-induced 
astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 
phosphorylation 
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8.1. Introduction 
Methamphetamine (METH) is an illicit substance that acts as an addictive psychostimulant by 
modulating monoamine signaling within the central nervous system (CNS). Chronic METH abuse results 
in several negative side effects, including dopaminergic nerve terminal toxicity (Romanelli and Smith, 
2006; Volkow et al., 2001a; Volkow et al., 2001b), altered morphology in the substantia nigra (Todd et 
al., 2013), and an increased risk of developing Parkinson’s disease later in life (Callaghan et al., 2010; 
Callaghan et al., 2012).  
 In addition to having dramatic effects on dopaminergic neurons, METH affects a variety of other 
cell types located within the CNS (Cadet and Krasnova, 2009), including astrocytes in regions of the brain 
affected by its neurotoxic actions (Bowyer et al., 1994; O'Callaghan and Miller, 1994; Pu et al., 1994). 
Astrocytes isolated from regions of the brain affected by the toxic effects of METH appear more 
sensitive to the effects of the drug than comparable cell populations from other areas (Lau et al., 2000; 
Stadlin et al., 1998). In vitro studies using isolated astrocytes have confirmed that METH can directly 
exert actions on these cells; however, it is currently unclear whether in vivo activation of astrocytes by 
METH also results from direct actions on this cell type or whether it is a consequence of neuronal 
damage and neuroinflammation (Hebert and O'Callaghan, 2000; Kelly et al., 2012; Lau et al., 2000; 
Narita et al., 2006; Sriram et al., 2004; Stadlin et al., 1998).  
 Astrocytes are activated in response to a variety of CNS insults through a process termed 
astrogliosis whereby they undergo distinct morphological changes and display an increase in the 
expression of glial fibrillary acidic protein (GFAP) (Raivich et al., 1999). One mechanism by which 
astrocytes can be activated is through the induction of STAT3 phosphorylation through JAK/STAT 
signaling events (Hebert and O'Callaghan, 2000). It is hypothesized that this phosphorylation occurs 
through gp130-mediated cytokine signaling events initiated by inflammatory processes (Hebert and 
O'Callaghan, 2000; Van Wagoner and Benveniste, 1999). The phosphorylation and therefore activation 
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of STAT3 in astrocytes can be mediated through oncostatin M (OSM)-mediated signaling through the 
oncostatin M receptor (OSMR) (Van Wagoner et al., 2000). OSMR is an IL-6-type cytokine receptor that 
dimerizes with gp130 and mediates intercellular signaling events, including STAT3 (Tyr-705) 
phosphorylation (Chen and Benveniste, 2004; Van Wagoner et al., 2000). Interestingly, OSM signaling 
through OSMRβ/gp130 is believed to modulate astrocyte function and the expression of GFAP is 
decreased in mice deficient in gp130 (Chen et al., 2006; Nakashima et al., 1999), providing evidence that 
signaling through OSMRβ/gp130 complexes is involved in GFAP upregulation and subsequent 
astrogliosis. Furthermore, METH results in increased expression of osmr and gfap in regions of the brain 
affected by the neurotoxic effects of the drug in rodents (Thomas et al., 2004b). There is, however, a 
paucity of studies confirming the effect of METH on the transcriptional regulation of osmr in astrocytes 
per se, although a recent report has shown that osmr expression increases in astrocytes activated in vivo 
by other insults, such as ischemic stroke or peripheral lipopolysaccharide (LPS) injections (Zamanian et 
al., 2012).    
 Exacerbating the problem of METH-induced neurotoxicity is the current lack of FDA approved 
pharmacotherapies for treating the negative health effects of METH usage. One potentially promising 
molecular target for the production of medications aimed at counteracting these effects are sigma 
receptors. There are currently two known subtypes of sigma receptors (Hellewell and Bowen, 1990). 
Sigma-1 receptors are ligand-activated chaperones that modulate various intracellular signaling 
cascades making them particularly interesting targets for the development of potential 
pharmacotherapies for the treatment of drug abuse (Matsumoto, 2009; Robson et al., 2012). METH 
interacts with both subtypes of sigma receptors, denoted sigma-1 and sigma-2 receptors, at 
physiologically relevant concentrations and sigma receptor antagonists have been shown to mitigate the 
neurotoxic effects of METH on dopaminergic and serotonergic systems within the CNS (Kaushal et al., 
2012b; Matsumoto et al., 2008; Nguyen et al., 2005). Sigma receptors are expressed in astrocytes and 
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sigma receptor modulation has been shown to modulate the activity of astrocytes both in vitro and in 
vivo (Ajmo et al., 2006; Klouz et al., 2003); however whether sigma receptor modulation alters METH-
induced astrocyte activation has yet to be determined.  
Therefore, the primary purpose of the current study was to determine if a prototypic sigma 
receptor antagonist mitigates METH-induced reactive astrogliosis and neuronal degeneration. Secondly, 
we wanted to determine if sigma receptor modulation results in a blockade of OSMRβ/gp130-induced 
STAT3 phosphorylation which has been implicated in the activation of astrocytes following CNS insults. 
Herein, we provide evidence that METH treatment results in an increase in OSMR expression and 
signaling through STAT3 in astroctyes with subsequent reactive astrogliosis, effects mitigated by 
treatment with the sigma receptor antagonist and potential drug development candidate, SN79 (6-
acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one). 
 
8.2. Materials and Methods 
 
8.2.1. Drugs and chemicals  
(+)-Methamphetamine hydrochloride was obtained from Sigma Aldrich (St. Louis, MO). SN79 
was synthesized as previously described (Kaushal et al., 2011e) and provided by Dr. Christopher R. 
McCurdy (University of Mississippi, University, MS). All drugs administered to animals were dissolved in 
sterile saline solution (0.1 ml/10 g body weight) (Teknova, Fisher Scientific, Pittsburgh, PA). All other 
chemicals were obtained from Sigma Aldrich (St. Louis, MO) unless otherwise specified.  
 
8.2.2. Animals  
Male, Swiss Webster mice (24-28 g; Harlan, Indianapolis, IN) were utilized for all experiments. 
Mice were housed in groups of five, on a 12:12 h light/dark cycle with food and water ad libitum. Mice 
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were randomly assigned to their respective treatment groups. All experiments were performed as 
approved by the Animal Care and Use Committee at West Virginia University.  
 
8.2.3. Repeated dosing paradigm 
Mice were randomly distributed for each experiment into one of four treatment groups: 1) 
Saline/Saline (0.1 ml/10 g body weight), 2) Saline/METH 5 mg/kg, 3) SN79 3 mg/kg/Saline, or 4) SN79 3 
mg/kg/METH 5 mg/kg. The first compound listed in each pair (Saline or SN79) was administered 
intraperitoneally (i.p.) as a pretreatment 15 min prior to the second compound in each treatment group 
(Saline or METH, i.p.). Each animal underwent four pretreatments/treatments at 2 h intervals as 
previously described (Kaushal et al., 2012b).  
The METH dose (5 mg/kg x 4) was selected based upon previous dose response experiments, 
where it consistently produced significant dopaminergic deficits in the striatum in this specific model 
(Matsumoto et al., 2008; Seminerio et al., 2012a). The dose of SN79 (3 mg/kg x 4) was selected due to 
previously reported dose response experiments assessing the ability of this compound to mitigate the 
striatal dopaminergic deficits elicited by METH treatment (Kaushal et al., 2012b). 
 
8.2.4. Quantitative real time PCR 
At various timepoints post-treatment (as measured from the last injection), bilateral striatum 
samples were collected, flash frozen in liquid nitrogen and stored at -80o C for later use. Total RNA was 
then extracted from flash frozen striatum samples using Trizol reagent (Invitrogen, Grand Island, NY) 
according to manufacturer’s instructions. The total RNA concentration for each sample was quantified 
by spectral absorption, and the purity of the sample checked to confirm that the 260/280 ratio was in 
the range of 1.8-2.1. Samples of cDNA were prepared by reverse transcription using a high capacity 
reverse transcription kit (Applied Biosystems, Foster City, CA). Each sample reaction included 
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MultiScribe TM Reverse Transcriptase and random primers, with thermal cycler conditions set as 
follows: step 1 at 25° C for 10 min, step 2 at 37° C for 120 min, step 3 at 85° C for 5 s, and step 4 at 4° C 
for 10 min.  
For PCR amplification, TaqMan® Universal PCR Master Mix and the following probes were 
obtained from Applied Biosystems (Foster City, CA): 18S (Hs99999901_s1) for use as an endogenous 
control gene, GFAP (Mm01253033_m1) and OSMR (Mm00495424_m1). The reaction mixture was 
prepared according to the manufacturer’s instructions, with the following thermal cycling conditions: 
initial holding at 50° C for 2 min required for optimal AmpErase® UNG activity, followed by a first 
denaturing step at 95° C for 10 min, then 45 cycles at 95° C for 15 s, and at 60° C for 1 min. Data from 
real-time PCR measurements were calculated using the ΔΔCt method. The threshold value was set at 0.2 
and the threshold cycle (Ct value) of each gene was then normalized to 18s rRNA. 
 
8.2.5. Immunohistochemistry 
  At 72 h post-treatment (after the last injection), animals were anesthetized and perfused 
transcardially with phosphate buffered saline (PBS) followed by 4% paraformaldehyde. The entire brain 
was removed and immediately placed in 4% paraformaldehyde for 24 h. Following fixation, the brains 
were processed using a Tissue-Tek VIP 5 automatic tissue processor (Sakura Finetek, Torrance, CA) and 
then embedded in paraffin with a Tissue-Tek TEC 5 embedding console system (Sakura Finetek). 
Embedded tissues were sliced in 6 m sections using a Leica RM2235 microtome (Leica Microsystems, 
Buffalo Grove, IL), and slices mounted on glass slides for staining. All slides were heat-fixed and 
deparaffinized via a series of xylene and alcohol washes prior to immunohistochemical procedures. 
Following deparaffinization and rehydration, endogenous peroxidases were quenched using a 10% 
methanol and 10% hydrogen peroxide solution in PBS for 30 min.  Slides were permeabilized for 1 h 
using a 1.8% L-lysine, 5% horse serum, and 0.1% Triton X-100 in Dulbecco's phosphate buffered saline 
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(DPBS).  Sections were then incubated in polyclonal antibody raised in rabbit against anti-cow GFAP 
(DAKO, Glostrup, Denmark) at a dilution of 1:500 in 5% horse serum in PBS overnight at 4° C.  Next, 
sections were washed twice for 10 min each in PBS prior to application of Alexa Fluor 488 goat anti-
rabbit IgG (Invitrogen, Grand Island, NY) at a dilution of 1:100 in PBS for 3 h. Following the incubation in 
Alexa Fluor 488 goat anti-rabbit IgG, slides were rinsed twice for 10 min each in PBS. Then, the tissues 
were incubated in polyclonal antibody raised in goat anti-mouse OSMR (LifeSpan Biosciences, Seattle, 
WA) at a dilution of 1:200 in 5% horse serum in PBS overnight at 4° C. Following the incubation in 
primary antibody, the slides were rinsed twice for 10 min each in PBS prior to the application of 
biotinylated anti-goat IgG (Vector Laboratories, Burlingame, CA) at a dilution of 1:10,000 in 5% horse 
serum in PBS for 2 h. Following the incubation in biotinylated anti-goat IgG, slides were rinsed twice for 
10 min each in PBS prior to the application of Streptavidin Alexa Fluor 546 (Life Technology, Carlsbad, 
CA) at a dilution of 1:100 in PBS for 1 h. Slides were rinsed in PBS for 10 min and then coverslipped with 
Vectashield Mounting Media with 4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, 
Burlingame, CA). Finally, slides were sealed with acrylic and stored in the dark in a laboratory 
refrigerator at 4o C. Images were acquired using a Zeiss Axio Imager 2 microscope (Oberkocken, 
Germany) and quantified using ImageJ software (NIH; http://rsbweb.nih.gov/ij/) by analyzing 
fluorescence intensity as compared to background using standard colocalization quantification 
techniques. 
 In addition to nerve terminal damage, METH has been reported to result in striatal apoptosis 
and cellular toxicity in vivo (Deng et al., 2001; Jayanthi et al., 2005). Fluoro-Jade staining is a viable 
marker of neuron degeneration as a result on amphetamine treatment in rodents (Eisch et al., 1998; 
Schmued and Hopkins, 2000); however whether sigma receptor ligands mitigate METH-induced striatal 
neuronal degeneration has yet to be determined. For Fluoro-Jade B staining, sections were incubated in 
0.06% potassium permanganate for 10 min, washed in deionized water, and incubated in 0.0004% 
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Fluoro-Jade B in 0.1% acetic acid for 20 min. Sections were then washed, coverslipped, and sealed. For 
bright-field visualization of GFAP, slides were rinsed in DPBS, permeabilized with 1.8% L-lysine, 4% horse 
serum, and 0.2% Triton X-100 in DPBS. Sections were incubated overnight with a polyclonal antibody 
raised in rabbit against anti-cow GFAP at a dilution of 1:500 in 4% horse serum in PBS. Sections were 
washed and incubated for 4 h in biotinylated anti-rabbit IgG (1:10,000) in PBS with 4% horse serum. 
Diaminobenzidine (DAB) was used as a chromagen following incubation in avidin D-horseradish 
peroxidase (HRP) for 1 h.   
Bright-field immunohistochemistry was quantified using stereology and the optical fractionator 
technique as previously described (Schmitz and Hof, 2005; Smith et al., 2012a; Turner et al., 2012). 
Briefly, a region of interest encompassing the striatum was drawn at low power using an Olympus AX70 
microscope and accompanying StereoInvestigator software (MBF Bioscience, Williston, VT). Counting 
frames were randomly selected by the software and the cell-type of interest marked by an observer 
blinded to treatment. The volume of the region of interest previously identified was then determined by 
the software and the number of cells marked by the observer returned. Counting frames were 75 μm on 
each side with a depth of 6 μm. 
 
8.2.6. Immunoblotting 
 Twelve hours post-treatment (time from last treatment), animals were sacrificed utilizing 
focused microwave irradiation (Muromachi Microwave Applicator, TMW-4012C, 10 kW output) to 
preserve the phosphorylation states of proteins within each animal post-mortem, including STAT3 (Tyr-
705) (O'Callaghan and Sriram, 2004). Mice were briefly restrained in a water-jacketed holder and 
inserted into the machine head. The microwave beam was then activated (5 kW power setting for 1 s) 
and animals were subsequently removed from the holder. Brains were then removed and bilateral 
striatum samples dissected, flash frozen and stored at -80o C. Protein was isolated from each respective 
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sample by sonication in 25 μl of hot (85-95o C) 1% sodium docecyl sulfate (SDS) as previously described 
(O'Callaghan and Sriram, 2004). The protein concentration of each sample was measured using a 
Coomassie Plus Bradford Assay Kit (Pierce, Rockford, IL) which is based upon a modified form of the 
Bradford assay (Bradford, 1976). Samples were run using 20 μg of protein/well using Tris-HCl 10% pre-
cast 15-well gels (Bio-Rad, Hercules, CA) in combination with 5X Lammeli sample buffer. Gels were run 
using a mini-PROTEAN system (Bio-Rad) and gels were equilibrated for 15 min in Towbin’s buffer prior to 
transfer to polyvinylidene fluoride (PVDF) membranes (Bio-Rad) using semi-dry electrophoretic transfer 
cells (Bio-Rad). Membranes were blocked using 5% fat-free milk/tris buffered saline and Tween 20 (TBS-
T) for 2 h at room temperature. Membranes were incubated with primary phosphoSTAT3 (Tyr-705) or 
STAT3 antibody (Cell Signaling, Danvers, MA) at a concentration of 1:1,000 overnight at 4o C. Anti-rabbit 
IgG HRP-linked antibody (Cell Signaling) was used as a secondary antibody at a concentration of 1:2000 
with gentle shaking for 2 h. An HRP-conjugated β-actin rabbit monoclonal antibody (Cell Signaling) was 
used as an endogenous control for all samples at a concentration of 1:10,000 and incubated for 1 h. 
Molecular weight determination was conducted using a biotinylated protein ladder (Cell Signaling). 
Imaging was conducted using 20X LumiGLO chemiluminescent substrate (Cell Signaling) according to 
manufacturer’s instructions. Images were converted to 8-bit and analyzed using densitometry with 
background subtraction and normalized to β-actin using ImageJ software (NIH; 
http://rsbweb.nih.gov/ij/). 
 
8.2.7. Statistical analysis 
Statistical analyses were conducted using either one-way or two-way analysis of variance 
(ANOVA), followed where applicable by post hoc Tukey’s or Bonferroni’s multiple comparison tests. 
Data was analyzed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA). p < 0.05 was considered 
statistically significant.  
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8.3. Results  
 
8.3.1. METH time dependently increases striatal gfap mRNA expression 
 Repeated treatment with METH (5 mg/kg x 4) resulted in significant increases in transcriptional 
upregulation of GFAP. As shown in Figure 8.1., two-way ANOVA revealed that METH caused time-
dependent increases in gfap mRNA expression (p<0.0001 for time, treatment and their interaction). 
Bonferroni’s post hoc tests revealed that METH treatment significantly increased gfap expression 12 and 
24 h post-treatment (t = 3.97, p < 0.01 and t = 7.66, p < 0.001, respectively).  
 
Figure 8.1. Methamphetamine (METH, 5 mg/kg x 4) treatment resulted in time-dependent increases in 
striatal gfap mRNA expression. METH was found to significantly increase gfap expression at both 12 and 
24 h post-treatment. Two-way ANOVA, followed by post hoc Bonferroni’s multiple comparison tests. 
**p < 0.01, ***p < 0.001, Sal/METH vs. Sal/Sal. Sal = Saline 
 
8.3.2. SN79 treatment blocks METH-induced astrogliosis 
 Treatment with SN79 mitigated METH-induced increases in gfap expression at 12 and 24 h post-
treatment. One-way ANOVA revealed significant differences between treatment groups at 12 h (F[3,38] 
= 16.20, p < 0.0001). Tukey’s post hoc multiple comparison analysis revealed a significant difference 
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between Saline/Saline and Saline/METH treated animals (q = 8.50, p < 0.001), similar to the results 
obtained during the time course experiment described above. SN79 pretreatment attenuated METH-
induced increases of gfap expression at 12 h post-treatment (q = 7.28, p < 0.001) (Figure 8.2.A.). 
Furthermore, one-way ANOVA revealed significant differences between treatment groups at 24 h post-
treatment (F[3,39] = 18.25, p < 0.0001). Post hoc Tukey’s multiple comparison tests revealed that METH 
treatment resulted in a significant increase in striatal gfap mRNA expression compared to control (q = 
9.19, p < 0.001), an effect that was mitigated by treatment with SN79 (q = 6.99, p < 0.001) (Figure 
8.2.B.).  
 Similar results were obtained through protein level analysis utilizing immunohistochemistry 
(Figure 8.3.A.). METH treatment (5 mg/kg x 4) resulted in astrogliosis 72 h post-treatment. As shown in 
Figure 8.3.B., one-way ANOVA revealed differences between treatment groups in the number of 
reactive astrocytes within the striatum (F[3,19] = 27.75, p < 0.0001). Tukey’s multiple comparison tests 
revealed that METH significantly increased reactive astrocytes as compared to control (q = 10.99, p < 
0.001). This effect was mitigated by treatment with SN79, indicative of a blockade of METH-induced 
reactive astrogliosis (q = 8.00, p < 0.001).  
 
Figure 8.2. Treatment with SN79 (3 mg/kg x 4) was found to attenuate METH-induced (5 mg/kg x 4) 
increases in striatal gfap mRNA expression at both 12 (A) and 24 h (B), indicating a blockade of astrocyte 
activation. One-way ANOVA, followed by post hoc Tukey’s multiple comparison tests. ***p < 0.001, 
Sal/METH vs. Sal/Sal; ###p < 0.001, SN79/METH vs. Sal/METH. Sal = Saline 
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Figure 8.3.A. Qualitative images of astrocyte activation in response to METH (5 mg/kg x 4) and blockade 
by SN79 (3 mg/kg x 4) treatment. Clockwise from top left: Sal/Sal, Sal/METH, SN79/METH, SN79/Sal. Sal 
= Saline. Arrows denote activated astrocytes that have undergone morphologic alterations. 
 
 
Figure 8.3.B. Quantification of the attenuation of methamphetamine (METH)-induced (5 mg/kg x 4) 
astrogliosis by SN79 treatment (3 mg/kg x 4). Sal = Saline. One-way ANOVA, followed by post hoc 
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Tukey’s multiple comparison tests. ***p < 0.001, Sal/METH vs. Sal/Sal; ###p < 0.001, SN79/METH vs. 
Sal/METH. 
 
8.3.3. SN79 treatment mitigates METH-induced increases in OSMR expression 
 METH treatment increased striatal mRNA osmr expression at 12 and 24 h. One-way ANOVA 
revealed significant differences in osmr mRNA expression between treatment groups at 12 h post-
treatment (F[3,38] = 36.06, p < 0.0001). Post hoc Tukey’s analysis showed that METH significantly 
increased striatal osmr expression as compared to saline-treated animals (q = 12.94, p < 0.001). This 
effect was mitigated by SN79 treatment (q = 9.74, p < 0.001) (Figure 8.4.A.). Similar effects were seen at 
24 h post-treatment. One-way ANOVA revealed differences in osmr expression between treatment 
groups (F[3,39] = 27.49, p < 0.0001). Tukey’s multiple comparison tests revealed that METH treatment 
increased osmr expression as compared to saline (q = 11.26, p < 0.001), an effect that was mitigated by 
SN79 treatment (q = 8.92, p < 0.001) (Figure 8.4.B.).  
 
 
Figure 8.4. SN79 (3 mg/kg x 4) treatment blocks methamphetamine (METH)-induced (5 mg/kg x 4) 
increases in striatal osmr mRNA expression at 12 (A) and 24 h (B). One-way ANOVA, followed by post 
hoc Tukey’s multiple comparison tests. Sal = Saline. ***p < 0.001, Sal/METH vs. Sal/Sal; ###p < 0.001, 
SN79/METH vs. Sal/METH. 
 
 To determine if increases in OSMR expression are occurring specifically in astrocytes located 
within the striatum, immunoflourescence studies were conducted to determine both levels of GFAP and 
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OSMR protein between treatment groups, and the specific colocalization of increases in OSMR 
expression to astrocytes. One way ANOVA revealed differences between groups in GFAP protein 
expression at 72 h post-treatment (F[3,19] = 10.07, p < 0.001). Tukey’s post hoc analysis revealed that as 
expected METH treatment significantly increased striatal GFAP protein levels as compared to saline-
treated controls (q = 6.67, p < 0.01). SN79 treatment mitigated METH-induced increases in GFAP protein 
(q = 5.69, p < 0.01) (Figure 8.5.A.). Furthermore, one-way ANOVA revealed significant differences in 
OSMR protein expression at 72 h post-treatment (F[3,19] = 11.74, p < 0.001). Post hoc analysis using 
Tukey’s multiple comparison tests showed that METH treatment increased OSMR expression compared 
to saline-treated controls (q = 7.63, p < 0.001). SN79 treatment blocked METH-induced increases in 
OSMR expression (q = 5.89, p < 0.01) (Figure 8.5.B.). 
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Figure 8.5. (A) Methamphetamine (METH) (5 mg/kg x 4) treatment increases the expression of striatal 
GFAP, indicating significant astrogliosis. SN79 (3 mg/kg x 4) treatment blocked METH-induced increases 
in GFAP expression. (B) METH treatment increased OSMR expression in striatal astrocytes, an effect 
mitigated by SN79 treatment. One-way ANOVA, followed by post hoc Tukey’s multiple comparison tests. 
**p < 0.01, *** p < 0.001, Sal/METH vs. Sal/Sal; ##p < 0.01, SN79/METH vs. Sal/METH (C) Representative 
images showing increases in GFAP expression and increases in astrocytic OSMR expression in the 
striatum by treatment group. Top to bottom: Sal/Sal, Sal/METH, SN79/Sal, SN79/METH Left to right: 
DAPI nuclear staining, GFAP, OSMR, overlay image. Sal = Saline. 
 
 Importantly, as shown in Figure 8.5.C., increases in GFAP and OSMR induced by METH were 
colocalized specifically to astrocytes within the striatum. METH treatment resulted in an increase in 
OSMR specifically in GFAP-labeled astrocytes, an effect that was blocked by SN79 treatment. 
  
8.3.4. SN79 treatment blocks METH-induced phosphorylation of STAT3 
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 Western blotting of bilateral striatal tissue 12 h post-treatment was conducted to determine the 
effect of METH on the phosphorylation of STAT3 (Tyr-705) and total STAT3 levels that has previously 
been linked to astrocyte activation by neurotoxicants, including METH in vitro (Hebert and O'Callaghan, 
2000; Sriram et al., 2004). One-way ANOVA revealed significant differences in pSTAT3 levels between 
groups (F[3,31] = 5.69, p < 0.01). Tukey’s post hoc analysis revealed that METH treatment significantly 
increased the phosphorylation of STAT3 as compared to saline-treated controls at 12 h (q = 4.90, p < 
0.01). SN79 treatment blocked the METH-induced phosphorylation of STAT3 (q = 4.34, p < 0.05) (Figure 
7.6.A.). Conversely, there were no significant differences found in total STAT3 levels in the striatum 
between any of the treatment groups (one-way ANOVA, n.s.) (Figure 8.6.B.).  
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Figure 8.6. SN79 mitigates methamphetamine (METH)-induced increases in the phosphorylation of 
STAT3 (Tyr-705). (A) METH treatment (5 mg/kg x 4) increases the phosphorylation of STAT3 (Tyr-705) at 
12 h; an effect that is mitigated by treatment with SN79 (3 mg/kg x 4). One-way ANOVA followed by 
post hoc Tukey’s multiple comparison tests. Sal = Saline. **p < 0.01, Sal/METH vs. Sal/Sal; #p < 0.05, 
SN79/METH vs. Sal/METH.  (B) No differences were detected between any of the treatment groups in 
total STAT3 expression.  
 
8.3.5. SN79 treatment attenuates METH-induced neuronal degeneration 
 One-way ANOVA revealed significant differences in the number of degenerating 
neurons within the striatum between treatment groups 72 h post-treatment (F[3,19] = 11.96, p < 0.001), 
as determined by Flouro-Jade B staining. METH treatment significantly increased the number of 
degenerating neurons in the striatum as compared to saline-treated controls (Tukey’s post hoc analysis, 
q = 8.12, p < 0.001). SN79 treatment mitigated METH-induced increases in neuronal degeneration (q = 
5.20, p < 0.01) (Figure 8.7.A. and 8.7.B.). 
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Figure 8.7. SN79 (3 mg/kg x 4) treatment attenuates methamphetamine (METH)-induced (5 mg/kg x 4) 
neuronal degeneration in the striatum as measured by Fluoro-Jade B staining. (A) Representative images 
of Fluoro-Jade B labeled degenerating neurons in the striatum for each respective treatment group. 
Clockwise from top left: Sal/Sal, Sal/METH, SN79/METH, SN79/Sal. Sal = Saline. (B) Quantification of 
striatal neuronal degeneration by treatment group. One-way ANOVA, followed by post hoc Tukey’s 
multiple comparison tests. ***p < 0.001, Sal/METH vs. Sal/Sal; ##p < 0.01, SN79/METH vs. Sal/METH 
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8.4. Discussion  
 The current study provides evidence that the sigma receptor antagonist and potential drug 
development candidate, SN79, mitigates METH-induced astrogliosis and neuronal degeneration in the 
striatum. Additionally, the current study provides evidence that the ability of SN79 to attenuate METH-
induced astrogliosis is mediated through a blockade of STAT3 phosphorylation initiated by OSMR 
signaling.  
 Our findings are consistent with earlier reports that METH-induced activation of astrocytes 
involves OSM interactions with OSMR and subsequent induction of JAK2/STAT3 signaling (Chen and 
Benveniste 2004; Hebert and O'Callaghan 2000; Heinrich et al. 2003). This induction of STAT3 
phosphorylation through IL-6-type signaling can result in a variety of genetic changes, including 
increases in GFAP expression that are associated with astrocyte activation (Hebert and O'Callaghan 
2000; Oliva et al. 2012; Sriram et al. 2004; Zhong et al. 1994). The current study is the first to show that 
treatment with a sigma receptor antagonist mitigates METH-induced increases in signaling through this 
pathway and thereby counteracts METH-induced astrogliosis.  
 The precise mechanism(s) by which SN79 modulates this pathway has yet to be fully elucidated. 
It is possible that SN79 is blocking METH-induced increases in OSM, thereby leading to a reduction of 
signaling through OSMR. A number of labs have shown that METH treatment results in an increase in 
striatal expression levels of osm mRNA (Cadet et al. 2002; Kelly et al. 2012; Kuhn et al. 2006). 
Furthermore, we have also shown that SN79 mitigates METH-induced increases in striatal osm mRNA 
expression (Robson et al. 2013). This could lead to a blockade of METH-induced STAT3 phosphorylation 
by decreasing signaling specifically through OSMR in astrocytes and leading ultimately to a reduction in 
METH-induced GFAP upregulation and astrogliosis as seen in the current study.  
   
 
136 
 
 
 
Figure 8.8. OSM signaling is known to occur through OSMR/gp130 heterodimers resulting in JAK2/STAT3 
signaling. The resulting phosphorylation of STAT3 (Tyr-705) causes STAT3 to homodimerize and 
subsequently induces gene expression alterations. This process is believed to be critical to astrogliosis in 
response to neurotoxicants such as METH. 
 
 
Another potential explanation is that sigma receptor modulation within astrocytes is having an 
effect downstream of OSMR on STAT3 phosphorylation directly. Sigma receptors themselves and sigma 
receptor ligands have previously been shown to modulate the function of astrocytes in vitro (Ruscher et 
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al. 2011). Furthermore, sigma receptor ligands have been shown to modulate protein expression within 
cultured astrocytes (Prezzavento et al. 2007), in addition to dose-dependently blocking reductions in 
astrocytic ATP resulting from hypoxia in vitro (Klouz et al. 2003). It is thus possible that sigma receptors 
within astrocytes are altering astrocytic responses to CNS insults that result in astrogliosis.  
One particular protein involved in the negative feedback of STAT3 signaling in astrocytes is 
suppressor of cytokine signaling 3 (SOCS3) (Baker et al. 2008). Astrocytic OSM signaling results in an 
upregulation of SOCS3 thereby suppressing the inflammatory actions of OSM, including the 
phosphorylation of STAT3 (Baker et al. 2008). Three distinct pathways are believed to contribute to 
these effects, including the phosphorylation of STAT3, ERK1/2 and JNK pathways (Baker et al. 2008). 
Although SN79 treatment was found to mitigate METH-induced increases in STAT3 phosphorylation, it 
may be possible that modulation of ERK1/2 and JNK pathways are contributing to increases in SOCS3, 
thereby leading to the blockade of STAT3 phosphorylation seen in the current report. Supporting this 
hypothesis are previous studies showing the modulation of ERK1/2 and JNK signaling by various sigma 
receptor ligands (Cantarella et al. 2007; Nishimura et al. 2008; Son and Kwon 2010; Tan et al. 2010; 
Tuerxun et al. 2010), although their effects specifically within astrocytes on these signaling pathways are 
currently unknown.  
 Our study provides evidence that METH-induced STAT3 phosphorylation occurs prior to the 
induction of increases in GFAP and OSMR expression elicited by METH. Previous studies have shown 
that maximal increases in GFAP post-treatment with METH occur between 48 and 72 h, indicative of a 
maximal increase in astrocyte activation (Hebert and O'Callaghan 2000; Kelly et al. 2012; Sriram et al. 
2006). Moreover, it is known that maximal METH-induced increases in the phosphorylation of STAT3 
occur prior to these effects (between 12 and 24 h) (Hebert and O'Callaghan 2000). Although protein 
changes in OSMR expression are protracted as compared to STAT3 phosphorylation, osm mRNA 
expression increases post-METH treatment are rapid (Kelly et al. 2012), suggesting that signaling 
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through this receptor may result in a positive feedback loop, whereby signaling increases the expression 
of the receptor. In the current study, increases in osmr mRNA and protein elicited by METH were 
detected at time points corresponding to and also after the phosphorylation of STAT3, respectively. 
Interestingly, increases in OSMR expression also coincided with increases in GFAP mRNA and protein. It 
is possible that initial OSM signaling through OSMR results in a positive feedback loop, where the 
increases OSMR expression result in increased signaling through astrocytic OSMR thereby potentiating 
its effects. It is known that OSM signaling can alter gene expression in astrocytes in a biphasic manner; 
however the specificity of STAT3 signaling in mediating these genetic alterations has yet to be confirmed 
(Van Wagoner et al. 2000). Furthermore, the second portion of this biphasic response has been reported 
to require de novo protein synthesis (Van Wagoner et al. 2000), indicating that the genetic alterations 
elicited through this pathway (such as increases in gfap mRNA expression) may require increased 
expression of specific proteins, including OSMR.  In support of this hypothesis, OSM signaling has 
previously been shown to increase levels of OSMRβ receptor subunits by enhancing the level of 
synthesis of these receptor subunits (Blanchard et al. 2001). This biphasic response could potentially be 
a manifestation of a positive feedback loop resulting in further increases in OSMR/gp130 signaling and 
increases in GFAP expression/astrocyte activation (Nakashima et al. 1999). The mitigation of METH-
induced increases in astrocytic OSMR by SN79 treatment could result in a blockade of the second half of 
this biphasic response, thereby shunting increases in GFAP expression elicited through OSMR/gp130 
signaling.  
 In addition to a potential role in neurotoxicity, astrocytes themselves are hypothesized to be 
involved in synaptic plasticity and may play large roles in the control of synaptic activity (Nedergaard 
and Verkhratsky 2012; Ullian et al. 2004). Substantial evidence points to astrocytes being involved in 
many aspects of synapse formation, maintenance and stability and they may be involved in activity 
dependent synapse formation (Ullian et al. 2004). These effects are hypothesized to be involved in the 
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actions of several drugs of abuse including METH and the modulation of astrocytes is believed to 
represent a novel target for the production of pharmacotherapies aimed at treating drug abuse (Cooper 
et al. 2012; Miguel-Hidalgo 2009; Narita et al. 2008; Rolan et al. 2009). Evidence of astrocyte modulation 
being involved in the behavioral actions of METH supports a role of these cells in the effects of the drug 
beyond neurotoxicity. Previous reports have shown that METH-induced astrocyte activation is 
associated with METH-induced behavioral sensitization, a behavioral assay believed to be associated 
with neuroplastic changes elicited by drugs of abuse (Chen et al. 2009; Narita et al. 2006; Narita et al. 
2005; Narita et al. 2008). Interestingly, sigma receptor ligands, have previously been shown to block the 
development and expression of behavioral sensitization to psychostimulants, including METH (Seminerio 
et al. 2012b; Ujike et al. 1992; Ujike et al. 1996; Xu et al. 2010); however, whether this effect is 
associated with astrocyte activation has yet to be determined.  
It should be noted that currently, there are no available pharmacologic agents targeting OSMR 
specifically and these results await confirmation through the use of genetic manipulations to 
conclusively confirm that OSMR signaling is specifically involved in METH-induced astrocyte activation. 
Furthermore, the current study lacks genetic manipulations of sigma receptors to conclusively 
determine that the effects seen are due exclusively to sigma receptor modulation. SN79, the particular 
sigma ligand used during the current study however, has been utilized previously to study the role of 
sigma receptors in the actions of psychostimulants such as METH (Kaushal et al. 2011; Kaushal et al. 
2012). Additionally, this ligand represents a potential drug development candidate aimed at treating the 
negative side effects of METH abuse such as neurotoxicity, as it has not only desirable pharmacologic 
effects, but also desirable pharmacokinetic parameters as well (Kaushal et al. 2011). These effects of 
SN79, combined with its ability to mitigate METH-induced astrocyte activation, neuronal degeneration 
and STAT3 phosphorylation as described within the current study make it a viable candidate for future 
drug development. Future studies aimed at the further delineation of the molecular mechanisms by 
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which SN79 and other sigma receptor ligands mitigate the neurotoxic consequences of METH are 
certainly warranted.  
 
8.5. Contributions 
 Matthew Robson conducted all in vivo studies, quantitative real-time PCR and western blots. 
Ryan Turner and Zachary Naser performed immunohistochemistry and immunofluorescence studies and 
data obtained was analyzed by Matthew Robson. James O’Callaghan and NIOSH graciously allowed the 
use of a small rodent microwave irradiation unit.  
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Chapter 9 
Summary and Conclusions 
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9.1. Summary: 
 
9.1.1. Sigma receptor involvement in the antidepressant-like effects of ketamine 
The studies contained within the current dissertation have thus demonstrated:  
 Sigma receptor modulation is involved in specific aspects of the antidepressant-like effects of 
ketamine, a drug known to have rapid and persistent antidepressant effects.  
 Sigma receptors are involved in the ability of ketamine to potentiate the effects of NGF on 
neurite outgrowth in vitro, an effect indicative of antidepressant-like actions. 
 
9.1.2. The involvement of sigma receptors in neurotoxic actions of METH 
 The ability of sigma receptor antagonists to mitigate METH-induced dopaminergic neurotoxicity 
is correlated to their ability to block METH-induced increases in core body temperature.  
 AC927, a protective, selective sigma receptor antagonist, blocks specific gene expression 
changes in the striatum elicited by METH 
 SN79, a protective sigma receptor antagonist, is unable to alter METH-induced PERK-mediated 
ER stress in an in vitro model of neurotoxicity.  
 SN79 mitigates METH-induced microglial activation in the striatum, an effect believed to 
contribute to the ability of METH to elicit neurotoxicity. 
 SN79 blocks METH-induced striatal increases in IL-6-type cytokine expression, an effect 
indicative of a blockade of neuroinflammation. 
 Furthermore, SN79 treatment blocks METH-induced astrocyte activation and OSMR/gp130 
signaling. 
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9.2. Conclusions:  
 The studies included in this dissertation have accomplished two primary aims: 1) determined 
that ketamine exerts effects on neurite outgrowth through the modulation of sigma receptors and 2) 
begun to elucidate potential mechanisms by which sigma receptor antagonists mitigate the neurotoxic 
actions of METH.  
 Our studies effectively show that ketamine interacts with both subtypes of sigma receptors and 
although it does not appear the antidepressant-like effects of ketamine in the forced swim test involve 
sigma receptors, the ability of ketamine to potentiate NGF-induced neurite outgrowth in vitro is 
dependent upon sigma receptor modulation. Currently, it is unclear how ketamine exerts its 
antidepressant effects and these studies provide a novel target by which ketamine modulates 
neuroplastic changes believed to be relevant to the actions of antidepressants. Future characterization 
of the molecular signaling pathways involved in these effects could point to new molecular targets for 
the production of pharmacotherapies with antidepressant actions similar to ketamine while also having 
reduced side effect liabilities.  
 Furthermore, these studies have begun to determine how sigma receptor antagonists mitigate 
the neurotoxic actions of METH. These studies are important as sigma receptors are believed to be a 
novel target for the production of pharmaceuticals aimed at countering the negative side effects and 
addiction liability to psychostimulants including METH. Our studies determined that sigma receptor 
antagonists are modulating glial cell function and neuroinflammation as a result of neurotoxic METH 
exposure. Glial cell activation and cytokine release, indicating neuroinflammation, is implicated in the 
ability of METH to cause neurotoxicity. Furthermore, an increase in neuroinflammation is present in 
several neurodegenerative disorders and may represent a future target for novel therapeutics aimed at 
treating these diseases. Our studies provide evidence that sigma receptor ligands may represent a class 
of novel therapeutics that are able to reduce glial cell activation and neuroinflammation as a result of 
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various CNS disorders. Future studies determining whether these effects are causal in the ability of 
sigma receptor antagonists to mitigate the neurotoxic actions of METH are warranted. Additionally, the 
determination as to whether the ability of sigma receptor antagonists to mitigate glial cell function and 
neuroinflammation are specific to METH, or whether this is a generalized effect across various models of 
neurodegenerative disorders, are certainly warranted.  
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